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ABSTRACT 
VICTORIA A. NEWTON: SOCS2 and EGF modulate insulin-like growth factor 
signaling in intestinal cancer. 
(Under the direction of Dr. Pauline Kay Lund) 
 
The insulin-like growth factor (IGF-I) pathway is associated with increased risk and 
progression of colorectal cancer. Understanding mechanisms that inhibit or promote this 
key pathway would be useful in developing better therapies and strategies for the 
treatment of colorectal cancer. Suppressor of cytokine signaling-2 (SOCS2) limits the 
trophic effects of IGF-I in the intestine and therefore, may negatively regulate intestinal 
tumorigenesis. We crossed SOCS2-/- mice with ApcMin/+ mice, a widely used model of 
spontaneous intestinal tumorigenesis, to test whether loss of SOCS2 promotes increased 
intestinal tumorigenesis and to identify possible mechanisms. Epidermal growth factor 
(EGF) is also associated with establishment and progression of colorectal cancer. Studies 
suggest that EGF impacts on IGF-IR signaling to synergistically increase growth in non-
transformed intestinal epithelial cells and that combined inhibition of EGF and IGF-I 
would be more effective in reducing growth and survival of intestinal tumors than 
inhibition of either pathway alone. Whether EGF and IGF-I synergistically promote 
activation of tumor-promoting pathways in normal intestinal epithelial cells is unknown. 
In addition, combined inhibition of IGF-I and EGF pathways in a model of sporadic 
intestinal tumorigenesis has not been tested. To test synergistic effects of EGF and IGF-I, 
we used IEC-6 cells, a non-transformed intestinal epithelial cell line, to assess 
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mechanisms of additive or synergistic activation of the IGF-IR and a key tumor 
promoting pathway in colorectal cancer, the β-catenin pathway. Combined inhibition of 
IGF-IR and EGFR signaling on intestinal tumor development was assessed using ApcMin/+ 
mice lacking one allele of IRS-1, a downstream signaling molecule that mediates trophic 
effects of IGF signaling, and given a specific EGFR inhibitor. Loss of SOCS2 promoted 
significant increases in tumor number, size, and load in the small intestine and colon of 
ApcMin/+ mice. This was associated with increases local IGF-I, serine-phosphorylation of 
STAT3, a downstream mediator of IGF-I action and a target of SOCS2, and enhanced 
AP-1 DNA binding. In IEC-6 cells, EGF treatment increases IGF-IR, activation and 
combined treatment of EGF and IGF-I additively increases nuclear β-catenin and its 
transcriptional activation. Combined heterozygous deletion of IRS-1 and inhibition of the 
EGFR dramatically reduced tumor number, size, and load, as well as tumor incidence, in 
the colon of ApcMin/+ mice. Surprisingly, this effect was confined to female mice and was 
not observed in male mice. Together, these studies identified novel mechanisms that 
regulate IGF-IR signaling. Our studies indicate that SOCS2 may be a useful biomarker of 
colorectal cancer. The interactions between IGF-I and EGF suggest that combined 
inhibition of these pathways will be more effective in treating colorectal cancer, than use 
of either treatment alone. Future studies using microarrays will identify molecular 
pathways that are activated tumors and normal tissue in response to complete loss of 
SOCS2 in ApcMin/+ mice or in response to combined activation or inhibition of EGF and 
IGF-I signaling. 
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A. The structure and physiology of the small and large intestine 
The primary function of the small intestine is to digest and absorb nutrients, 
water, and electrolytes.1 The large intestine concentrates waste and reabsorbs water and 
electrolytes.1 The intestine is a barrier to luminal toxins and microorganisms.1 The 
musocal layer consists of a lining of epithelial cells in contact with the lumen, the 
underlying lamina propria, and the muscularis mucosa (Figure 1.1A). The lamina propria 
is a supporting network of loose connective tissue containing fibroblasts, myofibroblasts, 
smooth muscle cells, capillaries, enteric neurons, and immune cells. The muscularis 
mucosa is a thin layer of smooth muscle found below the lamina propria. Under the 
mucosal layer lies the submucosa, a loose connective tissue that houses the submucosal 
neuronal plexus, large blood vessels, and fibroblasts. In the duodenum, the submucosa 
contains Brunner’s glands (Figure 1.1A). The muscularis externa contains two layers of 
smooth muscle, a circular inner layer and a longitudinal outer layer and is responsible for 
the peristalic waves of contraction that propel and churn luminal contents.1 Peristalic 
contractions are produced by the intrinsic rhythmic contractility of the smooth muscle 
cells, where gap junctions allow the propagation of electrical signals throughout the 
intestine.1 This process is regulated by the enteric nervous system, which functions as 
part of the autonomic nervous system (ANS). The submucosal (Meisner’s) plexus 
(located in the submucosa) and the myenteric (Auerbach plexus, located between the 
circular and longitudinal muscle layers) regulate intestinal motility and also epithelial 
function.1 While the enteric nervous system can operate independently of the central 
nervous system (CNS), the CNS can alter intestinal programs in response to external 
stimuli such as the sight or smell of food.  
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Digestion of food begins during mastication. Chewed material is propelled 
through the esophagus and into the stomach, where it is further broken down by 
mechanical churning and enzymatic and acidic digestion.1 When contents are almost 
completely digested into a mix called chyme, it enters the duodenum, the proximal 
portion of the small intestine. At that time, the gallbladder releases bile acids and the 
pancreas releases enzymes to chemically break down nutrients.1 Digestion continues as 
chyme moves from the duodenum to jejunum. Brush border enzymes in the intestinal 
epithelium finalize digestion and transport monosaccharides and amino acids across the 
epithelial layer into the interstitial space and into the bloodstream.1 Nutrients are taken 
through the portal circulation in the liver where they are distributed throughout the body.1 
Lipids are re-esterified into triglycerides and packaged into chylomicrons. Nutrients enter 
lymphatic vessels and then re-enter the venous circulation. Bile acids are reabsorbed in 
the ileum, the distal portion of the small intestine. Fecal contents are moved into the large 
intestine, where water and electrolytes are reclaimed and waste is concentrated and 
excreted.1 Immune cells and immune aggregates called Peyer’s patches aid in destroying 
pathogenic bacteria that are constantly exposed to the luminal environment, while 
maintaining normal intestinal microflora that aid in the breakdown of non-digestible 
components, promote fat deposition and prevent the overgrowth of pathogenic bacteria.1 
 
B. The intestinal epithelium and intestinal adaption. 
The intestinal epithelium is organized in a crypt-villus axis (Figure 1.1B). Villi 
are finger-like projections that start at the top of the crypt and are found only in the small 
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intestine. Crypts are deep invaginations that are throughout the entire intestine. This 
organization allows for a vast surface area, which aids in efficient nutrient digestion and 
the transport of nutrients, water, and electrolytes.1 Intestinal stem cells (ISCs) reside in 
the crypt base and undergo asymmetric cell division to maintain the resident stem cell 
and produce an undifferentiated transit amplifying (TA) progenitor cell, which continues 
to divide for several cycles and migrate up the crypt towards the lumen. TA cells 
differentiate, migrate onto the villus, towards the villus tip where they are sloughed off in 
a process called anoikis (Figure 1.1B). Thus, the crypt-villus axis functions to separate 
the proliferative zone in the crypt from the differentiation zone in the villus. This process 
completely replenishes of the intestinal epithelium every 3-5 days, though this varies with 
species.2 
Small intestine stem cells differentiate into four main cell types: 1) entero-
endocrine, 2) absorptive, 3) goblet, and 4) Paneth cells. Entero-endocrine cells store and 
secrete hormones that regulate digestive processes in response to neural or mechanical 
stimuli.3 Absorptive cells act to transport small peptides, amino acids, lipids, and basic 
sugars from the lumen to the bloodstream.4 Goblet cells secrete a lubricating layer of 
mucus to protect the epithelium and aid the movement of digestive contents.5 Paneth cells 
are differentiated cells that do not move up the crypt, but instead migrate downwards and 
reside at the very base of the crypt.6 These cells are highly granulated and are thought to 
play a role in microbial defense.7 
The intestinal epithelium must balance the rate of proliferation with the rate of 
apoptosis to maintain intestinal integrity, digestion, and nutrient uptake. In response to 
changes in these processes, the intestine alters its rate of proliferation and apoptosis to 
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produce morphological and functional changes in the mucosa, in a process called 
intestinal adaption.8 Fasted rats or those fed by total parenteral nutrition (TPN), which are 
fed intravenously, demonstrate a compensatory atrophy in the intestinal mucosa and show 
decreases in both villus height and crypt depth.8 Mice that have undergone surgical 
resection, where a large portion of the small intestine is removed, demonstrate increases 
in mucosal mass due to increases in villus height, crypt fission and overall increase in 
circumference of the small intestine to compensate for the loss of surface area.9 Growth 
factors influence the rates of these adaptive processes.10 GH or IGF-I promote increases 
in mucosal mass following TPN-feeding and transgenic models overexpressing GH or 
IGF-I show increases in the length and mass of the small intestine, as well as 
hyperplasia.11,12,13 EGF is also required for intestinal adaptation, as pharmacological or 
genetic inhibition of EGFR prevented the adaptive response in mice that had undergone 
proximal small bowel resection.14,15 
In contrast to the small intestine, the colon is organized into a crypt-surface axis. 
However, processes of stem and progenitor proliferation in the crypt and migration and 
differentiation of cells are similar to small intestine. The colon does not show as great a 
degree of adaptive growth as the small intestine, with less atrophy during fasting or TPN 
and less adaptive increases in mass after removal of the small intestine.16 The colon does 
exhibit dramatic regenerative changes and hyperplasia during mucosal healing in 
response to damage by acute or chronic inflammation or other insults such as 
irradiation.17, 18 The colon is also more susceptible to dysplastic changes leading to colon 
cancer.   
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C. Genetics of Colon Cancer 
Despite advances in screening and detection, colorectal cancer is the 3rd most 
common cancer among men and women and is the second-leading cause of cancer-
related deaths in the United States.19 Several risk factors have been identified that 
promote increased risk of colorectal cancer, including family history, lifestyle (i.e. diet, 
physical activity, etc), and bowel inflammation.20,21,22 These risk factors promote two 
major colorectal cancer pathways, sporadic colorectal cancer and inflammation-
associated colorectal cancer (Figure 1.2). Identification of the underlying mechanisms 
that promote colorectal cancer has lead to the development of targeted and combined 
therapies.23,24  
 
a. Sporadic colon cancer 
Sporadic colon cancer arises in the absence of overt family history and occurs as a 
result of activation of oncogenes and inactivation of tumor suppressor genes.25 Genomic 
instability leads to mutational accumulation and occurs primarily through two genetic 
pathways in colorectal cancer.26 One pathway is chromosomal instability (CIN), where 
allelic loss of tumor suppressor genes drives the formation of adenomas to large 
adenomas and adenocarcinomas.26 In CIN, the APC (adenomatous polyposis coli) gene is 
frequently mutated and promotes the development of adenomas (Figure 1.2).27 Adenomas 
develop subsequent K-ras mutations and p53 deletions and further allelic loss occurs 
during progression to adenocarcinoma (Figure 1.2).26 This progression occurs in patients 
who have familial adenomatous polyposis (FAP). These patients have germ-line 
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mutations in the APC gene and develop hundreds to thousands of adenomas in their 
colon.28 
Another pathway to colorectal cancer is microsatellite instability (MSI).  MSI is 
characterized by alterations in the number of tandem repeats of simple DNA sequences or 
microsatellites and is caused by mutations or epigenetic silencing of DNA mismatch 
repair genes (MMR).26 These repeats cause inactivating frameshift mutations in tumor 
suppressor genes.29 MSI is associated with another form of hereditary colon cancer called 
hereditary non-polyposis colorectal cancer (HPNCC) and is characterized by defects in 
DNA mismatch repair enzymes.26 CIN or MSI are found in sporadic colorectal cancer 
and a subset of MSI-high tumors have mutations in APC and p53 genes, characteristic of 
CIN.26 
 
b. Inflammation-associated colon cancer.  
Colon cancer can also develop in a setting of chronic inflammation and this is 
called inflammation- or colitis-associated colorectal cancer (CACC). Patients with 
ulcerative colitis and Crohn’s disease have increased life-time risk of developing colon 
cancer.30 In this setting, excessive immune responses drive chronic inflammation and 
mucosal damage leading to repeated cycles of would healing, involving the proliferation 
of damaged cells. As opposed to sporadic colon cancer, in CACC, cancerous lesions arise 
from areas of flat non-polypoid dysplasia that progress from low to high grade (Figure 
1.2).31 The development of cancerous lesions from regions of dysplasia is promoted by 
the accumulation of mutations in various regulatory pathways. Both sporadic colon 
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cancer and CACC develop mutations resulting from CIN or MSI at relatively the same 
frequency; however, the timing of the accumulated mutations differs between sporadic 
colon cancer and CACC (Figure 1.2).31 In CACC, APC mutations occur late in tumor 
development and are less frequent compared to sporadic CRC.30 Mutations in p53, while 
a late event in sporadic colon cancer, are detected relatively early in CACC and often in 
areas of non- or indefinite dysplasia.31 In addition, epigenetic silencing plays a large role 
in the early stages of CACC, where CpG methylation is found to precede the 
development of dysplasia and is frequently found in CAC tumors.31 
 
D. The APC gene in Colon Cancer 
APC is mutated in up to 85% of sporadic colon cancers and is mutated in most 
familial colon cancers such as FAP and Gardner syndrome.28,32 APC normally exists as a 
complex with axin, glycogen-synthase 3β (GSK-3β), and β-catenin (Figure 1.3).33 In the 
absence of Wnt ligands, β-catenin is serine/threonine phosphorylated by GSK-3β and 
targeted for proteasomal degradation.33 In the presence of Wnt ligands, GSK3-β is 
inactivated and	   β-catenin accumulates in the cytosol and translocates into the nucleus 
where it induces the activation of t-cell factor (TCF)/lymphoid enhancer factor (LEF) 
transcription factors (Figure 1.3).34 TCF/β-catenin complexes activate the expression of 
target genes such as c-myc and cyclin D1.35 β-catenin is also complexed at the lateral 
membranes and sites of cellular adhesion in normal intestinal epithelial cells (IEC).25 
Mutations in APC prevent docking with GSK-3β and β-catenin is not degraded.27 
	   9	  
Mouse models with inactivation of the APC/β-catenin pathway have established 
the role of aberrant β-catenin activation in the initiation of colorectal cancer. ApcMin/+ 
mice are heterozygous for a mutation that results in a truncated form of APC, which lacks 
the GSK-3β binding site.36 Depending on the genetic background, these mice develop 
tens to hundreds of spontaneous adenomas in the small intestine that typically arise due to 
focal loss of the remaining wild-type (WT) APC allele through somatic recombination 
resulting in cells homozygous for the APC mutation.37,34 This is a process called loss-of-
heterozygosity (LOH).34 The WT APC allele also may be epigenetically silenced due to 
failure of MMR pathways.38 ApcMin/+ mice develop tumors in colon as well as small 
intestine, but this is heavily dependent on genetic background.39 The ApcMin/+ model is 
widely used to study mediators and mechanisms that govern the initiation, establishment 
and progression of intestinal tumors.  
 
E. GH/IGF-I axis 
a. GH and physiological actions 
Growth hormone is a polypeptide hormone that regulates growth and metabolism. 
It is secreted by the anterior pituitary in a pulsatile manner into the bloodstream in 
response to growth hormone releasing hormone (GHRH) and ghrelin from the 
hypothalamus.1 GH acts on a number of organs, namely liver, muscle and bone. GH 
exerts its effects by binding to the growth hormone receptor (GHR). The GHR is a single 
transmembrane glycoprotein that is a member of the cytokine superfamily of receptors.40 
Because the GHR lacks an intrinsic kinase domain, it exerts signaling effects through 
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Janus Kinase 2 (JAK2), a cytoplasmic tyrosine kinase that is physically and functionally 
associated with the GHR.40 Upon receptor dimerization, JAK2 trans- and auto-
phosphorylates itself and the GHR. JAK2 also phosphorylates signal-transducers and 
activators of transcription (STATs) at SH2-domains, resulting in homo- or hetero-
dimerization. STAT dimers translocate into the nucleus and mediate gene-transcription 
by directly binding to the 5’ regulatory region of certain DNA sequences via their DNA-
binding domain. This induces the expression of genes associated with growth and 
metabolism, such as insulin, IGF-I, CYP genes and SOCS.40 
GH is most widely known for its role in promoting growth and also plays an 
important role in metabolism. GH is responsible for increases in post-natal growth and 
muscle mass.41 Excess secretion of GH, a condition called acromegaly, causes dramatic 
enlargement and thickening of the bones, coarse facial features and visceromegaly.42 In 
contrast, GH deficiencies are associated with proportionally short-stature and delayed 
bone and muscle growth.43 These effects are mimicked in mouse studies, where 
transgenic (Tg) overexpression of the bovine GH gene promotes gigantism and aberrant 
activation of GH/IGF-I signaling.12 In addition, ‘little mice”, which have a deficiency in 
GH due to a recessive mutation in the growth hormone releasing hormone (GHRH) 
exhibit dwarfism and severely reduced levels of serum IGF-I.44 GH is also exerts a 
number of metabolic effects, such as promoting lipolysis, protein synthesis, and 
hyperglycemia.45 
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b. IGF-I family 
The IGF system is composed of the ligands, IGF-I, IGF-II, and insulin, whose 
effects are mediated by the type I and type 2 IGF receptors (IGF-IR and IGF-IIR) and the 
insulin receptor (IR)46 (Figure 1.4). In addition, a family of 7 binding proteins (IGFBP1-
7) alters the bioavailability of circulating IGFs and locally expressed tissue IGFs. The 
IGF-IR binds IGF-I and IGF-II with high affinity and can also bind insulin. Hybrid 
IGF/insulin receptors exist and bind IGFs with high affinity and some bind insulin.47 The 
IGF-IR is the primary mediator of the trophic actions of both IGF-I and IGF-II. The 
insulin receptor mediates the metabolic actions of low physiological levels of insulin. At 
elevated levels, insulin can have proliferative and anti-apoptotic effects, which may be 
mediated by IR, IGF-IR, or hybrid IGF-I/IR. The type 2 IGF receptor specifically binds 
IGF-II and acts as a scavenger to limit IGF-II binding to IGF-IR.46 
Circulating levels of IGF-I are derived largely from liver (~75%) and are 
regulated by insulin, caloric intake, and growth hormone (GH).48 GH engages GHRs on 
hepatocytes to stimulate IGF-I production in the liver and its secretion into circulation. 
GH can acts on other organs, including the intestine to stimulate IGF-I synthesis.49 IGF-I 
is expressed in most, if not all, non-hepatic tissues.48 Studies from our lab have 
demonstrated that IGF-I is synthesized in mesenchymal cells within non-hepatic tissues, 
including intestine, and has paracrine effects on neighboring epithelium.48,50 Studies in 
mouse models suggest that IGF-II is critical for embryonic growth. Imprinting normally 
silences the maternal IGF-II allele.51 Loss of imprinting (LOI) for IGF-II increases local 
IGF-II in the intestine and this is prevalent in patients with adenoma.52  
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The IGF-IR consists of 2 extracellular α subunits and 2 intracellular β subunits. 
IGF-I or IGF-II bind the extracellular portion of the IGF-IR and induce a conformational 
change that results in autophosphorylation of the intracellular β subunits.46,48 This signal 
is enhanced by phosphorylation of additional tyrosine residues in the β subunit. 
Downstream docking proteins, such as insulin receptor substrate 1 (IRS-1) and Shc, are 
recruited to these sites and are subsequently tyrosine phosphorylated. This activates PI-
3K/Akt and Ras/Raf/MAPK signaling cascades to induce proliferation, inhibit apoptosis, 
and regulate differentiation.46 In vitro studies suggest that IGF-I increases the stability of 
β-catenin and that IGF-IR signaling components may interact with β-catenin.53,54 In C10 
colorectal cancer cells, IGF-IR and β-catenin co-immunoprecipitated with E-cadherin and 
this was reduced by IGF-I treatment.54 In embryonic fibroblasts, IGF-I stimulated IRS-1 
translocation to the nucleus and IRS-1 co-localization with β-catenin.53 
 
c. IRS-1 mediates the trophic effects of IGF-I 
IRS-1, IRS-2, and Shc are the main signaling substrates recruited to the IGF-IR or 
IR.46 While IGF-IR and IR can activate both IRS-1 and IRS-2 in cell lines, in vivo 
evidence suggests that IRS-1 and IRS-2 have distinct roles (Figure 1.4). IRS-1-/- mice 
show reduced body growth, modest reductions in small intestine weight and impaired 
glucose tolerance, but do not develop type II diabetes.55,56 IRS-2-/- mice have normal 
body and organ growth, but develop type II diabetes.57,58 Studies from our laboratory 
using IRS-1-/- mice crossed with mice overexpressing an IGF-I transgene demonstrated 
that IRS-1 is a major mediator of IGF-I-dependent growth in multiple organs, but the 
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degree of dependence on IRS-1 is organ-specific.59 IGF-I-stimulated skeletal muscle 
growth was the most impaired in IRS-1-/- mice, yet brain growth was not significantly 
affected.59 IGF-I induced intestinal growth showed intermediate dependence on IRS-1 
indicating that while IRS-1 is necessary for normal IGF-I-induced intestinal growth, other 
pathways can contribute to growth effects of IGF-I in intestine.59 Our studies examined 
the role of IRS-1 in IGF-I transgene-induced growth of colon mucosa or smooth muscle 
and revealed cell- and process-specific requirements for IRS-1. Enteric smooth muscle 
growth, induced by two different IGF-I transgenes (MT-hIGF-I or αSMactin-hIGF-I), 
was unaffected by homozygous disruption of both IRS-1 genes.60 Disruption of both IRS-
1 alleles attenuated IGF-I transgene-induced overgrowth of colon mucosa.60 This 
reflected complete loss of the anti-apoptotic effects of IGF-I in IRS-1-/- colon crypts, but 
only partial loss of IGF-I-induced crypt proliferation suggesting that IRS-1 is a required 
in vivo mediator of the anti-apoptotic effects, and to a lesser extent proliferative effects, 
of IGF-I in the colon.60 IRS-1-/- mice have increased basal and irradiation-induced 
apoptosis localized to the stem cell region of the crypts.61 Loss of IRS-1 also protected 
against tumor development in ApcMin/+ mice.61 Given the key role of IRS-1 in mediating 
IGF-I action in intestine, and the fact that IRS-1 likely mediates the proliferative and anti-
apoptotic actions of IGF-II, and possibly insulin, studies in chapter IV used IRS-1-/- 
ApcMin/+ mice to test for in vivo interactions of loss of function of the IGF-signaling in 
intestinal tumorigenesis.  
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F. IGF-I/insulin family in colon cancer 
Compelling evidence supports a role of the IGF-I family in the progression and 
survival of colorectal cancer (Figure 1.5). Elevated circulating IGF-I or IGF-II is 
associated with increased risk of colorectal cancer.62,63,64 Increased plasma insulin is also 
associated with increased adenoma risk and decreased apoptosis in the normal colon.65 
Loss of imprinting (LOI) of the IGF-II maternal allele elevates local levels of IGF-II and 
is associated with increased risk of intestinal adenomas.66,51 A recent meta-analysis 
containing ten prospective studies showed a modest positive association between 
circulating IGF-I and colorectal cancer risk.67 IGF-IR expression is increased in a number 
of tumors and this correlates with grade and stage of intestinal tumors.68,69,70 Expression 
of IGFBPs is often altered in tumors and low IGFBP3 expression in the colon is 
associated with increased risk of colorectal cancer.71,72 Recently, a polymorphism in the 
5’ promoter region of IGF-I in the consensus domain of the Oct1/Oct2 binding 
transcription factor binding site was associated with a 40% reduction in CRC risk.73 
Functional studies in mice strongly support a role for the IGF-I family in 
colorectal cancer. Multiple studies in mouse models demonstrate that exogenous IGF-I 
increases intestinal length, mucosal mass, and crypt cell proliferation and reduces 
apoptosis.59,74,75 Mice with a liver-specific deletion of IGF-I have a 50-70% reduction in 
circulating IGF-I and, when treated with the carcinogen azoxymethane (AOM), show 
reductions in tumor multiplicity and tumor size.76,77 This was associated with increased 
apoptosis and enhanced proliferation.76 Other studies have examined the role of LOI of 
IGF-II in the progression of colorectal cancer. A mouse model of LOI of IGF-II in 
ApcMin/+ mice showed dramatic increases in intestinal tumors compared to littermate 
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controls.78 This phenotype could be rescued by the introduction of a transgene expressing 
soluble full-length IGF-II.79 These studies suggest that intrinsic mechanisms or therapies 
that limit the IGF-I family may be useful preventative or therapeutic strategies against 
colon cancer.   
 
G. SOCS proteins (Adapted from 80) 
The family of suppressors of cytokine signaling (SOCS) was discovered in the 
late 1990s based on their ability to exert negative feedback on cytokine receptor signaling 
through the Janus Kinase (JAK), signal transducers and activators of transcription 
(STAT) pathway (Figure 1.6).81,82, 83,84 This family includes cytokine inducible SH2-
containing protein (CIS) and SOCS 1-7.84 Each SOCS family member shares a similar 
structural organization containing a COOH-terminal SOCS box, an SH2-domain and an 
N-terminal domain. The SOCS box is an approximately 40-residue motif showing strong 
homology across all SOCS family members.83,85 The SOCS box is essential for 
interactions with elongins to form an E3 ubiquitin ligase, which targets bound proteins 
for poly-ubiquitination and proteasomal degradation.85 The SH2-domain of SOCS 
proteins is critical for interactions between SOCS and phospho-tyrosine residues of target 
signaling proteins.84 The N-terminal domains of the SOCS proteins vary in length and 
sequence and may impact on specificity or mode of SOCS action.84 
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a. Pleiotrophic effects SOCS on cytokine actions 
 Consistent with the discovery of SOCS proteins as cytokine-inducible negative 
feedback inhibitors of cytokine receptor/JAK-STAT signaling, a wealth of evidence 
suggests that multiple cytokines and associated receptors can induce expression of one or 
more SOCS mRNAs and proteins.84 Conversely each particular SOCS can limit the 
activity of multiple cytokines. However as discussed, mouse models with targeted 
disruption of SOCS genes indicate specific or preferential roles of some SOCS in limiting 
particular cytokines and their receptors. This dissertation is focused on SOCS2. The 
SOCS proteins limit the magnitude or duration of cytokine signaling by multiple 
mechanisms that depend on the particular SOCS protein induced (Figure 1.6).85 These 
include: 
a) Direct inhibition of activated JAKs, which has been demonstrated for SOCS1 and 
SOCS3 and relies on a kinase inhibitory region (KIR) present in these SOCS. 
b) Binding of SOCS to the cytoplasmic domain of the cytokine receptor via SH2 
domain interactions and subsequent inhibition of JAK activity, which has been 
demonstrated for SOCS3. 
c) Binding to SH2 domains of cytokine receptors and competitively inhibiting STAT 
binding to the cytokine receptor, which occurs for SOCS2. 
d) Recruitment of the E3 ubiquitin ligase complex to the SOCS box, leading to 
ubiquitination and degradation of receptors/signaling molecules associated with 
SOCS. 
Of the SOCS family members, SOCS1 and SOCS3 are the most structurally and 
functionally similar.83 Both contain a kinase inhibitory region (KIR), which enables them 
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to directly bind and inhibit JAKs.86 SOCS1 and SOCS3 exhibit some functional 
redundancy in the modulation of cytokine signaling. SOCS1 is induced by and can 
modify signaling of multiple cytokines, including interleukin- (IL-4), IL-6, leukocyte 
inhibitory factor (LIF), and interferon (IFNγ).82,87,88 SOCS3 is an inhibitor of ligands 
which activate the family of cytokine receptors that share the gp130 receptor subunit, 
including IL-6, LIF, and oncostatin M (OSM).84,89,90 
SOCS2, which is the focus of chapter II, was originally discovered in an EST 
database search for SOCS-1 related genes.82 SOCS2 mRNA is expressed during 
embryogenesis and in a number of adult mouse and human tissues including liver, heart, 
lung, the small intestine and colon.91,82 SOCS2 expression is induced in various cell types 
by several cytokines including IL-6, IL-3, IL-4, granulocyte macrophage colony 
stimulating factor (GMCSF), IFNγ, LIF, erythropoietin (EPO), IL-1, and GH.82 Several 
features distinguish SOCS2 from SOCS3. SOCS2 lacks a KIR and is structurally similar 
to CIS. While cytokines typically induce rapid and transient expression of SOCS1 and 
SOCS3, SOCS2 expression gradually increases and persists for over 24 hours.82 
Although SOCS2 is activated by multiple cytokines, it does not seem to have a 
significant role in immune function.92 Considerable evidence summarized in detail below 
indicates a primary role of SOCS2 in regulating GH action via the GH receptor.93 In 
addition yeast two hybrid data and work from the Lund laboratory indicate that SOCS2 
can bind to and inhibit the IGF-IR.94,91, 95 Since IGF-IR is a receptor tyrosine kinase, 
structurally distinct from cytokine receptors, this is a novel action of SOCS2. It is 
noteworthy that some evidence suggests that SOCS3 can limit signaling via the insulin 
receptor, which shares structural similarity with IGF-IR.96  
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H. Physiological role of SOCS2 as a negative regulator of GH/IGF-I signaling. 
a. Role of SOCS2 in GH signaling 
Insights into the physiological role of SOCS2 have come from studies using 
genetic mouse models. Mice with targeted gene-deletion of SOCS2 (SOCS2-/-) have 
significant increases in post-natal growth and adult mice are, on average, 40% heavier 
than their WT littermates. The 40% increase in body weight reflects increased organ size 
although not all organs are affected equally or proportionally with body weight.92 
SOCS2-/- mice also display increases in body length, length of bones in the limbs, and 
collagen deposition in skin.92 This phenotype is similar to that seen in GH-transgenic 
mice.12,11,67,97 Genetic disruption of GH signaling completely reverses the body 
overgrowth phenotype seen in SOCS2-/- mice and the phenotype is regained by twice-
daily injections of GH.93 This body overgrowth phenotype is partially mediated by 
STAT5b as genetic activation of this protein partially reverses the SOCS2-/- phenotype.93 
SOCS2 is localized to the high growth (HG) region in mice, humans and pigs, where a 
breakpoint deletion in the SOCS2 coding sequence has been identified.98,99 The 
phenotypes of HG mice and SOCS2-/- mice are also very similar. SOCS2-/- mice have 
normal plasma insulin-like growth factor levels, where both GH-transgenic and HG mice 
have elevated plasma levels of IGF-I.98,93 This suggests that the SOCS2 phenotype has 
both GH-dependent and GH-independent effects.93 Surprisingly, widespread transgenic 
over-expression of SOCS2 also promotes increases in body weight, but much less as 
those seen with loss of SOCS2.100 This finding highlights another distinct feature of 
SOCS2 signaling, whereby low concentration of SOCS2 are inhibitory and high 
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concentrations of SOCS2 may, in fact, be stimulatory.101,100 A model of SOCS2 action on 
GH signaling is shown in Figure 1.7. 
 
b. Role of SOCS2 in IGF-IR signaling 
SOCS2 negatively regulates IGF-IR signaling (Figure 1.7). SOCS2 has also been 
shown to bind to the IGF-IR by yeast two-hybrid assays and by co-
immunoprecipitation.91,75 Co-transfection of SOCS2 with the IGF-IR and STAT3 in 293T 
cells demonstrated that SOCS2 inhibits IGF-I-induced STAT3 phosphorylation, but did 
not have an effect on IGF-I-induced receptor phosphorylation.102 Similar results were 
seen in primary embryonic fibroblasts from SOCS2-/- mice.91 However, further studies in 
Caco2 cells, a colon cancer cell line, demonstrate that overexpression of SOCS2 
attenuates IGF-I induced tyrosine phosphorylation of the IGF-IR, as well as IGF-I-
induced tyrosine phosphorylation of IRS-1.75 These results suggest that SOCS2 may have 
cell-type specific effects on IGF-IR signaling.  
 
I. Role of SOCS2 in the Intestine (Adapted from 80) 
a. Small Intestine 
SOCS2 is a negative feedback regulator of GH/IGF-I-induced growth of the small 
intestine and exerts these effects on both intestinal epithelial cells and myofibroblasts. 
SOCS2-/- mice have significant although modest ~25% increases in the length and mass 
of the small intestine, due to enhanced proliferation and reduced apoptosis in the 
crypts.75,95 These mice have longer villi and deeper crypts.75 In Caco2 cells and in IEC-6 
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cells, a non-transformed intestinal epithelial cell line, SOCS2 overexpression inhibited 
proliferation and promoted differentiation.95 Isolated crypts from SOCS2-/- mice showed 
increased basal proliferation that was further enhanced in response to GH or IGF-I 
treatment, though IGF-I effects were more pronounced.95 Treatment in SOCS2-/- mice 
with exogenous IGF-I promoted further increases in the weight and mass of the small 
intestine, which was accompanied by enhanced tyrosine-phosphorylation of the IGF-IR.75 
In addition, IGF-I-induced STAT3 DNA binding was also enhanced in the intestine, 
suggesting that SOCS2 normally limits IGF-I-induced STAT3 activation.75 Fibroblasts 
from SOCS2-/- mice show increased GH- and IGF-I-induced proliferation and collagen 
deposition.103 In a model of growth hormone excess, loss of one copy of SOCS2 
promoted increased body overgrowth and pronounced increases in small intestine weight 
and proliferation.49 (Unexpectedly, these mice also developed hyperplastic and lymphoid 
polyps in their large intestine, representing the first evidence that SOCS2 may normally 
inhibit tumor development and is discussed in more detail below.49)  
 
b. Colon 
The role of SOCS2 in GH/IGF-I-induced growth in the colon is similar to that in 
the small intestine, though effects on growth are more pronounced. SOCS2-/- mice have 
significant increases in colon weight and length and a pronounced thickening of the 
muscularis layer.75,95 Like in the small intestine, these effects in the colon are also due to 
changes in the balance of proliferation/apoptosis in the crypt.75,95 Infusion of either IGF-I 
or EGF in SOCS2-/- mice promotes further increases in the weight and mass of the colon, 
indicating that SOCS2 may normally negatively regulate the actions of EGF as well as 
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IGF-I.75 GH-Tg mice have increased colon growth and this is further enhanced by partial 
loss of SOCS2.49 Partial loss of SOCS2 in GH-Tg mice produced hyperplastic and 
lymphoid polyps composed of mostly B cells that were actively proliferating, as indicated 
by BrdU positive cells in the crypts.49 It is important to note that hyperplastic and 
lymphoid polyps are typically considered benign. In addition these polyps developed only 
in a model of GH excess and haplotype insufficiency of SOCS2. Thus the role of SOCS2 
in intestinal tumorigenesis in situations of normal GH states was not defined. 
 
J. SOCS as Tumor Suppressors in Colorectal Cancer 
Since their initial discovery as intrinsic mediators of cytokine signaling, SOCS 
proteins have now been hypothesized to act as tumor suppressors based on their ability to 
limit the effects of multiple proliferative, growth-promoting pathways. SOCS, namely 
SOCS1, SOCS2, and SOCS3 proteins are hypermethylated at CpG islands and show 
reduced expression in a number of cancers, including esophageal, melanoma, 
hepatocellular carcinoma, and colon cancer.104,105,106,107,108 The role of SOCS proteins in 
gastrointestinal cancers has been largely focused on SOCS1, SOCS2 and SOCS3. This 
introduction will briefly review evidence about SOCS1 and SOCS3 since SOCS2 is the 
focus of chapter II.  
As mentioned previously, patients with inflammatory bowel disease have an 
increased lifetime risk of developing colorectal cancer.109,110,111,112 A widely accepted 
mouse model of inflammation-associated CRC is treatment with azoxymethane/dextran 
sodium sulfate (AOM/DSS). AOM is administered at the onset of the study followed by 
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multiple cycles of inflammatory agent dextran sodium sulfate (DSS) given in the drinking 
water. When this regime was given to transgenic mice lacking SOCS3 in intestinal 
epithelial cells (IEC), tumor load was increased four-fold compared to controls, with 
associated increases in STAT3 and NFκB activation.113 Conversely, SOCS3 over-
expression was shown to decrease proliferation in colon cancer cells lines, further 
supporting the role of SOCS3 as a suppressor of tumor cell growth in this model.113 
Similar to SOCS3, SOCS1 may also have tumor suppressive properties in CRC. A 
SOCS1-/-Tg model, in which mice with global disruption of SOCS1 genes had SOCS1 is 
restored specifically in T and B cells, was used to study the role of SOCS 1 development 
of spontaneous colorectal tumorigenesis. Colitis occurred in these mice at 3 months, 
followed by tumor development in inflamed areas of the proximal colon by 6 months of 
age, with constitutively active STAT1.114 Treatment with anti-IFNγ antibody reversed 
this phenotype. Interestingly, these mice had an increase in STAT3 and NFκB activation 
attributed to increased local TNFα expression, as well as increased COX-2 and iNOS in 
tumor-associated macrophages.114 This model supports the concept that SOCS1 limits 
IFNγ-dependent tumorigenesis in the colon. It is important to stress that the spontaneous 
tumor formation in the SOCS1-/-Tg model arises from local inflammation, as other 
reports show that STAT1 does not play a significant role in the ApcMin/+ model of 
spontaneous intestinal tumorigenesis.115 
It is likely that loss of SOCS2 promotes increase risk of colon cancer; however, 
very few studies have examined the role of SOCS2 in colon cancer. Evidence for such a 
role has come from several studies in primary tumors of other organs, such as breast, 
endometrial cancer, and melanoma, which suggest that the promoter of SOCS2 is 
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hypermethylated in tumors, resulting in a decrease in SOCS2 expression [summarized in 
Table 1]. Evidence in vivo that SOCS2 may limit intestinal tumorigenesis comes from 
our studies in SOCS2+/-/GH-tg mice, which show a 50% reduction in SOCS2 
expression.49 In addition to enhanced GH-induced increases in body and intestinal 
weight, these mice also developed lymphoid and hyperplastic polyps in the colon 
suggesting that small decreases in SOCS2 expression in a model of GH-excess promote 
abnormal growth.49 While lymphoid and hyperplastic polyps are not generally considered 
pre-cancerous, this was the first indication that SOCS2 may limit aberrant growth in the 
intestine. When SOCS2+/-/GH-Tg mice were aged over 250 days, the colonic polyps did 
not progress into pre-cancerous lesions; however, GH-Tg mice heterozygous for SOCS2 
developed duodenal adenomas, which are considered pre-cancerous lesions.61 Strikingly, 
the one SOCS2-/-/GH-tg generated over 40 litters developed a duodenal polyp that was a 
pathologically confirmed adenocarcinoma, suggesting a dose-dependent effect of SOCS2 
to inhibit tumor growth.116 While these effects were specific to GH-Tg animals, a model 
of acromegaly, considering the inhibitory effect of SOCS2 on GH/IGF-I-induced 
proliferation and cell survival and evidence for a role of IGF-I in colon cancer, we 
hypothesized that loss of SOCS2 promotes neoplastic growth in setting of spontaneous 
tumorigenesis. This hypothesis was tested in studies described in chapter 2 and our recent 
publication.117  
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K. EGF family 
The EGF receptor family is composed of 4 related receptors: EGFR 
(ErbB1/Her1), ErbB2 (Her2/neu), ErbB3 (Her3), and ErbB4 (Her4) which are considered 
prototypical tyrosine receptor kinases (Figure 1.8).118,119 Several ligands are members of 
the EGF-family of growth factors and bind various EGFR receptors with different 
affinities. EGF, transforming growth factor-α (TGFα), and amphiregulin bind the EGFR 
(Figure 1.8).119 The EGFR has a ligand binding domain containing two cysteine rich 
regions, a transmembrane domain, and a kinase domain that catalyzes the transfer of 
phosphate molecules from ATP to an active site of the tyrosine kinase.118 The C-terminal 
tail is then auto-phosphorylated and allows the binding of proteins with SH2 or 
phosphotyrosine binding domains (PTB).118 One exception is the ErbB2 receptor, which 
does not contain a ligand-binding domain, and instead influences binding affinity of other 
EGFR family members for their ligands by heterodimerization (Figure 1.8).120 ErbB3 is 
an EGFR family member that has a kinase domain, but lacks intrinsic kinase activity due 
to evolutionary changes in its sequence (Figure 1.8).121 EGF is known to activate several 
signaling pathways in response to ligand binding and receptor dimerization. EGFR is 
known to activate Ras to lead to MAPK/ERK activation, activate JAK/STAT pathways 
and also activate PI-3K/Akt.118 Activation of these pathways seems to be context-specific 
and leads to proliferation, migration, or differentiation of enterocytes. 
The growth effects of EGFR activation in the intestine are well documented. EGF 
is a known mitogen that promotes intestinal adaptation after surgical resection in mice.122 
EGF expression is increased following intestinal resection, with increases in EGF mRNA 
specifically in the crypt enterocytes.122 Mice with a mutation in the EGFR kinase domain, 
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called waved-2 mice, have impaired kinase activity and show impaired adaptive response 
following surgical resection.15 EGF is a potent stimulator of DNA synthesis and 
proliferation of intestinal epithelial cells in vitro and in vivo.123,124,122,125,126 EGF promotes 
wound healing through a Rac-dependent mechanism in mouse colonic epithelial cells.127 
Increased EGF expression is found in mouse models of colitis and treatment with EGF 
partially restores ion transport in colons of colitis-induced mice.128,129 When EGF is 
inhibited in organ cultures of intestinal epithelium, this promotes apoptosis and reduces 
survival of the intestinal cultures.130 These studies suggest that EGF normally regulates 
the maintenance and repair of the intestinal epithelium. 
 
L. EGF family in colon cancer 
The EGFR and its ligands are up-regulated in a majority of colon cancers.24,131 
Strong EGFR staining in colorectal tumors is associated with higher tumor stage, shorter 
duration of disease-free survival, and worsened overall survival.132 EGFR expression is 
detected in 65-70% of human colon cancers and is associated with more aggressive 
disease and poorer prognosis.133 Studies in mouse models strongly support a role for 
EGFR signaling in the progression of colon cancer. Genetic or pharmacological 
inhibition of the EGFR in ApcMin/+ mice reduced tumor number by 90% or 60%.134 In 
ApcMin/+ mice, exogenous EGF treatment increased polyp size in the proximal 
intestine.135 In the AOM model, the EGFR tyrosine kinase inhibitor, gefitinib, reduced 
tumor number by 42% and was associated with decreased proliferation and reduced 
cyclin D1 and Cox2.136 Recently, an intestinal-specific deletion of ErbB3 resulted in loss 
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of ErbB4 expression and increased inflammation in response to DSS-induced intestinal 
injury.121 In addition, when these mice were crossed with ApcMin/+ mice, there was a 
complete absence of colon tumors and almost complete ablation of tumors in the small 
intestine, as a result of increased caspase-3-mediated apoptosis.121 As a result of human 
expression and mouse studies, several companies have developed targeted therapeutics 
against EGFR and IGF-IR, which are currently in clinical trials. 
As indicated above, loss of function of APC and aberrant transcriptional 
activation of β-catenin are considered to be key pathways driving tumorigenesis in the 
colon. Some evidence suggests that EGF activates β-catenin, although this may be 
indirect, by disassociating β-catenin from adherens junctions.137,138,139,140 In A431 
epidermoid carcinoma cells, treatment with EGF disrupted cell-cell junctions 
downregulating E-cadherin and caveolin-1 mRNA and increasing β-catenin/TCF 
transcriptional activity.137 EGF also disrupts the α-catenin/β-catenin complex at adherens 
junctions by promoting EGF-induced activation of ERK leading to α-catenin 
phosphorylation and β-catenin dissociation.138 Activation and nuclear translocation of β-
catenin is dependent on histone deacetylase-6 (HDAC-6) in colon cancer cell lines, where 
inactivation HDAC6 blocked EGF-induced nuclear localization of β-catenin and 
proliferation.139 Recent studies demonstrate that EGF induces β-catenin mediated 
transcriptional activation of TCF/lef in oral cancer cell lines and cultured dermal 
fibroblasts.140,141 Together, these studies support a role for EGF in β-catenin nuclear 
accumulation and transcriptional activation.  
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M. Synergistic effects of IGF-I and EGF  
Studies in our lab and others show that EGF and IGF-I synergistically stimulate 
DNA synthesis and proliferation in intestinal epithelial cells greater than either treatment 
alone.123,142,143 Studies in our lab using IEC-6 cells, a non-transformed rat intestinal 
epithelial cell line, showed that while IGF-I or EGF alone stimulated 3H-thymidine DNA 
synthesis, the combined treatment of both growth factors produced synergistic increases 
in DNA synthesis.123 There is a temporal order to this effect where EGF pretreatment 
followed by IGF-I treatment produces synergistic increases in DNA synthesis; however, 
IGF-I pretreatment followed by EGF treatment produces effects similar to EGF alone.123 
A small 30-minute pulse of EGF or continuous EGF treatment followed by 48 hour IGF-I 
treatment in IEC-18 rat intestinal epithelial cells synergistically increased proliferation, 
while IGF pretreatment followed by 48 hour EGF treatment had no effect.142 Studies in 
FHs74 human intestinal epithelial cells also show synergistic activation of DNA 
synthesis by combined treatment of IGF-I and EGF and this was similar to effects seen 
with low levels (2%) of serum.143 One suggested hypothesis for this temporal order is that 
EGF acts as a competence factor, promoting the transition from G0 to G1 and the addition 
of IGF-I then drives DNA synthesis from G1 to S phase.142 However, as each growth 
factor alone has been shown to promote DNA synthesis and proliferation, with EGF 
showing more potent effects, other unknown mechanisms are probably responsible for 
the synergistic mitogenic effects of EGF and IGF-I.123 Chapter III explores mechanisms 
underlying synergistic mitogenic effects of IGF-I and EGF in IEC-6 cells.  
 
	   28	  
N. Current tyrosine kinase receptor therapies 
There are currently two major classes of inhibitors that target either EGFR or 
IGF-IR: (1) monoclonal antibodies that bind to the extracellular domain and (2) small 
molecular tyrosine kinase inhibitors that block binding of adenosine triphosphate to the 
intracellular tyrosine kinase domain of the receptors.144,145  
a. EGFR therapeutics in colon cancer 
As previously mentioned EGFR inhibitors have been developed to specifically 
target the EGFR in human colon cancer. Both small molecule inhibitors and monoclonal 
antibodies have been developed. Panitumab and cetuximab are monoclonal antibody 
inhibitors that are FDA-approved for treatment against metastatic colon cancer as both 
have been shown to be effective in at least some patients.146 Small molecule inhibitors 
have also been developed, such as gefitinib and erlotinib, though erlotinib has shown 
more effectiveness and is currently approved for treatment in non-small cell lung cancer 
(NSCLC).144 These agents have potent in vitro and in vivo effects to inhibit proliferation 
and reduce tumor development in experimental settings, but have been effective in only a 
subset of patients with colorectal cancer.147,148,149 Patients with breast cancer or NSCLC 
respond to EGFR inhibitors but develop resistance to these therapies.150,151 This suggests 
that additional pathways are mediating tumor survival or growth when EGFR is inhibited. 
For this reason, there is increasing interest in combining anti-EGFR inhibitors 
with other therapies.131 In vitro studies in breast, prostate and other cancer cell lines 
suggest that up-regulation and activation of IGF-I/IRS-1 signaling mediates resistance to 
anti-EGFR therapies.152,153,151,154,155 Resistance to trastuzumab in breast cancer cells was 
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shown to be mediated by IGF-I stimulated phosphorylation of ErbB2 (HER-2).152 
Inhibition of the IGF-IR by a specific tyrosine kinase inhibitor decreased ErbB2 
phosphorylation.152 Other studies showed that IGF-I interferes with the growth inhibitory 
effects of trastuzumab in MCF7/HER2-18 cells, which overexpress ErbB2 receptors.151 
EGF treatment of MCF-7 breast cancer cells enhanced phosphorylation of IRS-1 on 
Y896, a Grb2 binding site that promotes MAPK signaling.154 IGF-II treatment induces 
IRS-1 phosphorylation on Y612, a P13-K recruitment site.154 When MCF-7 cells were 
treated with gefitinib, a selective EGFR inhibitor, association between IRS-1/EGFR was 
reduced and IRS-1/IGFIR interactions were promoted.154 
 
b. IGF-IR therapeutics in colon cancer 
Inhibitors that specifically target the IGF-IR are currently in Phase I and Phase II 
clinical trials in breast, lung, and colon cancer.156 The field was greatly enhanced by the 
ability to produce inhibitors that specifically target the IGF-IR, while having minimal 
effects to inhibit related insulin receptors, which may produce undesirable metabolic 
effects.145 Preclinical, in vitro studies demonstrate that specific small molecular inhibitors 
and monoclonal antibodies against the IGF-IR induce apoptosis in colon cancer cells and 
reduce tumors colon cancer derived-xenografts.157,158,159,68 The small molecule IGF-IR 
kinase inhibitor, NVP-AEW541, decreased tumor development in xenograft and in vitro 
models of colon, pancreatic, esophageal, and liver cancer in a dose-dependent manner 
and did not influence formation of IGFIR/IR hybrid receptors which may interfere with 
efficacy of treatment.158 NVP-AEW541 was also shown to inhibit proliferation of a panel 
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of colon cancer cell lines and primary cell cultures by inducing apoptosis and cell cycle 
arrest, leading to an increase in the apoptotic protein Bax, and decrease in the anti-
apoptotic Bcl-2.68 The promising results of these studies have led to the movement of 
these therapeutics into Phase I and Phase II clinical trials. Dosing studies using 
monoclonal antibodies that specifically target the IGF-IR, such as CP751,871 and AVE-
1642, have shown some measure of toxicity including hyperglycemia, anemia, and 
thrombocytopenia indicating that even inhibitors specific to the IGF-IR may perturb 
insulin signaling.160 Results of current clinical trials will help to elucidate the 
effectiveness of these molecules in promoting cancer survival and disease remission. In 
the current study we used ApcMin/+ mice with targeted disruption of one IRS-1 allele and 
treatment with an EGFR inhibitor to explore the in vivo effects of combined loss of 
function of IGF signaling and EGFR signaling on spontaneous intestinal tumorigenesis.  
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O. Hypothesis Tested 
I. Homozygous deletion of SOCS2 limits intestinal tumorigenesis in the 
intestine of ApcMin/+ mice. Studies testing this hypothesis are described in 
the chapter II. 
II. Increased intestinal tumorigenesis in SOCS2-/-/ApcMin/+ mice is due to 
increased IGF-I signaling and STAT activation. Studies testing this 
hypothesis are described in Chapter II. 
III. Combined IGF-I and EGF activation synergistically promotes increased 
proliferation by enhancing IGF-IR activation and additive activation of β-
catenin. Studies testing this hypothesis are described in Chapter III. 
IV. Combined heterozygous deletion of IRS-1 and pharmacological inhibition 
of EGFR in ApcMin/+ mice will additively or synergistically reduce 
intestinal tumor development. Studies testing this hypothesis are described 
in Chapter IV. 
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Figure 1.1. Structure of the Intestine. A. Illustration of the structure of the Intestine. B. 
Crypt-Villus axis in the small intestine (left) and crypt-surface axis in the colon (right).  
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Figure 1.2. Diagram comparing progression sporadic and inflammation-Associated 
Colorectal Cancer. Adapted from 31. Sporadic colon cancer progression (white). 
Inflammation-associated colorectal cancer (grey). MSI = microsatellite instability; LOI = 
Loss of Imprinting; DCC=deletion in colon cancer, loss of function of chromosome 
region 18q. 
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Figure 1.3. Illustration of the Wnt/β-catenin signaling pathway. (Left) In the absence 
of Wnt ligand or other activating factors, β-catenin is phosphorylated and degraded. 
(Right) In the presence of Wnt ligand, truncating mutations in Apc (tr Apc) or other 
factors, β-catenin is stabilized and translocates into the nucleus where it mediates gene 
transcription. 
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Figure 1.4. Schematic of the IGF-I/Insulin Family of ligands and receptors and 
effects of IRS downstream signaling. 
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Figure 1.5. Role of IGF-I family in the Progression of Colorectal Cancer. Adapted 
from “Fearon and Vogelstein model” of colon carcinogenenesis. 
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Figure 1.6. Pleiotrophic effects of SOCS to limit receptor signaling. A. Direct 
inhibition of JAKs. B. Binding to cytokine receptor and inhibiting JAKs. C. 
Competitively inhibiting STAT binding to cytokine receptors. D. Ubiquitination and 
proteasomal degradation. Adapted from 80. 
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Figure 1.7. SOCS2 is a negative regulator of GHR and IGF-IR signaling pathways. 
Left, SOCS2 negatively regulates GH signaling to inhibit cellular effects. Right, SOCS2 
binds to and inhibits IGF-IR signaling to limit growth-promoting effects. Adapted from 
80. 
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Figure 1.8. EGF Receptor Family: Ligand and Receptor Binding. 
TGFα=Transforming growth factor α; Amph = Amphiregulin; NRG = neuregulin. X 
indicates unable to bind ligand or lacks kinase activity. 
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Table 1.1. Summary of SOCS2 methylation and expression in cancer. 
 
Cancer Primary Tissue Expression Citation
Decreased expression
Increased promoter methylation
80% human HCC & cell lines
Correlates with loss of SOCS2 expression
Low-moderate expression
4/6 cell lines methylated
6/42 1° tumors methylated
10/43 LOH
Low expression in some cell lines
8/10 methylated
0/48 methylated
7/53 LOH
Low protein expression
Associated with low proliferation and high 
differentiation
High expression correlates with  increased survival
Independent predictor of good prognosis
Downregulated/low mRNA expression
No methylation
BCR/Ab1 increases SOCS2 expression
Downregulated by BCR/Abl inhibitors
CD34+ cells Overexpressed Zhang… 2006
Highly expressed in CML cell lines
SOCS2 overexpression reduced cell growth
Sensitizes to cell death
Decreased expression
80% 1° tumors/cell lines show methylation
High methylation Fiegl...2004
1°
1°
HCC
GNMT-KO mice Martinez-
Chantar...2008
1°
Calrisi.. .2006
Breast
Sutherland… 
2004
Farabegoli… 
2005
Haffner…2007
Ovarian
Cell lines
1°
Cell lines
1°
Pulminary 
adenocar-cinoma
1°
Endometrial 1°
Wikman… 2002
Cell lines: Phila-
delphia Chrom+
Häkansson… 
2008
Cell lines/CML
CML
Schultheis… 
2002
CML patients in blast crisis show high expression1°
1° serum
Increased methylation in 2 sites in SOCS2 promoter
Marini…2006
Lie...20081° tumors/cell lines
Melanoma
	   	  
 
 
CHAPTER 2 
SUPPRESSOR OF CYTOKINE SIGNALING-2 GENE DISRUPTION 
PROMOTES APCMIN/+ TUMORIGENESIS AND ACTIVATOR PROTEIN-1 
ACTIVATION 
 
 
 
 
 
 
 
 
Re-printed with permission from the American Society for Investigative Pathology. 
American Journal of Pathology 176(5):2320-32. Copyright ©2010, the American Society 
of Investigative Pathology. All rights reserved 
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A. Introduction 
The SOCS family of proteins consists of SOCS1-8 and CIS (cytokine-inducible 
SH2-containing protein).161 SOCS proteins were initially discovered as negative 
regulators of cytokine signaling via the janus kinase (JAK) and signal transducers and 
activators of transcription (STAT) pathway.161 Activated STATs form homo- and 
heterodimers and later translocate into the nucleus where they mediate gene transcription, 
proliferation, cell-survival and transformation.162 Cytokine receptor-mediated JAK-STAT 
activation induces the expression of SOCS, which inhibit or terminate cytokine signaling 
by inhibiting JAK activation, competing with STATs or other signaling proteins for 
binding sites on cytokine receptors, and by targeting signaling proteins for proteosomal 
degradation.161 
 SOCS2 has been found to exert negative feedback effects on growth hormone 
(GH) signaling. SOCS2-/- mice show enhanced body growth that is phenotypically similar 
to GH-transgenic mice and is reversed when GH is genetically inactivated, demonstrating 
a key role of SOCS2 in negatively regulating GH-induced body overgrowth.93 However, 
our recent studies indicate novel effects of SOCS2 deletion in the intestine whereby 
SOCS2-/- mice show enhanced growth promoting effects of IGF-I as well as GH.  
SOCS2-/- mice infused with IGF-I have significantly greater increases in mucosal mass of 
the small bowel compared with WT littermates, establishing a role for SOCS2 in 
regulating the potency of action of IGF-I.75 These studies also show that SOCS2 
deficiency enhances the proliferative and anti-apoptotic actions of IGF-I in the small 
intestine and colon, along with the ability of IGF-I to activate STAT3. Other studies in 
intestinal epithelial or colon cancer cell lines have demonstrated that SOCS2 directly 
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binds to the type I IGF-I receptor and limits its activation by IGF-I.75,95 Disruption of one 
SOCS2 allele in mice expressing a GH-transgene was found to enhance transgene-
induced increases in body weight and mucosal mass, to enhance colon and jejunal crypt 
proliferation, and to promote the formation of hyperplastic and lymphoid polyps in the 
colon.49 Though hyperplastic and lymphoid polyps are generally considered benign, this 
was novel in vivo evidence that SOCS2 may negatively regulate aberrant growth in the 
intestine in a model of GH and IGF-I excess.163 However, the role of SOCS2 in 
development of spontaneous precancerous adenomas in the intestine has not been 
established.  
 Limited evidence in cancers of other organs suggests that the SOCS2 gene may be 
epigenetically silenced by hypermethylation of CpG islands within the 
promoter.164,165,166,167,168 In melanoma patients, SOCS2 has been found to be silenced by 
methylation and its transcription is reduced in primary tumor samples.165 High SOCS2 
expression inversely correlates with tumor grade of breast cancers and favors a good 
prognostic value.169 Another study in breast carcinoma samples showed that SOCS2 
protein expression is positively correlated with low grade tumors.167 While these studies 
in primary human tumors and cancer cell lines suggest a potential role of SOCS2 in 
suppressing tumor growth, this has not been directly evaluated in an in vivo model of 
intestinal cancer. 
 The current study tested whether SOCS2 gene disruption enhances spontaneous 
intestinal tumor formation in ApcMin/+ mice. The ApcMin/+ mouse model is widely used to 
study mediators and mechanisms that govern the initiation, establishment and progression 
of intestinal tumors.34 ApcMin/+ mice are heterozygous for a mutation that results in a 
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truncated form of APC, a gene frequently mutated in human colon cancer that leads to 
aberrant activation of the β-catenin pathway.36 An APC-containing complex normally 
degrades cytoplasmic β-catenin.32 In the absence of APC, β-catenin accumulates in the 
nucleus and coactivates the transcription of proliferative and pro-survival genes in 
conjunction with T-cell factor/lymphoid enhancer factor transcription factors.170 
Depending on the genetic background, ApcMin/+ mice develop tens to hundreds of 
spontaneous adenomas in the small intestine and fewer adenomas in colon, both of which 
typically arise due to focal loss of the remaining wild-type Apc allele.34 We cross-bred 
SOCS2-/- and ApcMin/+ mice to test the hypothesis that disruption of one or both SOCS2 
alleles will increase tumor number or size in ApcMin/+ mice. Studies in our lab have 
shown that ex vivo treatment with IGF-I in the intestine induces STAT3 DNA binding 
activity and this effect is enhanced and prolonged in SOCS2-/- mice.75 Therefore, we 
postulated that loss of SOCS2 could increase activation of STAT3, which is increasingly 
linked to normal growth and tumorigenesis in the intestine.171 STAT3 is activated by 
tyrosine phosphorylation which permits the formation of STAT3 homo- or heterodimers 
with other STATs as well as DNA binding activity. STAT3 is also serine-phosphorylated, 
which has recently been linked to AP-1 activation, cell proliferation, and transformation 
in cancer cell lines.172,173,174 Our studies demonstrate that SOCS2 gene deletion in 
ApcMin/+ mice enhanced serine- but not tyrosine-phosphorylation of STAT3, especially in 
tumors, and this was associated with increased AP-1 but not STAT3 binding activity. 
Together, these findings provide in vivo evidence that SOCS2 deletion promotes ApcMin/+ 
tumorigenesis and this is associated with novel effects on serine phosphorylation of 
STAT3 and AP-1 activation. 
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B.  Materials and methods 
Laboratory animals 
ApcMin/+ male mice on the C57BL/6 background were purchased from Jackson labs (Bar 
Harbor, Maine). C57BL/6 mice with targeted disruption of both SOCS2 alleles were 
developed as previously described and provided by Dr. Christopher Greenhalgh.92 To 
generate SOCS2 knockout mice on the ApcMin/+ background, SOCS2+/- mice were 
crossbred with ApcMin/+ mice, and SOCS2+/-/ApcMin/+ male progeny were bred with 
SOCS2+/- females to generate ApcMin/+ mice with SOCS2-/-, SOCS2+/- or SOCS2+/+ 
genotypes. Genotyping was performed on tail DNA as previously described.49,134 Age-
matched ApcMin/+ males and females with different SOCS2 genotypes were studied for 
number and size of tumors. Our studies emphasized female ApcMin/+ mice because male 
ApcMin/+ mice were primarily used as breeders since female ApcMin/+ mice exhibit 
complications during pregnancy.37 The Institutional Animal Care and Use Committee of 
the University of North Carolina approved all animal studies. Study protocols were in 
compliance with the Guide for the Care and Use of Laboratory Animals published by the 
National Institutes of Health (NIH).175 
 
Sample Preparation, Tumor and Blood Measurements 
At least 6 age-matched mice of each genotype were studied at 13-17 weeks of age. 
Animals were weighed and anesthetized and blood was collected by cardiac puncture. 
The entire colon was dissected.  The small intestine was dissected and separated into 3 
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segments roughly equal in length. Each intestinal segment was flushed with PBS 
supplemented with vanadate (2mM), PMSF (1mM), and phosphatase inhibitor cocktail 
(diluted 1:100, Sigma, P2850). Intestinal segments were splayed open onto 3MM 
Whatmann paper and fixed in 10% zinc-formalin (Fischer, Pittsburgh, PA) overnight at 
4º C, then dehydrated in 70% ethanol. Adenoma number for small and large intestine of 
each animal was counted under a Leica dissecting scope, using an in-lens micrometer to 
measure adenoma diameter. A portion (2-3cm) of proximal ileum was flash frozen for 
RNA isolation. For immunohistochemistry, intestinal segments were rolled into a 
pinwheel, paraffin-embedded, and sectioned at 5mm. Embedding was performed by the 
CGIBD Histology Core Facility. The presence and morphology of adenomas were 
confirmed by hematoxylin and eosin (H&E) staining and by immunohistochemistry for 
b-catenin. Because ApcMin/+ mice develop severe anemia as polyposis progresses, 
hematocrit was measured as an indirect marker of tumor load and disease severity176 and 
was performed by the Animal Clinical Chemistry core facility at UNC. 
 
Immunohistochemistry 
De-waxed and rehydrated sections underwent epitope retrieval in Reveal Decloaker 
(Biocare Medical, Concord, CA) and endogenous peroxidase activity was blocked with 
3% H2O2. Sections were incubated in normal blocking serum either from a Vectastain 
ABC kit (Vector laboratories, Burlingame, CA) for rabbit antibodies or from a MOM kit 
(BD Transduction laboratories, Franklin Lakes, NJ) for mouse antibodies. Sections were 
incubated overnight with mouse monoclonal antibody to β-catenin (BD Transduction 
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Laboratories, Franklin Lakes, NJ), rabbit anti-pS727-STAT3 (Cell Signaling, Beverly, 
MA), or rabbit anti-STAT3 (Cell Signaling, Beverly, MA). Bound antibody was detected 
with a Vector Elite kit or biotinylated anti-mouse IgG (Vector laboratories, Burlingame, 
CA), followed by DAB substrate. Tissues were counterstained with hematoxylin. Primary 
antibody was omitted as a negative control. Sections from both SOCS2+/+/ApcMin/+ and 
SOCS2-/-/ApcMin/+ mice were stained on the same slide and all slides for a particular 
antibody were stained in the same batch. Sections were examined on a Zeiss Axio imager 
A.1. and photographs taken using AxioCam MRc5 and associated AxioVision software 
(v4.6). Comparisons were made between sections from pairs of SOCS2+/+/ApcMin/+ and 
SOCS2-/-/ApcMin/+ mice mounted on the same slide. Brightness and contrast of 
photographs was selected to maximize the clarity for publication. 
 
Plasma IGF-I Assay 
Plasma IGF-I was measured by ELISA. ELISA was performed by the CGIBD 
immunotechnologies core at UNC-Chapel Hill on plasma that was acid-ethanol extracted 
and cryoprecipitated to remove IGF-I binding proteins (IGFBPs) as previously 
described.177,49 ELISA used a Mouse IGF-I Quantikine kit (R&D Systems, Minneapolis, 
MN) according to maufacturer’s protocols, except that samples were diluted 1:500. 
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Quantitative RT-PCR 
 Total RNA was extracted from frozen ileum from at least 5 mice per genotype 
using TRIzol reagents and standard methods (Invitrogen, Carlsbad, CA). Concentration 
was determined by nanodrop (Thermo Scientific, Willmington, DE). Aliquots of each 
RNA sample were run on a 1% agarose gel to verify RNA integrity and concentration. 
RNA (4 µg) was DNAse-treated using the TURBO DNA-free Kit (Ambion, Foster 
City, CA) and transcribed into cDNA with AMV-Reverse Transcriptase (Promega, 
Madison, WI). A no-RT control was also generated for each sample. 
 To quantify IGF-I mRNA, a SYBR-green-based real-time PCR (SYBR® Green 
JumpStart Taq ReadyMix, Sigma, St. Louis, MO) was used with the following primers: 
mIGF-I (F: 5’-GTG TGG ACC GAG GGG CTT TTA CTT C-3’; R: 5’-GCT TCA GTG 
GGG CAC AGT ACA TCT C-3’). To measure c-Fos and c-Jun mRNA, Taqman Gene 
Expression Assays (Applied Biosystems, Foster City, CA) were used according to 
manufacturer’s protocol (c-Fos, Mm_00487425_m1; c-Jun, Mm_00495062_s1). Mouse 
HMBS (hydroxymethylbilane synthase) mRNA was also quantified as an invariant 
control using mouse SYBR green primers (F: 5’-TGT GTT GCA CGA TCC TGA AAC-
3’; R: 5’-CTC CTT CCA GGT GCC TCA GAA-3’) or Taqman Assay 
(Mm_01143545_m1). A standard curve was generated from dilutions (1x107–1x103 
copies/µL) of a PCR product using conditions optimized for each primer or primer-probe 
set. DNA sequencing was performed by the UNC-CH genomic analysis facility to 
confirm correct sequence of PCR product. A no-template control was included in each 
run as a negative control as well as a standard to normalize the standard curve across 
runs. A cDNA pool generated from intestine and liver RNA from multiple mice was 
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added to each run to control inter-run variability. A melt was performed after each run to 
confirm that a single product was generated. Reactions were run on the Rotor-Gene 2000 
(Corbett Research, Sydney, Australia) and analyzed with Rotor-Gene Software 6.0.14. 
Data for each sample were calculated as absolute copy number based on comparison of 
test sample data with standard curve and normalized to HMBS.  
 
Nuclear Extracts and Immunoblotting 
 In a subset of SOCS2+/+/ApcMin/+ and SOCS2-/-/ApcMin/+ mice, tumors were finely 
dissected under a dissecting scope from the middle third of the small intestine (~12cm in 
length) and tissue was immediately used for extraction of nuclear proteins. Size-matched 
biopsies of grossly normal, tumor-free intestinal mucosa were also dissected for 
comparison. Tumor or non-tumor samples were homogenized using a dounce 
homogenizer in 1mL of ice-cold 1X Tris-buffered saline supplemented with vanadate 
(2mM) and PMSF (1mM). Nuclear proteins were extracted as previously described.178 
Concentration was determined by Bradford Assay using Coomasie Plus reagent (Pierce 
Chemicals, Rockford, IL) and confirmed by examining samples on an SDS-PAGE gel 
using the NuPAGE gel system (Invitrogen, Carlsbad CA). Gels were visualized and 
analyzed using the LI-COR Odyssey Infrared Imaging System v3.0 (LI-COR 
Biosciences, Lincoln, NE).  
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Western Immunoblotting 
Equal amounts of protein (30µg) were size fractionated on 4-12% TEO-CI SDS-
PAGE gel (PAGEgel, Fischer Scientific, Pittsburgh, PA) and transferred onto a 
nitrocellulose membrane (Biorad, Hercules, CA) using a NuPAGE gel system 
(Invitrogen, Carslbad, CA). After blocking in Blocker™ Casein in PBS (Pierce, 
Rockford, IL), blots were incubated with primary antibodies against phospho-serine727 
STAT3 (Cell Signaling, Beverly, MA), phospho-tyrosine705 STAT3 (Cell Signaling, 
Beverly, MA), total STAT3 (Santa Cruz Biotechnology Santa Cruz, CA) or Histone H1 
(Santa Cruz Biotechnology, Santa Cruz, CA) for 16 hours at 4°C. Blots were washed in 
PBS containing 0.1% Tween and incubated with secondary antibodies conjugated to 
Dylight800 for ~1 hour at room temperature. Immunoreactive proteins were visualized 
and analyzed using the LI-COR Odyssey Infrared Imaging system. Densitometry was 
performed on visualized bands and normalized to the total protein gel. 
 
Electromobility Shift and Supershift Assays 
 DNA:Protein binding reactions were carried out in 20µl total volume containing 
100 mM NaCl, binding buffer (20% glycerol, 1 mM MgCl2, 1 mM EDTA, 0.5 mM DTT, 
0.2 ng poly dI:dC), 20-30µg nuclear protein extract and 100,000–400,000 cpm of a 32P-
labeled double-stranded oligomer corresponding to a consensus STAT3 binding site 
(STAT3-RE; Santa Cruz Biotechnology, Santa Cruz, CA) or consensus AP-1 binding site 
(AP-1-RE; Promega, Madison, WI). Binding was performed at room temperature for 20 
min. For cold competition, an excess of unlabeled oligomer that was specific to either 
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AP-1 or STAT3, or unrelated oligomer specific to the TCF DNA response element 
(Integrated DNA Technologies Inc, Coralville, IA; S: 5’- GGT AAG ATC AAA GGG 
3’).179 Samples were then loaded onto non-denaturing 4% polyacrylamide gels and 
electrophoresed in 0.5 × TBE (1X = 89 mM Tris borate pH 8.0, 2 mM EDTA) for 2–3 h. 
After electrophoresis, gels were dried on 3MM Whatmann paper and exposed to 
phospho-imager screens. Screens were viewed on the Typhoon 6400 scanner (GE 
Healthcare, Piscataway, NJ). Intensity of shifted DNA:STAT3 and DNA:AP-1 
complexes was quantified using Image-Quant Software v1.2. and expressed as a 
percentage of values in non-tumor samples for SOCS2+/+/ApcMin/+  mice, which was set 
as 100%. 
 Supershift assays were performed to establish the composition of AP-1 binding 
activity according to previously published methods.178 Antibodies used for supershift 
assays were obtained from Santa Cruz Biotechnologies (Santa Cruz, CA). Each supershift 
reaction included equal amounts of nuclear extract and 6µg of one of the following 
antibodies: rabbit antibodies specific for c-Jun, JunD, or c-Fos or mouse antibody specific 
for phospho-c-Jun (p-c-Jun, phosphorylated at serine 63). Nuclear extracts were 
incubated for 30 minutes at room temperature followed by the addition of γ32P-labeled 
AP-1 oligomer and further incubated for 20 minutes. Samples were analyzed on 4% non-
denaturing polyacrylamide gels as described above for EMSA. Intensities of super-
shifted complexes were quantified using ImageQuant Software v1.2.  
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SOCS2 overexpression in IEC-6 cells 
 IEC-6 cells infected with SOCS2-expressing adenovirus or empty virus were used 
as a simple in vitro system to confirm in vivo findings that SOCS2 impacts on AP-1 
binding activity. IEC-6 cells are a non-transformed intestinal epithelial cell line 
previously shown to exhibit robust AP-1 activation in response to combined IGF-I and 
EGF.123 IEC-6 cells at 80% confluence were infected with either FLAG-tagged SOCS2 
(Ad-SOCS2) or empty control adenovirus (Ad-Empty) in 10 cm2 dishes as previously 
described.75 Briefly, growth medium+FBS was removed and serum-free medium (SFM) 
containing the appropriate virus at a multiplicity of 100 viral particles/cell was added. 
Twenty-four hours after infection, fresh SFM or SFM plus rhIGF-I (20ng/mL, Genetech, 
San Francisco, CA) and rhEGF (5ng/mL, Sigma, St. Louis, MO) was added for 0, 15, and 
30 minutes. Cells were scraped and nuclear extracts prepared as described above. AP-1 
binding activity was assessed by EMSA and super-shift as described above. Data were 
quantified as a percentage of the values in Ad-Empty infected cells in SFM alone. 
 
Statistical analyses 
Values for average adenoma number, size, and tumor load and hematocrit were expressed 
as mean ± SEM. Analysis of variance (ANOVA) was used to compare data derived from 
ApcMin/+ mice with SOCS2+/+, SOCS2+/-, or SOCS2-/- genotypes to determine if there was 
a significant effect of SOCS2 deletion. Plasma IGF-I and IGF-I, c-Jun, and c-Fos mRNA 
data were compared between SOCS2+/+/ApcMin/+ and SOCS2-/-/ApcMin/+ mice by student’s 
t-test. Densitometry data for STAT3 and AP-1 DNA binding in tumor versus non-tumor 
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tissue of SOCS2+/+/ApcMin/+ and SOCS2-/-/ApcMin/+ mice were analyzed by ANOVA. Pair-
wise comparisons were performed using Fischer’s Exact test. Densitometry on AP-1 
DNA binding in in vitro studies were compared between Ad-SOCS2 and Ad-Empty 
infected cells using student’s t-test. Statistical tests were performed using Statview 4.1.  
 
C. Results 
Disruption of both SOCS2 alleles modestly affects body weight 
 SOCS2-/- mice have a body overgrowth phenotype.93 We determined whether 
SOCS2-/- mice retained this phenotype when crossbred onto the ApcMin/+ line. 
SOCS2+/+/ApcMin/+ mice had a final body weight of 21.4±0.4 g at sacrifice. Loss of one 
SOCS2 allele had no significant effect on body weight (21.8±0.3 g). However, SOCS2-/-
/ApcMin/+ mice had body weights of 27.8±2.6 g, representing a significant 29.6% increase 
in final body weight (p<0.05).  
 
SOCS2 gene disruption dramatically increases ApcMin/+ tumorigenesis 
Small Intestine 
 Figure 2.1A shows representative images of tumors in small intestine of ApcMin/+ 
mice with SOCS2+/+, SOCS2+/- or SOCS2-/- genotypes. Quantitative data for tumor 
number, size or total tumor burden (number x size) are shown in Figure 1 for the entire 
small intestine (Figure 2.1B) or different regions of small intestine (Figure 2.1C). 
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Compared with SOCS2+/+/ApcMin/+ mice, SOCS2-/-/ApcMin/+ mice showed significant and 
dramatic increases in total tumor number and tumor size, together representing a 441% 
increase in overall tumor burden in the small intestine. ApcMin/+ mice with disruption of 
one SOCS2 allele showed an intermediate phenotype with a significant increase in tumor 
number and tumor size (Figure 2.1B). This suggests that SOCS2 has a gene-dosage effect 
on ApcMin/+ tumorigenesis. Examination of different regions of the small intestine 
revealed that SOCS2-/-/ApcMin/+ mice showed significant increases in tumor number, size, 
and load in all segments (Figure 2.1C). While a trend for increased tumor number and 
size was observed in all small bowel regions of SOCS2+/-/ApcMin/+ mice, this was 
statistically significant only for tumor number in the most distal small bowel segment.  
 
Colon 
 SOCS2 gene disruption in ApcMin/+ mice also had a dramatic effect on tumor 
number and size in colon. By 13-17 weeks of age, 100% of SOCS2-/-/ApcMin/+ mice (6/6) 
and 71% of SOCS2+/-/ApcMin/+  (5/7) mice had at least one colon tumor, whereas only one 
of six SOCS2+/+/ApcMin/+ mice studied (17%) had an observable colon tumor. Figure 2.2A 
shows representative images of colon tumors and Figure 2.2B shows quantitative data for 
tumor number and size. These analyses revealed significant increases in tumor number, 
size, and burden in colon of SOCS2-/-/ApcMin/+ mice compared with SOCS2+/+/ApcMin/+. 
As was seen with the small intestine, SOCS2+/-/ApcMin/+ showed an intermediate 
phenotype. 
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We used hematocrit as an indirect measure of tumor burden. Consistent with 
increases in tumor burden, we found that SOCS2+/+/ApcMin/+ mice had hematocrit within 
normal range (34.2±5.9%), SOCS2-/-/ApcMin/+ mice had significant reductions in 
hematocrit (22.4±5.3%, p<0.05), and SOCS2+/-/ApcMin/+ mice had an intermediate 
hematocrit (29.5±7.7%). Further studies compared SOCS2+/+/ApcMin/+ and SOCS2-/-
/ApcMin/+ mice, in which the most dramatic changes in tumor number and size were 
observed. 
 
β-catenin immuno-staining 
 Tumor development in ApcMin/+ mice is driven by focal loss of heterozygosity of 
the Apc gene.34 This leads to translocation of β-catenin from the lateral membranes of the 
epithelium to the nucleus where it promotes gene transcription. In the normal small 
intestine of both SOCS2+/+/ApcMin/+ and SOCS2-/-/ApcMin/+ mice, β-catenin was detected 
at the lateral and basement membranes of epithelial cells along the villi and in cell 
membranes and some nuclei in the crypts (Figure 2.3A). Adenomas in the small intestine 
of both SOCS2+/+/ApcMin/+ and SOCS2-/-/ApcMin/+mice showed positive nuclear and 
cytoplasmic staining for β-catenin in epithelial-like cells of adenomas, but no obvious 
differences in staining intensity or nuclear localization were observed (Figure 2.3B). 
Colon adenomas in SOC2-/-/ApcMin/+ mice were positive for nuclear and cytoplasmic β-
catenin, indicating activated β-catenin signaling (Figure 2.3C). Since so few 
SOCS2+/+/ApcMin/+mice develop colon tumors, β-catenin was not analyzed. The data 
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confirm that increased nuclear β-catenin occurs in adenomas of both SOCS2+/+/ApcMin/+ 
and SOCS2-/-/ApcMin/+ mice but provide no evidence that loss of SOCS2 enhances nuclear 
β-catenin accumulation. 
 
SOCS2-/-/ApcMin/+ mice show increased IGF-I expression in the small intestine, but 
no elevation in plasma IGF-I 
 We used real-time PCR to assess if the enhanced tumorigenesis in small intestine 
of SOCS2-/-/ApcMin/+ mice was associated with increases in local IGF-I mRNA. Figure 
2.4A shows that compared to the liver, which is the major target of GH-induced IGF-I 
expression, the small intestine expresses relatively low amounts of IGF-I mRNA. As 
shown in Figure 2.4B, SOCS-/-/ApcMin/+ mice had small but statistically significant 1.5 
fold increases in IGF-I mRNA in the ileum. In contrast, plasma IGF-I levels did not differ 
significantly in SOCS2+/+/ApcMin/+and SOCS2+/+/ApcMin/+ mice (Figure 2.4C). These data 
indicate that disruption of both SOCS2 alleles in ApcMin/+ mice promotes increased local 
intestinal IGF-I expression, without affecting circulating IGF-I. 
 
 
SOCS2 gene disruption promotes serine-phosphorylation but not tyrosine 
phosphorylation of STAT3 in ApcMin/+ mice.  
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 In normal intestine, SOCS2 gene disruption has previously been linked to 
enhanced IGF-I-induced STAT3 DNA binding activity.75 Therefore, we examined 
whether grossly normal mucosa (non-tumor) or dissected tumors of SOCS2+/+/ApcMin/+ 
or SOCS2-/-/ApcMin/+ mice showed altered levels of nuclear tyrosine-phosphorylated 
STAT3 (pY705), which is integral to STAT3 DNA binding activity, and compared this 
with levels of serine-phosphorylated STAT3 (pS727). Surprisingly, levels of pY705-
STAT3 did not differ in tumors or non-tumor tissue from SOCS2-/-/ApcMin/+ versus 
SOCS2+/+/ApcMin/+ mice (Figure 2.5). However, the immuno-reactive pY705-STAT3 in 
SOCS2-/-/ApcMin/+ tumors was an obvious doublet, most likely due to concurrent serine-
phosphorylation. Western immunoblot of the same samples revealed that pS727-STAT3 
was upregulated in non-tumor tissue from SOCS2-/-/ApcMin/+ mice and especially tumors 
of SOCS2-/-/ApcMin/+ mice, showing an overall 2.5±0.45 fold increase in pS727-STAT3 
(p<0.05) (Figure 2.5). When analyzed across multiple blots, total STAT3 did not 
significantly differ in tumor and non-tumor tissues between SOCS2+/+/ApcMin/+ and 
SOCS2-/-/ApcMin/+ mice (Figure 2.5). 
 To confirm increased serine phosphorylation of STAT3 in the tumors of SOCS2-/-
/ApcMin/+ mice, we performed immunohistochemistry on small intestine and colon. In 
SOCS2+/+/ApcMin/+ mice, pS727-STAT3 immunoreactivity was barely detectable except 
at the base of the crypts (Figure 2.6A). Immunostaining revealed dramatic increases in 
pS727-STAT3 in the nucleus and cytoplasm of crypt and villus epithelial cells in the 
normal small intestine of SOCS2-/-/ApcMin/+ mice (Figure 2.6A). Serine-phosphorylated-
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STAT3 was detectable in the adenomas of SOCS2+/+/ApcMin/+ mice. However, small 
intestine adenomas of SOCS2-/-/ApcMin/+ mice showed dramatic increases in pS727-
STAT3 in the cytoplasm and nucleus (Figure 2.6B). Intense staining of pS727-STAT3 
was also detected in colon adenomas from SOCS2-/-/ApcMin/+ (Figure 2.6C). We also 
examined total STAT3 by immunohistochemistry and detected strong staining throughout 
the epithelium in the normal intestine that did not differ between SOCS2+/+/ApcMin/+ and 
SOCS2-/-/ApcMin/+ (Figure 2.6D). Compared to non-tumor tissue, tumors from both 
SOCS2+/+/ApcMin/+ and SOCS2-/-/ApcMin/+ mice showed stronger cytosolic and nuclear 
STAT3 immunostaining but, in contrast to pS727-STAT3 immunostaining, there was no 
dramatic difference in total STAT3 in SOCS2-/-/ApcMin/+ versus SOCS2+/+/ApcMin/+ 
tumors (Figures 2.6E and F). These studies suggest that deletion of SOCS2 genes 
promotes serine-727 phosphorylation of STAT3 in intestinal epithelium and that this is 
further enhanced in small intestine and colon tumors. 
 
SOCS2 deficiency enhances AP-1 but not STAT3 DNA binding. 
 Since serine phosphorylation of STAT3 was increased in the tumors of SOCS2-/-
/ApcMin/+ mice, we tested whether this was associated with changes in STAT3 DNA 
binding activity. STAT3 DNA binding activity was evaluated in nuclear extracts from 
pooled tumors and matched biopsies of grossly normal intestine from SOCS2+/+/ApcMin/+ 
and SOCS2-/-/ApcMin/+ mice. As shown in Figure 2.7A, tumor or non-tumor samples from 
SOCS2+/+ and SOCS2-/- carrying the ApcMin/+ mutation had multiple STAT3 DNA 
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binding complexes. Tumors from both SOCS2+/+/ApcMin/+ and SOCS2-/-/ApcMin/+ mice 
showed a trend for increased STAT3 DNA binding activity relative to non-tumor tissue, 
but this achieved statistical significance only when comparing tumor and non-tumor 
tissues of SOCS2-/-/ApcMin/+ mice (Figure 2.7B). Surprisingly, however, there was no 
difference in STAT3 DNA binding activity in tumor or non-tumor tissues of SOCS2-/-
/ApcMin/+ mice compared with SOCS2+/+/ApcMin/+ mice (Figure 2.7B). Thus, loss of 
SOCS2 did not significantly increase overall STAT3 binding activity as might have been 
expected.  
 Because phosphorylation of serine 727 of STAT3 has been linked to AP-1 
activation in tumor cell lines, we analyzed whether SOCS2 deletion affected nuclear AP-
1 DNA binding. This revealed enhanced AP-1 binding activity in non-tumor and 
particularly tumor tissue of SOCS2-/-/ApcMin/+ compared to SOCS+/+/ApcMin/+ (Figure 
2.8A). The results of three independent experiments were quantified using densitometric 
volume analysis and demonstrated significant increases in AP-1 DNA binding activity in 
the tumors of the SOC2-/-/ApcMin/+ mice compared to both tumor and non-tumor tissue 
from SOCS2+/+/ApcMin/+ mice (Figure 2.8B).  
 To verify specificity of enhanced AP-1 DNA binding activity in SOCS2-/-
/ApcMin/+ mice, we performed supershift analysis for c-Jun, JunD, phosphorylated c-Jun 
and c-Fos, as well as competition with unlabeled AP-1 oligomer versus an unrelated 
oligomer (TCF consensus sequence). As shown in figure 2.8C, AP-1 DNA binding 
complexes in tumors from SOCS2-/-/ApcMin/+ mice showed supershifted complexes with 
JunD, p-c-Jun, and c-Jun antibodies and showed specific competition with AP-1, but not 
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TCF oligomers. Antibodies to c-Fos did not elicit a supershifted complex or major shift-
inhibition (i.e. reduction in intensity of DNA:protein complex). Thus, the enhanced AP-1 
DNA binding activity in tumors from SOCS2-/-/ApcMin/+ mice contains primarily p-c-Jun, 
JunD and c-Jun. Supershifted complexes were lower in intensity in non-tumor samples, 
yet qualitatively similar in composition (Figure 2.10). 
 To assess if the enhanced AP-1 DNA binding activity reflected increased 
expression of c-Jun or c-Fos, we quantified mRNA using quantitative real-time PCR. 
This revealed no significant difference in c-Fos or c-Jun between SOCS2-/-/ApcMin/+ (c-
Fos, 1.20 ± 0.45 ; c-Jun, 1.09 ± 0.10) versus SOCS2+/+/ApcMin/+ (c-Fos, 1.0 ± 0.3; c-Jun 
1.0 ± 0.1). 
 
SOCS2 overexpression reduced AP-1 DNA binding in IEC-6 cells 
 Previous studies from our lab have demonstrated that IGF-I and EGF act 
synergistically to promote proliferation of IEC-6 cells and induce AP-1 transcriptional 
activity greater than either alone.123 We therefore used this in vitro system to directly test 
if SOCS2 affects AP-1. As shown in Figure 2.9, IGF and EGF induced AP-1 binding 
activity in IEC-6 cells and SOCS2 overexpression significantly attenuated growth factor-
induced AP-1 DNA binding (Figure 2.9A-B). This complements the in vivo data in 
SOCS2-/-/ApcMin/+ mice, providing additional evidence that SOCS2 affects AP-1 
transcriptional activity in intestinal epithelial cells. Super-shift analysis demonstrated that 
the AP-1 complex in untreated or IGF/EGF treated IEC-6 cells contained c-Jun, JunD, 
and p-c-Jun, as observed in SOCS2-/-/ApcMin/+ tumors. Growth factor treatment increased 
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the intensity of p-c-Jun supershifted complex (Figure 2.9C). Super-shifted complexes 
were uniformly lower in intensity in SOCS2 overexpressing cells (Figure 2.9C) but the 
relative percentage of AP-1 binding represented by JunD, phosphorylated c-Jun and c-Jun 
was similar between empty vector and SOCS2 overexpressing cells (Figure 2.9C). This 
indicates that SOCS2 down-regulates all Jun isoforms within AP-1 DNA binding 
complexes to an approximately similar extent. 
 
D. Discussion  
Our studies show that disruption of both SOCS2 alleles in ApcMin/+ mice 
dramatically increases tumor number and tumor size in the small intestine and colon. We 
found this to be associated with increased local intestinal IGF-I expression. Serine 
phosphorylation of STAT3 was increased in the tumors of SOCS2-/-/ApcMin/+mice and, to 
a lesser extent, in grossly normal intestine of SOCS2-/-/ApcMin/+mice. Neither tyrosine 
phosphorylation of STAT3 nor STAT3 DNA binding activity was enhanced by SOCS2 
gene deletion. The pro-tumorigenic effects of SOCS2 gene disruption were, however, 
associated with enhanced AP-1 DNA binding activity in the tumors of SOCS2-/-/ApcMin/+ 
mice, where the AP-1 complex contained c-Jun, phosphorylated c-Jun, and JunD. 
Overexpression of SOCS2 in IEC-6 cells reduced AP-1 DNA binding, with 
approximately equal reduction in c-Jun, phosphorylated c-Jun, and JunD. 
The increases in tumor number in SOCS2-/-/ApcMin/+ mice occurred across all 
regions of the small intestine, with maximal effects in the most distal regions. Effects of 
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SOCS2 deletion on tumor size were less dramatic, but represent a significant finding 
since most modifiers of ApcMin/+ tumorigenesis alter tumor number, but not size.180 Our 
findings, therefore, suggest that loss of SOCS2 impacts the rate of tumor growth as well 
as the number of initiated tumors or their survival. This is strongly supported by data in 
the colon of SOCS2-/-/ApcMin/+mice. Very few SOCS2+/+/ApcMin/+mice developed colon 
tumors at the time studied. In contrast, 100% of SOCS2-/-/ApcMin/+mice and 71% of 
SOCS2+/-/ApcMin/+mice developed colon tumors by 13-17 weeks, and tumor size was 
increased in colon as observed in small intestine. The current findings in the ApcMin/+ 
model are consistent with our prior findings that loss of one SOCS2 allele in GH-
transgenic mice promotes benign colon polyps.49 However, to our knowledge, this current 
study is the first to demonstrate that deletion of one or both SOCS2 alleles promotes 
spontaneous pre-cancerous lesions that are driven by aberrant β-catenin activation, a 
pathway that is disregulated in many human intestinal tumors. This suggests that 
epigenetic SOCS2 silencing may be relevant to colon cancer risk in humans. 
 A number of studies have shown that SOCS2 genes are epigenetically inactivated 
by hypermethylation of CpG islands within the promoter region of biopsies of primary 
human tumors or cancer cell lines from a number of organs, including prostate, 
melanoma, breast, ovary, and endometrium and this correlates with reduced SOCS2 
expression.165,164,167,166,168 Other SOCS genes, including SOCS1 and SOCS3, have also 
been shown to be hypermethylated in Barrett’s adenocarcinoma.104 SOCS1 is 
hypermethylated in breast cancer biopsies and in glioblastoma cells.181,182 SOCS3 is also 
methylated in glioblastoma cells and hypermethylation of SOCS3 is associated with 
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unfavorable clinical outcome.181 However, relatively few studies have shown a functional 
role for SOCS in tumor development or growth in vivo. Mice with SOCS3 deleted 
specifically in liver parenchymal cells exhibited increased tumor development when 
treated with the carcinogen diethylnitrosamine.183 Deletion of SOCS3 specifically in 
intestinal epithelial cells (IEC) led to greater tumor load in the azoxymethane/dextran 
sodium sulfate (AOM/DSS) mouse model of inflammation-induced colon cancer.113 This 
indicates a role for SOCS3 in normally limiting inflammation-associated colon cancer. 
Our current data in SOCS2-/-/ApcMin/+mice indicate that endogenous SOCS2 normally 
limits the development of tumors that derive from disregulated β-catenin, a pathway that 
is integral to the development of many human colon cancers. To date, the relative roles of 
SOCS2 compared with SOCS1 or SOCS3 in tumor development have not been formally 
compared in the same animal model of intestinal tumorigenesis. In this regard, 
preliminary findings in the AOM/DSS model provided no evidence that SOCS2 gene 
disruption affects tumor number or load (SOCS2+/+ = 2.2 ± 0.6, SOCS2-/- = 2.9 ± 0.4; 
n=5) in this model of inflammation-associated colon cancer. While more study is needed, 
this would suggest that SOCS2 and SOCS3 should be compared as potentially useful 
biomarkers of the risk of human colon tumors driven by two distinct and major initiating 
factors, activation of β-catenin versus inflammation. 
 Our findings suggest some novel regulatory mechanisms by which SOCS2 
deletion may promote ApcMin/+-mediated intestinal tumorigenesis. We initially assessed 
local IGF-I because SOCS2 gene deletion was shown to increase local IGF-I gene 
expression in some tissues and to increase GH-stimulated, local IGF-I expression in the 
intestine.49,75,92 Our findings demonstrate a modest upregulation of local IGF-I expression 
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in SOCS2-/-/ApcMin/+intestine, which may contribute to enhanced tumor load. IGF-I 
signaling has been reported to enhance stability, nuclear localization and transcriptional 
activation of β-catenin.53,54 This is thought to occur through insulin receptor substrate-1 
(IRS-1), which is an immediate downstream mediator of IGF-I receptor signaling.53,54 
However, observations that tumors from SOCS2+/+/ApcMin/+and SOCS2-/-/ApcMin/+mice 
show comparable increases in β-catenin accumulation argue against a major effect of 
SOCS2 deletion or accompanying increases in local IGF-I on β-catenin activation or 
accumulation at least at the stage of tumor development examined. We note that 
increased local IGF-I expression in the intestine of SOCS2-/-/ApcMin/+ was not 
accompanied by an elevation in plasma IGF-I. This is consistent with prior findings in 
SOCS2-/-/ApcMin/+ mice and suggests that SOCS2 gene disruption impacts preferentially 
on local intestinal IGF-I expression rather than circulating IGF-I levels.49,93 
 We examined the STAT3 pathway because of our prior findings that SOCS2-/- 
mice show enhanced IGF-I-induced STAT3 activation in normal intestine.75 STAT3 
activation is frequently associated with colon cancer in a setting of chronic 
inflammation.184,185,186 Recent studies demonstrated that specific STAT3 deleted in 
intestinal epithelial cells reduces tumor multiplicity in ApcMin/+ mice.187 Phosphorylation 
of STAT3 at tyrosine residue 705 is required for dimerization, nuclear translocation and 
DNA binding.173,188 Unexpectedly, we found similar levels of tyrosine-phosphorylated 
STAT3 in normal small intestine tissue and tumors from SOCS2-/-/ApcMin/+compared to 
SOCS2+/+/ApcMin/+mice. Instead, our studies revealed an increase in serine 727-
phosphorylated STAT3 in SOCS2-/-/ApcMin/+ mice. Serine-phosphorylated STAT3 
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localized to epithelial cells in normal intestine and to tumors in SOCS2-/-/ApcMin/+mice. 
The increased pS727-STAT3 in SOCS2-/-/ApcMin/+ compared to SOCS2+/+/ApcMin/+ 
observed by western immunoblot was independently confirmed by 
immunohistochemistry. This is intriguing because a series of recent papers has 
demonstrated upregulation of pS727-STAT3 in mammary gland tumors189 and in a 
number of tumor cell lines including ras-transformed fibroblasts, bladder and lung tumor 
cell lines,174 and medullary thyroid tumor cell lines.172 Studies using prostate cancer cell 
lines have shown that a phosphomimetic mutation of serine727 to a glutamine promoted 
anchorage-independent growth, invasion, and increased tumor number in xenograft 
models.190 These effects were reversed by an un-phosphorylatable STAT3 mutant.190 In 
another study, mutation of serine727 in STAT3 to an alanine decreased post-natal growth 
and survival in mice lacking one functional STAT3 allele.191 This correlated with reduced 
circulating GH and IGF-I.191 Together, these studies provide evidence that serine 
phosphorylation of STAT3 may regulate normal and neoplastic growth. Our current 
findings add novel evidence that loss of SOCS2 preferentially enhances pS727-STAT3 in 
the intestine in vivo and this is associated with dramatically increased intestinal tumor 
development and growth in animals carrying an inactivating Apc mutation. 
 The role of pS727-STAT3 in DNA binding and transcriptional activation of 
STAT3 is not fully defined. Prior studies have linked pS727-STAT3 to reduced tyrosine 
phosphorylation and transcriptional activation of STAT3.192,193 Other reports indicate that 
serine phosphorylation of STAT3 does not impact DNA binding.194 More recent studies 
indicate that there are context-, cytokine- and growth factor-dependent differences in 
serine phosphorylation versus tyrosine phosphorylation of STAT3.195,172,173,196,197 
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Importantly, a recent report in medullary thyroid carcinoma cell lines demonstrated that 
pS727-STAT3 is essential to transcriptional activation of AP-1 DNA binding activity.172 
This is consistent with the current observations that nuclear AP-1 DNA binding activity 
is dramatically upregulated in tumors from SOCS2-/-/ApcMin/+ mice. Our findings that 
SOCS2-/-/ApcMin/+ mice show enhanced AP-1 DNA binding activity, but no detectable 
increase in c-Fos or c-Jun mRNA indicates that loss of SOCS2 promotes activation of 
AP-1 rather than increased synthesis of AP-1 components. Futhermore, supershift data 
indicate that the AP-1 binding complex in SOCS2-/-/ApcMin/+ mice contains primarily c-
Jun, and particularly phosphorylated c-Jun and JunD. These results were complemented 
with in vitro studies in IEC-6 cells, demonstrating that adenoviral overexpression of 
SOCS2 reduced basal and growth factor-stimulated AP-1 DNA binding activity with 
approximately equal inhibitory effects on c-Jun, phosphorylated c-Jun, and JunD. This is 
intriguing since recent studies suggest that Jun proteins are strongly expressed in tumors 
of mice with specific activation of β-catenin in intestinal epithelium.198 Activation of c-
Jun N-terminal kinase (JNK), which mediates c-Jun phosphorylation at serine 63, was 
also shown to activate TCF4/β-catenin gene targets and increase crypt proliferation.199 
These studies provide indirect evidence to support a concept that the enhanced AP-1 
activity observed here in SOCS2-/-/ApcMin/+ may contribute to the increased 
tumorigenesis. Additional studies will be required to fully delineate the mechanisms by 
which loss of SOCS2 expression promotes serine phosphorylation of STAT3 and AP-1 
DNA binding activity, whether these two effects are causally connected, and their 
functional roles in enhanced tumorigenesis in SOCS2-/-/ApcMin/+ mice. However, our 
findings provide novel evidence that SOCS2 normally serves as a suppressor of ApcMin/+ 
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tumorigenesis in intestine and acts on pathways other than tyrosine-phosphorylation of 
STAT3. 
 In summary, the results from our study suggest that SOCS2 gene deletion 
promotes tumor initiation and progression in the ApcMin/+ model of spontaneous 
intestinal cancer driven by β-catenin activation and this is associated with local increases 
in IGF-I, serine phosphorylation of STAT3, and AP-1 activation but not increased 
tyrosine phosphorylation of STAT3. These studies provide novel evidence that SOCS2 
normally limits tumor growth in both the small intestine and colon and suggest that 
reduced expression or epigenetic silencing of SOCS2, and activation of pS727-STAT3 or 
AP-1 may be potential biomarkers for intestinal tumor development and growth in a 
setting of APC mutation or β-catenin activation.  
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Figure 2.1. SOCS2 gene disruption in ApcMin/+ mice increases tumor number and 
size in the small intestine. A. Representative gross images of adenomas in small 
intestine of SOCS2+/+/ApcMin/+, SOCS2+/-/ApcMin/+, and SOCS2-/-/ApcMin/+ mice taken at 
12.3x under a dissecting scope with white light optics underneath the specimen. B. 
Histograms show mean ± SE for tumor number (top), size (middle), and load (number x 
size)(bottom) in entire small intestine. C. Mean ± SE for tumor number, size, and load in 
different regions of the small intestine. SI-1 is the first third of the small intestine that 
contains the duodenum and is most proximal, whereas SI-3 contains the ileum and is 
most distal. a = p < 0.05 vs. SOCS2+/+/ApcMin/+ mice and b = p < 0.05 vs SOCS2+/-
/ApcMin/+. 
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Figure 2.2. SOCS2 gene disruption in ApcMin/+ mice increases tumor number and 
size in the colon. A. Representative gross images of colon adenomas of female 
SOCS2+/+/ApcMin/+, SOCS2+/-/ApcMin/+, and SOCS2-/-/ApcMin/+ mice at 13-17 wks of age 
taken at 12.3x under a dissecting scope. Colon tumors from female mice are shown since 
they demonstrated the greatest increases in tumor size compared to age-matched female 
SOCS2+/+/ApcMin/+. At this time, 17% of age- and sex-matched SOCS2+/+/ApcMin/+mice 
had colon tumors, whereas 71% of SOCS2+/-/ApcMin/+ and 100% of SOCS2-/-
/ApcMin/+mice had tumors. The small lesions visible in SOCS2+/+/ApcMin/+ colon were 
determined to be lymphoid aggregates. B. Histograms show mean ± SE for tumor number 
(top), tumor size (middle), and tumor load (bottom) in colon. a = p<0.05 vs. 
SOCS2+/+/ApcMin/+ mice by ANOVA. 
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Figure 2.3. Tumors of SOCS2+/+/ApcMin/+ and SOCS2-/-/ApcMin/+ mice are positive for 
nuclear β-catenin. Representative histological images of A. grossly normal small 
intestine of SOCS2+/+/ApcMin/+ and SOCS2-/-/ApcMin/+ mice immunostained for β-catenin 
taken at 20X (top) and 40X (bottom). B. β-catenin positive adenomas in the small 
intestine of SOCS2+/+/ApcMin/+ and SOCS2-/-/ApcMin/+ mice at 5X (top) and 40X 
(bottom), C. adenoma in the colon of a SOCS2-/-/ApcMin/+ mouse positive for β-catenin 
immunostaining at 5X (left) and 40X (right). Scale bar indicates 200 µm unless otherwise 
noted. 
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Figure 2.4. Homozygous SOCS2 gene disruption increases local intestinal IGF-I 
expression, but not plasma IGF-I. A-B. Real-time PCR was performed on RNA 
extracted from WT liver and small intestine (ileum) or entire ileum from SOCS2+/+ or 
SOCS2-/- mice carrying the ApcMin/+ mutation. Absolute copy number was calculated 
from Ct values for either IGF-I or HMBS using a standard curve. Histograms show the 
relative expression (mean ± SE) of three runs for IGF-I/HMBS. A. Histogram shows fold 
change of IGF-I expression in the liver relative to the small intestine. n ≥ 3. Note 
expression in the liver is ~45 fold higher compared to the small intestine. a = p < 0.05 vs 
SOCS2+/+/WT. B. Histograms show IGF-I expression in ileal RNA from SOCS2-/-
/ApcMin/+ mice relative to SOCS2+/+/ApcMin/+ mice analyzed in the same run. a = p < 0.05 
versus SOCS2+/+/ApcMin/+. C. ELISA for plasma IGF-I levels (mean ± SE) in 
SOCS2+/+/ApcMin/+ and SOCS2-/-/ApcMin/+ mice. Binding proteins were removed prior to 
detection of IGF-I. Samples were run in duplicate, n > 4. 
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Figure 2.5. Tumors of SOCS2-/-/ApcMin/+ mice show increased serine 
phosphorylation of STAT3. Western blots on nuclear extracts from either normal 
intestine or a pool of tumors from the small intestine of SOCS2+/+/ApcMin/+ or SOCS2-/-
/ApcMin/+ mice. Duplicate blots were immunoblotted for pY705-STAT or pS727-STAT3. 
Blots were then reprobed for H1, a nuclear protein used as a loading control, or total 
STAT3. Shown are reprobes for H1 on the pY705 blot and total STAT3 on the pS727-
blot. Protein stain of nuclear proteins is shown in the bottom panel to demonstrate equal 
loading. A ~86kDa band was detected by both the pY and pS-STAT3 antibodies, 
although a doublet was apparent in the tumor samples with the pY705 antibody, most 
likely due to serine phosphorylation of STAT3. Overall, no difference in pY705-STAT3 
was detected between SOCS2+/+/ApcMin/+ (100 ± 9%) and SOCS2-/-/ApcMin/+(108 ± 10%) 
(values normalized to H1 control). SOCS2-/-/ApcMin/+ mice had a significant increase in 
serine phosphorylation (normalized to total STAT3) compared to SOCS2+/+/ApcMin/+ 
mice (258 ± 45% versus 100 ± 23%, p<0.05). Although total STAT3 appeared elevated 
in tumors of SOCS2-/-/ApcMin/+ on this representative blot, across multiple blots and 
independent samples (n = 5) there was no significant difference in total STAT3 between 
SOCS2+/+/ApcMin/+ and SOCS2-/-/ApcMin/+ mice (tumor: 1.13 ± 0.06 versus 1.15 ± 0.06; 
non-tumor: 1.00 ± 0.05 versus 1.00 ± 0.08). 
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Figure 2.6. Increased pS727-STAT3 but not total STAT3 immunostaining in 
SOCS2-/-/ApcMin/+ mice. Representative images of tissue sections from 
SOCS2+/+/ApcMin/+ and SOCS2-/-/ApcMin/+ mice immunostained for pS727-STAT3 (A-C) 
or total STAT3 (D-F). A-C show immunostaining for pS727-STAT3 in: A. Normal small 
intestine from SOCS2+/+/ApcMin/+ or SOCS2-/-/ApcMin/+ mice at 20X (top) and 40X 
(bottom), B. Small intestine adenoma from SOCS2+/+/ApcMin/+ and SOCS2-/-/ApcMin/+ 
mice at 10X (top) and 40X (bottom), or C. Colon adenoma from SOCS2-/-/ApcMin/+ mouse 
at 5X (top) and 40X (bottom). D-F show immunostaining for total STAT3 in D. Jejunum 
(20X), E. Small intestine adenoma (10X) from SOCS2+/+/ApcMin/+or SOCS2-/-
/ApcMin/+mice, or F. Colon adenoma from SOCS2-/-/ApcMin/+ mouse (5X). Scale bars for 
all images indicate 50 µm unless otherwise noted 
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Figure 2.7. SOCS2 gene disruption does not increase nuclear STAT3 DNA binding 
activity in ApcMin/+ mice. A. Autoradiogram of EMSA for nuclear binding activity to a 
STAT3 DNA binding sequence in either tumors or grossly normal small intestine of 
SOCS2+/+/ApcMin/+ and SOCS-/-/ApcMin/+ mice. cc, inhibition of DNA:protein binding 
complexes by an excess of unlabeled oligomer. Both panels are from the same blot. 
Multiple DNA:protein binding complexes were detected with the STAT3 response 
element. B. Densitometric analysis of STAT3 DNA binding complexes. Results show 
mean ± SE for intensity of DNA:protein complexes from 3 independent experiments 
expressed as a percentage of the SOCS2+/+/ApcMin/+ non-tumor samples. a = p < 0.05 vs 
non-tumor tissue from SOCS2-/-/ApcMin/+ mice. 
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Figure 2.8. SOCS2 gene disruption promotes increased nuclear AP-1 DNA binding 
activity in ApcMin/+ mice. A. Autoradiogram of EMSA for nuclear binding activity to an 
AP-1 DNA binding sequence in either tumors or grossly normal small intestine of 
SOCS2+/+/ApcMin/+ and SOCS2-/-/ApcMin/+ mice. cc, inhibition of shifted complexes by 
an excess of unlabeled oligomer. B. Densitometric analysis of AP-1 DNA Binding 
complex. Results show mean ± SE for intensity of AP-1:DNA binding complexes 
expressed as a percentage of the SOCS2+/+/ApcMin/+ non-tumor samples run on the same 
gel (n = 3 independent experiments). a = p < 0.05 vs SOCS2+/+/ApcMin/+ non-tumor tissue 
and b = p < 0.05 vs SOCS2+/+/ApcMin/+ tumor tissue by ANOVA. C. Autoradiograms of 
supershift asays and cold competition specificity controls on pooled tumors from SOCS-/-
/ApcMin/+ mice. SS, indicates supershift reactions. Triangles indicate super-shifted 
complexes. Left, super-shifted complexes for JunD, p-c-Jun, c-Jun. Middle, image 
intensity was increased to visualize c-Jun super-shifted complex. Right, shows cold 
competition with excess of unlabeled AP-1 oligomer and no inhibition of AP-1 binding 
with an unrelated oligomer corresponding to the TCF binding site. 
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Figure 2.9. Overexpression of SOCS2 reduces nuclear AP-1 DNA binding activity in 
IEC-6 cells. A. Representative autoradiogram of EMSA with radiolabeled AP-1 oligomer 
on nuclear extracts from IEC-6 cells infected with either empty adenovirus (Ad-Empty) 
or adenovirus containing FLAG-tagged SOCS2 (Ad-SOCS2). Cells were treated with 
serum-free medium (SFM) alone (0) or combined rhIGF-I (20ng/mL) and rhEGF 
(5ng/mL) (I + E) for 15 or 30 minutes. cc, cold-competition. S, unlabeled AP-1 oligomer. 
NS, unrelated TCF oligomer. B. Densitometric anlaysis of AP-1 DNA binding complex. 
Results show mean ± SE for intensity of AP-1 DNA binding complex expressed as a 
percentage of the Ad-Empty in SFM alone (n = 3 independent experiments). a = p<0.05 
vs Ad-Empty; b = p<0.05 vs no treatment. C. Autoradiogram of super-shift assays on 
extracts from Ad-Empty or Ad-SOCS2 infected IEC-6 cells treated with SFM (left) or 
IGF-I and EGF for 30 minutes (I + E; right).  Triangles indicate super-shifted complexes 
with JunD, p-c-Jun, and c-Jun antibodies relative to no antibody (no Ab) control. 
Numbers at the bottom indicate the percent JunD, p-c-Jun, or c-Jun in the AP-1:DNA 
protein complex (assessed as intensity super-shifted band/intensity shifted complex in no 
antibody control x 100) in each treatment group. Note that while the intensity of super-
shifted complexes is lower in Ad-SOCS2 vs Ad-Empty cells, the relative proportions of 
JunD, p-c-Jun, or c-Jun in AP-1 complexes are similar. Thus SOCS2 overexpression 
reduces all Jun isoforms within AP-1 complexes. 
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Figure 2.10. Supplemental Figure. Autoradiogram of pooled tumor and non-tumor 
tissue from SOCS2-/-/ApcMin/+ mice showing super-shifted complexes for c- Jun (top) and 
JunD and p-c-Jun (bottom). Pre and post indicate whether antibody was incubated before 
(pre) or after (post) the addition of labeled-oligomer. SS, super-shifted reactions. 
Triangles indicate super-shifted complexes. Note that the shifted and super-shifted 
complexes are reduced in intensity in non-tumor tissue compared to tumor. Relative 
levels of c- Jun, JunD or p-c-Jun (calculated as intensity of super-shifted 
complex/intensity of shifted complex in no Ab control x 100) were approximately equal 
in tumor and non-tumor samples (data not shown). 
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CHAPTER 3 
INSULIN-LIKE GROWTH FACTOR-I (IGF-I) AND EPIDERMAL GROWTH 
FACTOR (EGF) PROMOTE SYNERGISTIC INCREASES IN 
PROLIFERATION, ENHANCES IGF-IR ACTIVATION, AND PROMOTES β-
CATENIN ACTIVATION IN INTESTINAL EPITHELIAL CELLS 
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A. Introduction 
The intestinal epithelium is constantly renewed by proliferation of crypt stem and 
progenitor cells. Many factors including nutrient intake, hormones and growth factors can 
influence the rate of proliferation and apoptosis of the crypt epithelial cells.48 Growth 
factor-stimulated proliferation of normal crypt IEC can have beneficial effects to increase 
the mass of the intestinal epithelium, but may also contribute to tumor development and 
growth. 
 It is well-established that insulin-like growth factor I (IGF-I) and epidermal 
growth factor (EGF) stimulate growth of intestinal epithelium in vivo.125,67,200,201 Previous 
studies have shown that combined treatment of IGF-I and EGF synergistically increases 
proliferation in IEC-6 cells.142,123,143 IEC-6 cells are a non-transformed intestinal 
epithelial cell line that were derived from rat small intestine and retain the characteristics 
of normal intestinal crypt cells.123,202 In these studies, EGF or IGF-I were each shown to 
stimulate DNA synthesis and proliferation, but EGF was more potent than IGF-I. 
Importantly, EGF in combination with IGF-I synergistically increased IEC 
proliferation.142,123 A temporal order to this interaction was identified such that EGF 
pretreatment, followed by IGF-I produced synergistic increases in DNA synthesis and 
proliferation, yet this effect was not seen with IGF-I pretreatment followed by EGF.142,123 
The mechanisms underlying this synergy are not fully characterized. IGF-I and EGF act 
via the type 1 insulin-like growth factor receptor (IGF-IR) or epidermal growth factor 
receptor (EGFR), which are both receptor tyrosine kinases. IGF-IR and EGFR can 
activate common downstream mediators of proliferation and cell survival, including PI-
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3K or MAPK/ERK, although the degree to which these mediators couple to IGF-IR or 
EGFR may depend on cell type or context.203,204,205,126,206 
 Both IGF-I and EGF have been implicated in regulating the Wnt/β-catenin 
pathway. The Wnt/β-catenin pathway is important for the maintenance of the intestinal 
epithelium and aberrant activation of this pathway is key in the progression of colorectal 
cancer.28,27,32 Mutations in this signaling cascade are considered some of the first that 
occur in the transition from normal mucosa to precancerous lesions in colorectal 
cancer.27,34 Normally β-catenin is found at cell-cell junctions in complex with E-cadherin 
and α-catenin.32 In the cytosol, a complex containing Adenomatous Polyposis Coli 
(APC) and glycogen synthase kinase3-β (GSK3β) targets β-catenin for degradation by 
phosphorylating β-catenin at the N-terminus.32,33 In the presence of Wnt ligand or other 
factors, GSK3β is inhibited, thus stabilizing β-catenin and allowing its nuclear 
translocation. In the nucleus, β-catenin binds to TCF/lef transcription factors and this 
transcription complex regulates expression of genes involved in proliferation.170 IGF-I 
has been shown to stabilize β-catenin protein in the cytosol and promote β-catenin 
nuclear translocation in colon and liver cancer cell lines, as well as intestinal smooth 
muscle cells.207,208,209,53,210,211 In some cases, this resulted in increased TCF/lef 
transcriptional activity.54,207,53,211 These effects have been shown to be dependent on 
activation of PI-3K/Akt pathways and MAPK pathways, though it seems PI3-K/Akt 
pathways have more potent effects.207,208,53,210,212 EGF has also been shown to have a role 
in β-catenin activation, whereby in oral cancer and other cell lines EGF treatment 
increases β-catenin protein and induces transcriptional activity.140,213,139,141 EGF disrupts 
E-cadherin and β-catenin at cell-cell junctions, releasing β-catenin into the cytosol, 
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increasing the pool of β-catenin.139,214,215,137,216,217 What is not known is whether IGF-I 
and EGF pathways interact to additively or synergistically promote β-catenin activation 
in normal intestinal epithelial cells. 
Many colon cancer cell lines secrete ligands for EGFR or IGF-IR, which act in an 
autocrine manner on cell proliferation and survival. This is illustrated by the fact that dual 
inhibition of EGFR and IGFR more effectively reduces proliferation and survival of 
colon cancer cells to a greater extent than inhibition of either receptor alone.218 Recent 
studies demonstrate overexpression and co-expression of IGF-IR and EGFR in a large 
proportion of human CRC in situ, and that high IGF-IR expression predicted poor 
prognosis.219 However, mechanisms underlying the functional interaction of EGF and 
IGF-I signaling in normal IEC or CRC are not well defined. 
 This study examined the mechanisms of IGF-I and EGF synergy in IEC-6 cells. 
We hypothesized that EGF alters IGF-I receptor expression or activation to facilitate 
synergistic increases in DNA synthesis and proliferation when subsequently exposed to 
IGF-I. In addition, we also hypothesized that the differential or additive effects of EGF 
and IGF on PI3-K, MAPK or β-catenin contribute to their synergy. We used IEC-6 cells 
because they are non-transformed IECs, which exhibit little to no expression of 
endogenous IGF-I or EGF or other EGF family members, allowing us to specifically test 
the effects of exogenous EGF and IGF-I.123 We found synergistic mitogenic effects of 
EGF and IGF-I involved EGF induction of IGF-IR and required EGF-induced activation 
of both MAPK and PI3K, but IGF-I activation of only PI-3K. Combined IGF-I and EGF 
had additive effects on nuclear β-catenin and β-catenin/TCF transcriptional activation. 
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These finding provide novel evidence that IGF and EGF interact at multiple levels to 
stimulate synergistic proliferative responses of intestinal epithelial cells. 
 
B. Materials and Methods 
Cell Culture and Reagents 
IEC-6 cells were obtained from American Type Culture Collection (CRL 1592) and were 
cultured as previously described.123 Briefly, cells were grown in 75-100 cm2 flasks in 
37°C with 95% air and 5% CO2. Cells were propagated in growth medium: dulbecco’s 
minimal essential medium with high glucose, 4.5 g/L (DMEM-H, GIBCO, Grand Island, 
NY) supplemented with 10% heat-inactivated fetal bovine serum (FBS, GIBCO), 
10µg/mL insulin, 5µg/mL transferrin, 0.67µg/mL sodium selenite (I.T.S. GIBCO), 
50U/mL penicillin, and 50µg/mL of streptomycin (GIBCO). Cells were passaged weekly 
and experiments conducted on cells between passages 10-20. Growth factors were 
purchased as follows:  EGF (R&D Systems, Minneapolis, MN) IGF-I (Genentech, S San 
Francisco, CA).  Antibodies were purchased from the following vendors:  Anti-IGF-IRβ 
from Santa Cruz Biotechnology (sc-713, Santa Cruz, CA); Anti-phosphotyrosine (PY20, 
BDTransduction Laboratories, San Jose, CA, and 4G10, Millipore, Billerica, MA). 
InfraRed (IR) secondary antibodies (for use with LiCor Odyssey IR technology) were 
purchased from Pierce Biochemicals (Dylight800-conjugated goat anti-rabbit or 
Dylight680 conjugated-goat anti-mouse). 
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EGF and IGF-I treatments 
For all assays of EGF/IGF-I interaction, cells were grown to 50-70% confluence 
in growth medium, switched to serum-free medium (SFM) for at least 16h and then 
treated with/without growth factor(s) for defined times. To examine EGF/IGF-I 
interaction, doses of EGF and IGF-I shown previously to elicit maximal effects (EGF 
5ng/mL; IGF-I 20ng/mL) were used in two types of experiments. In one, cells were 
treated with EGF, IGF-I or both growth factors combined. In other “pretreatment” 
experiments, cells were treated with one growth factor for varying time periods as 
specified and then the growth factor removed and replaced with fresh SFM plus or minus 
a second growth factor. 
 
3H-thymidine assay 
3H-thymidine incorporation into DNA was used as a measure of proliferative 
response. Assays were conducted as previously described using 2µCi/mL 3H-thymidine 
(3000 Ci/mmol, Perkin Elmer, Boston, MA) added for the last 16 hours of incubation, 
followed by TCA precipitation of DNA and scintillation counting (Wallac Model 1414 
LSC, PerkinElmer, Waltham, MA). 
 
PI3-Kinase and MAPK inhibitors 
 To assess the role of PI-3K or MAPK in synergistic responses to EGF and IGF-I, 
PI-3K inhibitor LY294002 (14µM, Sigma-Aldrich, St Louis, MO) or MAPK inhibitor 
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PD98059 (20µM, Sigma-Aldrich) were incubated with cells during pretreatment or 
treatment with EGF or IGF depending on the experiment. 
 
Analysis of IGF-I receptor 
 125I-IGF-I binding: Binding of 125I-IGF-I to cell membranes was used as a 
measure of IGF-IR. For these assays, 125I-IGF-I (106 cpm/mL/well) was added to serum-
deprived, IGF-I-treated or EGF-treated cells. Lysates were collected and counted in a 
Packard Cobra II D5005 automatic gamma counter (PerkinElmer, Waltham, MA).  
Specificity of 125I-IGF-I binding was confirmed by demonstrating that unlabeled IGF-I, 
but not insulin, decreased 125I-IGF-I binding in a dose-dependent manner. 
 
Immunoprecipitation and Western blotting of IGF-IR: Cells were grown to 50-
70% confluency, serum-starved in SFM for 24 hours, then switched to SFM+EGF for 18 
hours. Media was removed and cells were treated with SFM+IGF-I for 3 minutes. Whole 
cell extracts were prepared in lysis buffer containing 50mM HEPES (pH7.4), 150mM 
NaCl, 20mM Na pyrophosphate, 100mM NaF, 1.5% Triton X-100, and 100mM EDTA, 
supplemented with phosphatase and protease inhibitors (1µg/mL aprotinin, 1mM PMSF, 
and 2mM vanadate). Lysates were centrifuged at 12,000 x g for 1 minute and 
supernatants collected. Lysate concentrations were determined by BCA (bicinchoninic 
acid) assays (Pierce, Thermofisher Scientific, Rockford, IL) and lysate integrity was 
verified by PAGE followed by Coomasie Blue staining. 
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 IGF-I receptor was immunoprecipitated by incubating 1000 ug of cell lysate with 
2µg of anti-IGF-IR β (sc-713, Santa Cruz Biotechnology, Santa Cruz, CA)  with mixing 
at 4oC for 18 hours. 20µL of 50% slurry of Protein A (Sigma-Alrich) was added for a 1-
hour incubation.  Following centrifugation and washing with lysate buffer (recipe above), 
immunoprecipitates were disrupted in gel loading buffer [95’C, 3 minutes, 10% glycerol, 
1% SDS, 30mM Tris-HCl (pH 6.M), 2.5% b-mercaptoethanol], then size-fractionated on 
an 8.5% SDS-polyacrylamide gel run at 32mA for 3 hours, transferred onto nitrocellulose 
membrane (BioRad, Hercules, CA) and blocked in Blocker™ Casein in PBS (Pierce, 
Rockford, IL) overnight. Membranes were immunoblotted with antibodies against 
phospho-tyrosine (mouse monoclonal antibodies PY20, BD Transduction Laboratories, 
San Jose, CA, and 4G10, Millipore, Billerica, MA) and rabbit anti-total IGF-IR (sc-713, 
Santa Cruz Biotechnologies, Santa Cruz, CA) at 4°C for 16 hours. Blots were washed in 
PBS containing 0.1% Tween and incubated with secondary antibodies conjugated to 
Dylight800 (Pierce, goat anti-rabbit) or Dylight680 (goat anti-mouse) for 1 hour at room 
temperature. Immuno-reactive proteins were visualized and quantitated using the LI-COR 
Odyssey infrared imaging system (Version 3, Li-Cor, Lincoln, NE). Densitometric data 
are expressed as fold-change versus the no treatment control.  
 
Immunoblot for Nuclear β-catenin 
 IEC-6 cells were grown as described above.  Cells were grown media plus FBS in 
150 mm dishes to 70-80% confluency, then switched to SFM. After 18-24 hours, fresh 
SFM was added with or without EGF (5ng/mL) for another 18-24 hours.  IGF-I 
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(20ng/mL) was then added for 10, 30, 60, or 180 minutes. Nuclear proteins were isolated 
as previously described178, concentration determined by BCA (bicinchoninic acid) assay, 
(Pierce, ThermoFisher Scientific, Rockford, IL) and verified by PAGE followed by 
Coomasie Blue staining. Equal amounts of protein (20 ug) were size-fractionated on 4-
12% SDS-PAGE gel (PAGEgel, Fischer Scientific, Pittsburgh, PA) and transferred onto a 
nitrocellulose membrane (Biorad) using a NuPAGE gel system (Invitrogen). After 
blocking in blocking buffer, blots were incubated with primary antibodies against β-
catenin (BD Biosciences, San Jose, CA) for 16 hours at 4°C. Blots were washed in PBS 
containing 0.1% Tween and incubated with secondary antibodies conjugated to 
Dylight800 for ~1 hour at room temperature. Immuno-reactive proteins were visualized 
and analyzed using the LI-COR Odyssey Infrared Imaging system. Densitometry was 
performed on visualized bands and normalized to the total protein gel. Values are 
expressed as fold change versus the no treatment control.  
 
TOPflash Luciferase Reporter Assay 
 106 cells were co-nucleofected (Nucleofector, Lonza Cologne AG, Koln, 
Germany) with 3.5 ug of TOPflash plasmid (TCF reporter plasmid, Millipore, Temecula, 
CA) and 0.5µg of TK renilla plasmid as control for tranfechon efficiency (Clontech, 
Montain View, CA). Cells were then seeded into 24-well plates for overnight growth. 
Cells were serum-starved (SFM) for 24 hours, then switched to SFM containing EGF, 
IGF-I, or IGF plus EGF for 24 hours. After washing, cells were collected in passive lysis 
buffer (Promega Corporation, Madison, WI). Luciferase assay was performed using a 
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Luciferase Reporter Assay (Promega, Madison, WI) according to manufacturer’s 
protocol.  Luciferase activity was read on Molecular Dynamics LMax luminometer. Data 
are expressed as fold-change versus the no treatment controls.  
 
Statistical Analysis 
 Data are expressed as mean + S.E.M or mean + S.E.M of fold change in each 
sample versus the mean value in control cells treated with SFM alone. Data were 
analyzed by ANOVA followed by post-hoc tests for pair-wise comparisons. P<0.05 were 
considered statistically significant. 
 
C. Results 
Combined IGF-I and EGF treatment synergistically increases 3H-thymidine 
incorporation 
 3H-thymidine incorporation into DNA was used as a measure of the proliferative 
responses to EGF and IGF-I alone or in combination. As shown in Figure 3.1A and 
consistent with prior data, treatment with IGF-I produced small, but significant increases 
in DNA synthesis (Figure 3.1A). EGF had more potent effects and combined treatment 
with EGF plus IGF-I promoted synergistic increases in DNA synthesis (Figure 3.1A). In 
previous studies, we demonstrated a temporal order to this effect such that pretreatment 
with EGF followed by IGF-I synergistically increases DNA synthesis, yet pretreatment 
with IGF-I followed by EGF treatment produced effects no different from EGF alone.123 
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Here, we examined the minimum time required for EGF pretreatment and demonstrated 
that 3 hours of EGF pretreatment is sufficient to permit synergistic effects upon 
subsequent treatment with IGF-I (Figure 3.1B). Longer duration of EGF pretreatment 
followed by IGF-I resulted in similar synergistic effects (Figure 3.1B).  
 
EGF pretreatment enhances IGF-I receptor levels and activation 
Radio-ligand binding assays and western immunoblot were used to test if EGF 
pretreatment affected IGF-IR. As shown in Figure 3.2A, 125I-IGF-I specifically bound to 
the IGF-I receptor, since un-labeled IGF-I dose-dependently decreased binding of 125I-
IGF-I, while insulin, at similar molar concentrations, had little or no effect (Figure 3.2A). 
We found that compared to no treatment controls, IGF-I significantly reduced 125I-IGF-I 
binding. In contrast, EGF significantly increased 125I-IGF-I binding indicative of 
increased IGF-I receptor (Figure 3.2B). Western immunoblots were used to confirm this 
observation 
Figure 3.3A shows results for immunoprecipitation of IGF-IR followed by 
western immunoblot for total IGF-IR or phosphotyrosine. Consistent with the 125I-IGF-I 
binding assays, pretreatment with EGF significantly increased total IGF-IR with a mean 
increase of 2.3 + 0.2 fold compared to cells treated with IGF-I alone (Figure 3.4B). 
Figure 3.3B shows immunoblots for tyrosine phosphorylated receptor to demonstrate that 
this effect was associated with dramatic increases in IGF-I-stimulated, but not basal 
levels of tyrosine phosphorylated IGF-IR. Levels of IGF-I-stimulated tyrosine 
phosphorylation of IGF-IR were 3.3 + 0.7 fold greater in EGF pretreated cells given 
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subsequent IGF-I compared with cells treated only with IGF-I. Together, these data 
suggest that EGF increases the levels of IGF-I receptor leading to enhanced IGF-I-
induced tyrosine phosphorylation of IGF-I receptor. It is important to note that EGF 
pretreatment alone is not sufficient to induce tyrosine phosphorylation of IGF-IR without 
subsequent addition of exogenous IGF-I (Figure 3.3B). 
 
Differential roles of MAPK and PI-3K in EGF/IGF interaction 
 To assess the role of MAPK or PI3-K pathways in IGF-I/EGF interactions, IEC-6 
cells were treated with PD98059 or LY294002 during pretreatment with SFM or EGF or 
during subsequent treatment with IGF-I or SFM. Both inhibitors significantly reduced 
basal DNA synthesis observed in the absence of growth factors (Figure 3.4). The 
stimulatory effects on DNA synthesis observed with EGF pretreatment for 7 hours were 
significantly inhibited by PD98059 or LY294002 (Figure 3.4). In contrast, the modest but 
significant effect of IGF-I or DNA synthesis was significantly inhibited by LY294002, 
but not PD98059 (Figure 3.4). Effects of these inhibitors on the synergistic responses to 
EGF pretreatment followed by IGF-I demonstrate different roles of these pathways. Use 
of either PD98059 or LY294002 during EGF pretreatment inhibited the synergistic 
response by approximately equal degrees (Figure 3.4). In contrast, when added only 
during IGF-I treatment of EGF pretreated cells, only LY294002 and not PD98059 
attenuated the synergistic proliferative responses. When PD98059 was given during both 
EGF pretreatment and subsequent treatment with IGF-I, the inhibitory effect was similar 
to when PD98059 was given orally during EGF pretreatment. In contrast, when 
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LY294002 was given during both EGF treatment and subsequently IGF-I, its effects were 
more potent than when administered only during EGF pretreatment. However, this was 
not significantly different from effects of LY294002 during EGF pretreatment only. 
Together, these findings support a model proposed in the schematic in Figure 3.4, 
whereby mitogenic effects of EGF pretreatment requires both MAPK and PI3-K 
pathways, but responses to IGF-I alone or synergistic responses to IGF-I in EGF-
pretreated cells are dependent only on PI3-K pathways. 
 
Additive effects of EGF and IGF-I on β-catenin/TCF pathways  
 Immunoblot for nuclear β-catenin and TCF luciferase reporter assays were used 
to assess if EGF and IGF-I interact to regulate this key growth-promoting pathway that is 
relevant to early stages of intestinal cancer. To assess nuclear β-catenin, we pretreated 
cells with SFM or EGF for 18 hours followed by subsequent treatment with SFM or IGF-
I for 10 – 180 minutes. Neither EGF pretreatment alone, nor 60 minutes treatment with 
IGF-I alone significantly increased nuclear β-catenin, although there was a trend for a 
modest increase in nuclear β-catenin in EGF pretreated cells (Figure 3.5A). EGF 
treatment followed by 60 or 180 minutes IGF-I treatment lead to significant increases in 
nuclear β-catenin (Figure 3.5A). Figure 3.5B shows controls to illustrate that the 
cytosolic marker tubulin is absent from nuclear extracts but is detected in whole cell 
extracts and that the nuclear marker Histone H1, is present in nuclear extracts. 
 We then assessed whether IGF-I or EGF, alone or in combination, enhance the 
transcriptional activity of β-catenin, using a TCF-luciferase reporter assay.170 IEC-6 cells 
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were pretreated with either IGF-I or EGF and followed by IGF-I or EGF treatment. IGF-I 
or EGF treatment produced approximately two-fold increases in TCF-reporter activity 
compared to no treatment controls (Figure 3.6). This activity was increased, at least 
additively, by combined EGF and IGF-I treatment, producing a four-fold increase in TCF 
promoter activity (Figure 3.6). These results suggest that while either IGF-I or EGF alone 
can induce TCF promoter activity, combined treatment of EGF and IGF-I significantly 
and additively increased TCF promoter activity. Together with immunoblots results, 
these studies suggest that EGF and IGF-I interact to promote increases in nuclear β-
catenin and enhanced β-catenin/TCF transcriptional activation. 
 
D. Discussion 
Our studies show that IGF-I and EGF interact to promote synergistic increases in 
DNA synthesis and β-catenin activity in IEC-6 cells. Two independent assays, 125I-IGF-I 
binding and western blot, demonstrate that EGF pretreatment increased IGF-IR. In 
addition, EGF pretreatment enhanced IGF-IR and IGF-I-induced receptor 
phosphorylation. Maximal synergistic effects of EGF and IGF-I on proliferation required 
both MAPK and PI-3K during EGF pretreatment, but only PI-3K during subsequent IGF-
I treatment. We also demonstrate that combined treatment of IEC-6 cells with IGF-I and 
EGF in IEC-6 cells promotes significant increases in nuclear β-catenin and enhanced 
TCF transcriptional activation greater than treatment with either growth factor alone. 
These studies define novel mechanisms of EGF and IGF-I interaction and demonstrate 
that these two growth factors interact to promote enhanced activation of the key growth 
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promoting TCF/β-catenin pathway, which is implicated in early stages of tumorigenesis 
in the intestine. 
Our findings that EGF alone is a more potent mitogen than IGF-I, and the synergy 
between EGF and IGF-I confirm and extend previous studies in our lab and others.123, 142 
Other studies in IEC-6 cells showed that continuous IGF-I treatment produced non-
significant increases in cell number, while continuous EGF treatment promoted increased 
cell numbers.142 However, combined treatment with IGF-I and EGF over 48 hours 
produced synergistic increases in cell number and were recapitulated when a short pulse 
of EGF was given prior to IGF-I treatment.142 The reverse is not true because IGF-I 
pretreatment does not lead to synergistic effects in response to subsequent addition of 
EGF.123 This and our prior study indicate that EGF is able to ‘prime’ IEC-6 cells for a 
synergistic response to IGF-I. One potential mechanism we considered is that EGF may 
serve as a competence factor promoting transition from G0  G1 phase and that IGF-I 
acts as a proliferative agent promoting transition from G1  S phase, where DNA 
synthesis occurs as this interaction has been demonstrated in fibroblasts.123,142 However, 
in IEC-6 cells, this does not appear to be a likely explanation since both growth factors 
promote DNA synthesis, a biomarker of transition into S phase, and EGF alone has more 
potent effects than IGF-I alone.123 Thus, in IEC-6 cells, it appear that there are different 
mechanisms of interaction whereby both EGF and IGF-I each promote S phase and act in 
a synergistic manner when combined or when cells are first exposed to EGF and then 
IGF-1.  
Our prior and current studies suggest that one level of interaction between EGF 
and IGF-I resides at the level of IGF-IR expression. Our previous report demonstrated 
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that EGF and IGF-I interact at the level of IGF-IR mRNA.123 EGF alone did not affect 
IGF-IR mRNA, but when in combination with IGF-I prevented a dramatic down-
regulation of IGF-IR mRNA by IGF-I.123 In the current study, we show that in contrast to 
the IGF-I mRNA data, EGF pretreatment up-regulates IGF-IR as assessed by I125–IGF-IR 
binding assays or by western blot. In turn, this permits more dramatic tyrosine 
phosphorylation of IGF-IR when cells are subsequently exposed to IGF-I. This 
interaction appears not to reflect trans-activation of IGF-IR by EGF/EGFR because cells 
pretreated with EGF did not show tyrosine phosphorylation of IGF-IR until exposed to 
IGF-I. Thus, the current data suggest that EGF pretreatment acts at a protein level to 
increase the number of available IGF-I receptors for subsequent activation by IGF-I. 
Precisely how EGF increases IGF-IR protein will require additional studies, but this 
could involve either recruitment or maintenance of IGF-IR at the plasma membrane. 
Whatever the mechanism, this is relevant to combinatorial effects of EGF and IGF-I to 
more potently promote growth of normal IEC in vivo or cancer cells. Prior studies have 
shown that in normal or irradiated intestine in vivo EGF more potently promotes mucosal 
growth or crypt mitosis than IGF-I.75,125 To our knowledge, no studies have tested the 
effects of combined treatment with EGF and IGF-I on intestinal growth and repair. 
However, emerging evidence in the literature documents additive or synergistic effects of 
EGFR combined with IGF-IR inhibitors in colon cancer cells, which are known to 
express endogenous ligands for the two receptors.220,218,221 Our documentation of synergy 
between exogenous EGF and IGF-I in non-transformed IEC-6 cells suggests that 
situations where both growth factors might be upregulated, i.e. early stage transformation 
of normal IEC towards tumor phenotype, may permit the two growth factors to interact to 
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synergistically expand aberrant precancerous cells. This is speculative at present but 
ongoing studies in our laboratory are addressing effects of combined inhibition or genetic 
loss of EGFR and IGF-IR signaling in spontaneous intestinal tumor models and will be 
discussed in chapter IV. 
Our studies addressed the role of two key downstream pathways, MAPK and PI-
3K, in mediating the synergistic responses to EGF and IGF-I. These studies revealed that 
the proliferative effects of EGF or its ability to promote synergistic proliferative 
responses with subsequent IGF-I treatment required both MAPK and PI-3K pathways. In 
contrast, only PI-3K and not MAPK inhibitors affected the synergistic response when 
added only during IGF-I treatment following EGF. The predominant role of PI-3K versus 
MAPK in mediating IGF-I action in this setting is consistent with findings in other 
systems which show a major role for PI-3K in growth promoting effects of IGF-
I.222,205,204 It is noteworthy that a number of studies indicate that IGF-I activation of PI-
3K is critical for anti-apoptotic actions of IGF-I.46 In IEC-6 cells under the conditions and 
time course of growth factor treatment analyzed, there is essentially no detectable 
apoptosis. Thus, in this situation, PI-3K appears essential to the proliferative rather than 
anti-apoptotic action of IGF-I and importantly, to the synergistic interaction between 
EGF and IGF-I in mediating IEC proliferation.  
Both IGF-I and EGF have been implicated in the activation and regulation of the 
APC/β-catenin pathway. Our studies show that IGF-I treatment alone did not promote 
increases in nuclear β-catenin protein and EGF alone had a non-significant trend to 
increase nuclear β-catenin. When IEC-6 cells were pretreated with EGF and followed by 
IGF-I, nuclear β-catenin was enhanced at 60 minutes above either treatment alone and 
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this increase was sustained. Previous studies have shown that either IGF-I or EGF 
induced nuclear β-catenin activation in other cell types.207,208,209 In primary 
oligodendrocytes and oligodendrocyte cell cultures, IGF-I increased β-catenin protein 
and mRNA levels and increased transcription of β-catenin target gene cyclin D1.207 
SiRNA against β-catenin reversed IGF-I-induced cell survival.207 In mouse embryonic 
fibroblasts overexpressing the IGF-IR, IGF-I treatment induced nuclear translocation of 
β-catenin that was dependent on a downstream mediator of IGF-I action, insulin receptor 
substrate-1 (IRS-1).53 IRS-1 co-localized with β-catenin in the nucleus. This co-
immunoprecipitation of IRS-1 and β-catenin indicates that these proteins may interact to 
promote activation of β-catenin target genes.53 With regards to EGF, studies in other 
systems indicate that EGF can induce the nuclear translocation and increase β-catenin 
transcriptional activity in oral and colon cancer cells.139,140,223,213 Recently, studies in oral 
cancer cells show that EGF increases the amount of nuclear β-catenin while reducing β-
catenin localized to plasma membranes and also increased β-catenin transcriptional 
activity.140 In colon cancer cell lines, EGF increased β-catenin protein and nuclear 
localization through a mechanism involving HDAC-6.139 Our studies did not demonstrate 
an increase in nuclear β-catenin with IGF-I or EGF alone, but both growth factors were 
required. Previous studies primarily used transformed cancer cell lines, which are known 
to express endogenous growth factors, and may have contributed to the ability of EGF or 
IGF-I alone to promote nuclear translocation of β-catenin. Since IEC-6 cells express little 
or no endogenous EGFR ligands, our studies in these cells allowed us to test the 
individual effects of IGF-I and EGF, with minimal effect of endogenous growth factors.  
	   97	  
Using a TCF luciferase reporter assay, which reflects functional effects on 
transcription. IGF-I or EGF treatment in IEC-6 cells did increase in transcriptional 
activation of a β-catenin/TCF reporter, which is consistent with previous models.211,140 
Additional studies in C10 cells, a colorectal cancer cell line, and oesophageal cell lines 
found that IGF-I alone did not induce TCF transcriptional activity, indicating that IGF-I 
regulation of β-catenin activation may occur in a cell- or context-specific manner.224,54 In 
one previous study, IEC-6 cells treated with EGF did not show an increase in nuclear β-
catenin or an effect on transcriptional activity; however, these studies were done in the 
presence of low serum and may not adequately reflect effects due solely to EGF.124 
We found that EGF pretreatment, followed by IGF-I treatment significantly 
increased nuclear β-catenin and dramatically enhanced transcriptional activity greater 
than either treatment alone. This suggests that these growth factors interact to promote 
enhanced β-catenin signaling and represents, to our knowledge, the first evidence that 
these growth factors interact to additively increase transcriptional activation of this key 
pathway. One obvious future direction is to examine β-catenin gene targets and define 
specific genes whose transcription is induced by EGF, IGF-I or most importantly, genes 
that show additive or synergistic responses to combined EGF and IGF-. Ongoing gene 
microarray analyses are addressing this issue. Few studies have examined activation of β-
catenin by IGF-I or EGF in combination with each other or additional growth factors. In 
IEC-6 cells, 2% FBS plus EGF had no effect on β-catenin activation, yet increased 
proliferation greater than EGF treatment alone or with 2% FBS.124 EGF given in 
combination with LiCl, an inhibitor of GSK3β, led to increased cytoplasmic pools of β-
catenin and decreased pools at the membrane.223 IGF-I treatment has been given in 
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combination with LiCl. In one study, IGF-I increased the number of surviving colon 
cancer cells greater than LiCl treatment alone, where combined treatment did not lead to 
a further increase.207 When β-catenin siRNA was given, this reversed the effect of IGF-I 
on cell survival.207 Combined LiCl and IGF-I treatment was shown to increase β-catenin 
transcriptional activity above either treatment alone.54 These effects of combined 
treatment highlight, not only the effects on β-catenin activation, but also support our 
previous results where combined growth factor treatments synergistically enhance 
proliferation. These studies also provide support for further study of interactions of 
EGFR and IGF-IR signaling pathways. This becomes especially important for cancer 
prevention and treatment. 
Both IGF-I and EGF are implicated as risk factors for colorectal 
cancer.62,134,219,225,52 Both IGF-IR and EGFR are overexpressed in colorectal cancer and 
preclinical models have demonstrated a role for each of these receptors or associated 
signaling pathways in colon and other cancers.61,78,77,133,134,136 In response, a number of 
inhibitors have been developed to target these pathways in human cancers and are 
currently in clinical trials.226,227,158,68 EGFR inhibitors have potent in vitro and in vivo 
effects to inhibit proliferation and reduce tumor development in experimental settings, 
but have been effective in only a subset of patients with colorectal cancer.147,221,149,228,229 
Patients with breast and NSCLC respond to EGFR inhibitors but develop resistance to 
these therapies.150,137,230 Recent studies provide evidence that activation of the IGF-IR 
signaling pathway may contribute to resistance to EGFR inhibitor.220,154,231,151 In human 
glioblastoma multiform cell lines, IGF-I expression significantly correlated with 
resistance of erlotinib (an EGFR inhibitor).232 IGF-I and IGF-I-induced Akt pathways 
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were found to be activated in erlotinib resistant cancer cells and in epithelial cells, 
activation of both EGFR and IGF-IR induced Akt signaling.221 This has lead to studies of  
combined EGFR and IGF-IR inhibitors in several in vitro and a few in vivo 
studies.218,220,221,233,234,235 Combined siRNA knock-down of both IGF-IR and EGFR in 
colorectal cancer cell lines significantly decreased proliferation and induced apoptosis 
greater than inhibition of either receptor alone.218 Additional studies in breast, sarcoma, 
and colon cancer cells using pharmacological inhibition of IGF-IR and EGFR, show 
synergistic reductions in proliferation and cell survival.218,231 The findings of Kaulfuss et 
al218 are particularly relevant. This study revealed that synergistic reduction in 
proliferation of colon cancer cells by combined EGFR and IGFR inhibitors led to more 
effective inhibition of both Akt and MAPK pathways.218 Knockdown of IGF-IR alone 
affected Akt, but not EGF-induced MAPK. Akt is downstream of PI-3K and, thus, these 
results are consistent with our findings in non-transformed cells that EGF activation of 
both MAPK and PI-3K but IGF activation of only PI-3K are required for synergy. 
Xenograft models of breast and lung cancer cells demonstrate in vivo that combined 
treatment of an anti-tumor IGF-IR human antibody (h7C10) with either an anti-EGFR 
antibody (225) or a chemotherapeutic agent almost completely inhibited tumor growth.234 
These studies highlight the importance of defining mechanisms of EGF/IGF-I 
interactions and furthering examining the effects and mechanisms underlying more 
effective anti-tumor effects of combined EGFR and IGF-IR inhibitors. 
Together, these studies show that interactions between IGF-I and EGF to promote 
synergistic increases in IEC proliferation require both PI-3K and MAPK and enhanced 
IGF-IR upregulation and activation. These studies also demonstrate novel effects of EGF 
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and IGF-I to enhance nuclear β-catenin and synergistically increase TCF/lef 
transcriptional activity. These effects are important in understanding the role of multiple 
growth factors in growth of normal intestinal epithelium and provide support for use of 
combined inhibitors of IGF-IR and EGFR in treating cancer. 
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Figure 3.1. EGF pretreatment followed by IGF-I treatment synergistically increases 
DNA synthesis. A-B. Histogram shows mean + SEM for 3H-thymidine incorporation in 
IEC-6 cells, shown as total counts per minute (CPM). A. Cells were treated with EGF 
(5ng/mL), IGF-I (20ng/mL), or EGF and IGF-I combined at the same time for 18 hours. 
Untreated cells were used as a control. B. Cells were pretreated with EGF for 1, 3, 5, or 7 
hours, media removed and subsequently treated with IGF-I for 18 hours. a=p<0.05 vs. no 
treatment, b=p<0.05 vs. additive effects of IGF-I + EGF 
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Figure 3.2. EGF pretreatment increases competitive IGF-IR binding activity in IEC-
6 cells. A. Competitive radio-ligand binding assay of 125I-IGF-I with increasing 
concentrations of unlabeled (cold) IGF-I (closed circles) or cold-insulin (open circles). 
Assay shows specificity for IGF-I as cold IGF-I, and not insulin, compete for binding to 
IGF-IR. B. IEC-6 cells were treated with IGF-I or EGF for 18 hours, washed and 
incubated with 125I-IGF-I. 125I-IGF-I was measured from isolated membranes. Mean + 
S.E.M of IGF-I receptor evaluated by direct assays of specific 125I-IGF-I to isolated 
membranes. a=p<0.05 vs. No treatment.  
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Figure 3.3. EGF pretreatment upregulates IGF-IR and IGF-I-induced receptor 
phosphorylation. Representative Western immunoblots of A. total IGF-IR or B. tyrosine 
phosphorylated IGF-IR in IEC-6 cells pretreated with EGF followed by IGF-I treatment 
(3 min, 25ng/µL) and immunoprecipitated for total IGF-IR. Note EGF treatment alone 
increases total IGF-IR. Below each immunoblot, densitometric analysis of immunoblots 
showing change in both total- and tyrosine-phosphorylated-IGF-IR. Results show mean + 
S.E.M for two independent experiments, a=p<0.05. 
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Figure 3.4. MAPK and PI-3K are required during EGF pretreatment but PI-3K is 
required during IGF-I treatment. Top. IEC-6 cells were pretreated with EGF (5ng/mL) 
and subsequently treated with IGF-I (20ng/mL). Either a MAPK inhibitor (PD98059) or a 
PI-3K inhibitor (LY294002) was given during the indicated treatment. Histograms show 
mean + S.E.M 3H-thymidine incorporation as a measure of synergistic effects on DNA 
synthesis and expressed as fold change vs. the no-treatment control. a = p<0.05 versus 
treatment without inhibitor. Bottom. A diagram summarizing the results. 
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Figure 3.5. EGF promotes IGF-I-induced nuclear β-catenin in IEC-6 cells. IEC-6 
cells were pretreated with EGF (5ng/mL) for 18 hours or SFM alone, media removed, 
and subsequently treated with SFM alone or IGF-I (20ng/mL) for indicated times. 
Nuclear proteins were isolated and immunoblotted for β-catenin. A. Top. Representative 
immunoblot of nuclear β-catenin in IEC-6 cells treated with EGF and/or IGF-I. Shown 
underneath is the corresponding total protein gel. Bottom. Histogram showing 
densitometric analysis of β-catenin, expressed as fold change versus no treatment. n > 4 
blots. a = p<0.05 versus no treatment; b = p<0.05 versus EGF alone. B. Representative 
immunoblots showing β-catenin following combined IGF-I + EGF treatment in whole-
cell extracts (WCE, lane 1) and nuclear extracts (NE, lanes 2-3). Lanes 1 and 2 are from 
the same blot and lane 3 from a separate blot. Membranes were first immunoblotted for 
β-catenin then reprobed for either tubulin or histone H1. Note that tubulin appears only in 
WCE and not NE. 
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Figure 3.6. EGF promotes synergistic increases in IGF-I-induced TCF/lef promoter 
activity by TOP-Flash luciferase assay. IEC-6 cells were nucleofected with a TCF/lef 
luciferase reporter (TOP-GAL) and TK-renilla to measure transfection efficiency. Cells 
were pretreated with either EGF (5ng/mL) or IGF-I (20ng/mL) for 6 hours, SFM 
removed, then subsequently treated with EGF or IGF-I for 16 hours to allow for 
luciferase expression. Histogram shows resulting luciferase activity expressed as fold 
stimulation versus the SFM control. p < 0.05 versus no treatment, b = p < 0.05 versus 
additive effects of IGF plus EGF.  
	   	  
 
 
CHAPTER 4 
HETEROZYGOUS DELETION OF IRS-1 COMBINED WITH 
PHARMACOLOGICAL INHIBITION OF EGFR REDUCES TUMOR 
DEVELOPMENT IN THE COLON OF FEMALE BUT NOT MALE APCMIN/+ 
MICE 
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A. Introduction 
Colorectal cancer is the second leading cause of cancer-related deaths among men 
and women combined, with an overall 5.2% lifetime risk of developing colorectal 
cancer.19 The progression of colorectal cancer is well-documented where genetic 
mutations in the normal epithelium accumulate, leading to the formation of precancerous 
adenomas.26 Further allelic loss or mutations promotes additional neoplastic changes that 
lead to carcinoma.26 One of the most frequent mutations in the initial stages of sporadic 
colorectal cancer occurs in the APC tumor suppressor gene, which is mutated in over 
85% of sporadic colorectal cancer.32 Mutational inactivation of this gene promotes 
aberrant activation of the β-catenin pathway.27 The ApcMin/+ mouse is a mouse model of 
APC inactivation, which develops tens to hundreds of adenomas in the small intestine 
and, depending on the genetic background, develops adenomas in the colon as well.37,36,34 
In addition to APC/β-catenin pathway, other signaling pathways are known to influence 
the initiation and progression of colorectal cancer. 
 The IGF-I and EGF family are both implicated in the initiation and progression of 
colorectal cancer. Both IGF-IR and EGFR are frequently up-regulated in primary colon 
adenoma and adenocarcinoma samples.236,69,70,132,219,133 Increased circulating IGF, IGF-II 
or insulin are associated with increased risk of colorectal cancer.237,63,238,62,65,239 Studies in 
mice strongly support a role for IGF-IR and EGF in tumor development or progression in 
the intestine. Mice homozygous for a hypomorphic Egfrwav2 allele have a 90% reduction 
in receptor kinase activity and when, bred to the tumorigenic ApcMin/+ background have a 
90% decrease in tumor number.134 Pharmacological inhibition of EGFR in ApcMin/+ mice 
also leads to a reduction in tumor number, though this is not as dramatic as in mice with 
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Egfrwav-2 mice.134 Mice with a liver-specific deletion of IGF-I have a 50-75% reduction in 
circulating IGF-I, and exhibit reduced number and size of colon tumors after treatment 
with AOM.76,77 These results have lead to the development of targeted therapeutics that 
specifically inhibit these signaling pathways. 
 Small molecules or monoclonal antibodies that specifically target and inhibit the 
EGFR or IGF-IR are currently in clinical trials, with EGFR inhibitors being the most 
studied of the two. Agents specifically targeting the EGFR have shown potent effects to 
inhibit tumorigenesis in preclinical in vitro and in vivo models.147,148,149 However, when 
these studies were translated to humans, only a subset of patients responded to EGFR 
inhibitors and patients treated with these agents also develop resistance to these 
therapies.150,151,240,228 These resistance mechanisms may be mediated by increases in other 
growth promoting pathways, such as the IGF-IR pathway. In breast, prostate, and liver 
cancer cells, resistance to gefitinib, a small molecule EGFR inhibitor, was associated 
with increased activation of the IGF-IR and increased sensitivity to IGF-IR 
inhibitors.153,212,150 Increased IGF-IR signaling interferes with effects of trastuzumab, an 
anti-HER2/neu receptor monoclonal antibody, to reduce proliferation.151 These studies 
suggest that combined inhibition of IGF-IR and EGFR pathways would be more effective 
at reducing colon tumor development, greater than inhibition of either pathway alone. 
Several in vitro studies demonstrate that combined inhibition of the IGF-IR and 
EGFR synergistically decreases proliferation and increases apoptosis greater than 
activation of either receptor alone.218,221 In colon cancer cells, combined siRNA 
knockdown of IGF-IR and EGFR inhibited proliferation and increased apoptosis greater 
than knockdown of individual receptors.218 Similar effects were seen with combined 
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treatment of the small molecule IGF-IR inhibitor, NVP-AEW541, and the EGFR 
inhibitor erlotinib.218 Combined inhibition of IGF-IR and EGFR additively inhibited the 
growth of colon cancer cells.220 To date, in vivo studies investigating the therapeutic 
potential of combined IGF-IR and EGFR inhibition have been confined to xenograft 
tumor models.234 These studies show that combined treatment with the anti-IGF-IR 
antibody h7C10 (and an anti-EGFR inhibitor) almost completely inhibited tumor growth 
and prolonged survival.234 While these studies show promise, further in vivo 
investigation in models of spontaneous intestinal tumors is needed to fully determine the 
effects of combined IGF-IR and EGFR signaling and ultimately address their roles at 
different stages in the colon cancer pathway. 
 We hypothesized that combined inhibition of IGF-IR and EGFR signaling will 
additively or synergistically decrease tumor development in the ApcMin/+ model of 
spontaneous tumorigenesis. To test this hypothesis, we used mice with genetic disruption 
of the IRS-1 gene. We reasoned that loss of IRS-1 signaling would inhibit growth 
promoting effects of all IGF-I/insulin family ligands. Our previous studies in ApcMin/+ 
mice demonstrated that mice heterozygous or homozygous for IRS-1 gene disruption had 
significantly reduced tumor load in both the small intestine and colon, thus demonstrating 
gene dosage effects of IRS-1.61 The current study treated IRS-1+/-/ApcMin/+ mice with 
EGFR inhibitor to test combinational effects. We had aimed also to test EGFR inhibitor 
in IRS-1-/-/ApcMin/+mice. However this has proved impractical because of extremely low 
frequency of birth or survival of IRS-1-/-/ApcMin/+ mice. In addition, we reasoned that 
heterozygous deletion of IRS-1 may reflect more physiological reductions in IRS-1 
expression. We therefore treated either IRS-1+/+/ApcMin/+ or IRS-1+/-/ApcMin/+ mice with a 
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specific EGFR inhibitor AG1478, which has previously been shown to inhibit cancer cell 
growth and to be effective at reducing tumor burden in ApcMin/+ mice.241 We found that 
heterozygous deletion of IRS-1 or pharmacological inhibition of EGFR reduced tumor 
development in the small intestine and colon; however the small intestine did not show 
additive effects to reduce tumor development when both pathways were inhibited. The 
colon showed dramatic reductions in tumorigenesis when IRS-1 deletion and EGFR 
inhibition are combined. Interestingly, these effects in the colon were confined to female 
ApcMin/+ mice and were not seen in male ApcMin/+mice.  
 
B. Materials and Methods 
Laboratory Animals 
ApcMin/+ mice on the C57BL/6J background were purchased from Jackson laboratories 
(Bar Harbor, ME). IRS-1+/- mice were generated on a purebred C57BL6 background as 
previously described.56 and provided by Dr. Ronald Kahn (Harvard, Cambridge, MA). 
We used a two-step breeding process as previously described to generate IRS-1+/+ 
/ApcMin/+, IRS-1+/-/ApcMin/+, or IRS-1-/-/ApcMin/+.61 Because IRS-1-/- mice were born at a 
very reduced frequency, we were unable to generate IRS-1-/-/ApcMin/+ mice across more 
than 40 litters. Therefore, we confined our studies to wild-type or heterozygous IRS-1 
mice on the ApcMin/+ background. Genotyping was performed on tail DNA as previously 
described.134,59 All animal studies were approved by the Institutional Animal Care and 
Use Committee of the University of North Carolina. Study protocols were in compliance 
with the NIH Guide for the Care and Use of Laboratory Animals.175 
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AG1478 diet treatment 
Tyrophostatin (AG1478, LC Laboratories, Woburn, MA) was kindly provided by Dr. 
David Threadgill and mixed with AIN-93G (Research Diets, Inc, location) at a 
concentration of 144mg/kg. (Research Diets, Inc, New Brunswick, NJ). Starting at 
weaning (3 weeks of age), mice were given either diet containing AG1478 or control diet 
(AIN-93G alone). Mice remained on diet continuously for 12 weeks. At this time (15 
weeks of age), mice were sacrificed and small intestine and colon examined 
 
Tissue Dissection and Adenoma Counts 
Animals were weighed and anesthetized. Blood was collected by cardiac puncture. Entire 
small intestine and colon were dissected and flushed with 1 X PBS supplemented with 
2mM vanadate 2mM, 1mM PMSF, and 100mM NaF. Small intestine was divided into 3 
segments, roughly equal in length and a 0.5cm segment of proximal ileum was flash 
frozen in liquid nitrogen for RNA/protein analysis. The remaining small intestine 
segments, as well as the entire colon, were splayed open on filter paper. Tissues were 
fixed in 10% zinc-formalin overnight at 4°C then dehydrated in 70% ethanol. Number of 
adenomas in the small and large intestine of each animal were counted under a Leica 
dissecting scope, using an in-lens micrometer to measure adenoma diameter. Tumor load 
was calculated as number x size.  
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Statistical Analysis 
Tumor number, size, and load are expressed as mean + S.E.M. Two-way ANOVA was 
performed to determine if there were main effects of genotype, inhibitor, or importantly 
an interaction between genotype and inhibitor, which would suggest an effect of loss of 
IRS-1 on efficacy of EGFR inhibitor. Since small intestine shows differences in tumor 
number across different segments, with distal segments showing the greatest number of 
tumors, we analyzed data for segment-specific differences in effects of IRS-1+/- genotype, 
AG1478 treatment, or both conditions in ApcMin/+ mice. Pair-wise comparisons were 
performed using Fischer’s PLSD post-hoc test. In addition, we expressed tumor number, 
size, or load in each individual animal as a percentage of the mean of IRS-1+/+/ApcMin/+ 
mice on vehicle diet and then subtracted this from 100 to establish a percent reduction in 
tumor number, size, or load due to loss of one IRS-1 allele alone, AG1478 alone, or both 
combined. These values were compared by one-way ANOVA followed by Tukey’s test 
to identify interactions. We also examined effects of IRS-1+/-, AG1478, or both on tumor 
incidence and relative frequency of small versus large tumor number or size. All analysis 
was conducted on measurements with both sexes combined and also in males or females 
separately to test for gender-specific differences in efficacy of EGFR inhibitor or loss of 
IRS-1. 
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Limitations to the study and statistical analysis 
1. Two-way ANOVA revealed main effects of IRS-1 genotype and AG1478, but not a 
significant interaction in small intestine or colon, or when broken down into males and 
females. This may not be the optimal test. 
2. In pair-wise comparisons, instances where there is a significant difference between 
IRS-1+/-/ApcMin/+ vehicle-treated mice and IRS-1+/-/ApcMin/+ mice given AG1478 
demonstrate that EGFR is effective at further reducing tumor number or size in mice 
with loss of one IRS-1 allele. However, in no instance did we achieve a statistically 
significant difference between IRS-1+/+/ApcMin/+ mice and IRS-1+/-/ApcMin/+ mice 
treated with AG1478 to statistically verify additional effects of adding loss of IRS-1 
allele to EGFR inhibitor treatment.  
3. The trends observed for interactions between loss of IRS-1 and EGFR inhibition 
between males and females are illustrated in the tables and figures and described in the 
results and discussion. 
4. Additional different statistical tests or increases in n (sample size) of particular groups 
may be required to confirm these trends. 
 
C. Results 
Partial Loss of IRS-1 or EGFR inhibition does not affect body weight 
 Complete loss of IRS-1 in mice results in post-natal growth retardation.55 In 
C57BL/J6 mice, chronic exposure to the EGFR inhibitor, AG1478, resulted in reduced 
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weight gain.242 We therefore determined whether heterozygous deletion of IRS-1, EGFR 
inhibitor, or both had an effect on final body weight in ApcMin/+ mice. As shown in Table 
4.1, neither disruption of one IRS-1 allele nor EGFR inhibitor treatment significantly 
affected mean body weight, nor did the two conditions combined. 
 
In the small intestine and colon, inhibition of IRS-1 or EGFR show gender-specific 
effects in efficacy to reduce tumor number and combined loss of IRS-1 and EGFR 
inhibitor are more effective, especially in females. 
Table 4.2 summarizes the percent inhibition of tumor number in the small 
intestine and colon as a result of disruption of one IRS-1 allele, AG1478 treatment, or 
both. Table 4.3 and 4.4 present the means for tumor number, size and load across these 
groups. The data reveal some interesting effects. Taking males and females together, in 
small intestine loss of IRS-1 and EGFR inhibition both decrease tumor number (Table 
4.2, Table 4.3). The decrease is greater with both loss of one IRS-1 allele and EGFR 
inhibitor combined although the effects are not statistically additive and maximum 
inhibition of tumor number is 65.5 + 4.8%. The data become more interesting when 
separated by gender. They reveal that, in males, loss of IRS-1 leads to slightly greater 
reductions in tumor number than with EGFR inhibitor, while in females, EGFR is 
considerably more effective than haploid insufficiency for IRS-1 (Table 4.2, Table 4.3). 
However, combined effects of IRS-1+/- genotypes and EGFR inhibitor are similar 
between the two sexes in ApcMin/+ mice. 
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In the colon, gender effects on tumor number are more striking. In males, loss of 
IRS-1 has considerably greater effects than AG1478; in females, both are very effective 
(Table 4.2, Table 4.4). Maybe most interesting is that in females, and not in males, 
combined IRS-1+/- genotype and AG1478 almost completely inhibits tumor development 
(Table 4.2, Table 4.4). This is further emphasized in Figure 4.1, which shows tumor 
incidence in colon. In females, loss of IRS-1+/- or EGFR inhibition alone each reduces 
tumor incidence, but when combined, they dramatically reduced tumor incidence to 18% 
of animals, essentially 2 out of 11 animals having a detectable tumor. 
 
Loss of IRS-1 and EGFR inhibition has gender-specific effects in efficacy to reduce 
tumor number and tumor load in all regions of the small intestine. 
Data for tumor number, size, and load in different small intestine segments are 
illustrated in figure 4.2 and also demonstrate gender-specific differences in efficacy of 
IRS-1+/- genotype or AG1478 treatment in ApcMin/+ mice. In female mice, loss of IRS-1 
alone had no significant effect on tumor number in any segment. EGFR inhibitor alone 
significantly reduced tumor number in two of three segments and tumor number was 
lowest in all segments when inhibitor was combined with loss of IRS-1 allele (Figure 
4.2A). In males, all segments showed reduced tumor number as a result of loss of one 
IRS-1 allele, while EGFR inhibitor effects did not reach statistically significance when 
considered in separate segments (although means were lower) (Figure 4.2A). Effects of 
combined IRS-1+/- genotype and AG1478  treatment were not significantly greater than 
IRS-1+/- genotype alone.  
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Combined heterozygous deletion of IRS-1 and EGFR inhibition dramatically 
reduces tumor size in colon of female ApcMin/+ mice. 
These gender effects in colon were also apparent when considering tumor size 
(Table 4.4, Table 4.5, Figure 4.3). Examining mean tumor size in the small intestine, 
EGFR inhibitor treatment reduced tumor size while loss of IRS-1 had no effect alone or 
combined with EGFR inhibitor in both sexes (Table 4.3, Table 4.5). In the colon of male 
ApcMin/+ mice, neither loss of one IRS-1 allele nor AG1478 dramatically affected mean 
size. Combined effects of loss of IRS-1 and EGFR inhibitor treatment did not differ from 
EGFR inhibitor alone (Table 4.4, Table 4.5). However, in female ApcMin/+ mice, loss of 
IRS-1 or EGFR inhibition tended to reduce mean tumor size while combined their effect 
was much greater (Table 4.4, Table 4.5). Since mean values can be disproportionately 
affected by a single, these data we presented differently in Figure 4.3, which plots the 
percent of colon tumors of different size in females and males. In females, 100% of 
detected tumors were very small (<1mm) when IRS-1+/- mice were given EGFR inhibitor. 
In contrast, in males distribution of tumor size was similar in all groups except that mice 
given AG1478 alone had fewer tumors greater than 2mm in size and only IRS-
1+/+/ApcMin/+ mice given vehicle had tumors greater than 3mm in size. Thus, together 
these data suggest that combined loss of EGFR and IGF-IR/IRS-1 signaling more 
profoundly affects both number and size of colon tumors in females than loss of either 
IRS-1 or EGFR signaling alone 
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D. Discussion 
Our studies showed that combined heterozygous deletion of IRS-1 and 
pharmacological inhibition of EGFR had region- and sex-specific effects to additively 
reduce tumor development in ApcMin/+ mice. Inhibition of IRS-1 and/or EGFR alone did 
not have an effect to reduce body weight (Table 4.1). In the small intestine, although 
heterozygous deletion of IRS-1 or inhibition of EGFR reduced tumor number and tumor 
load, there was not an additive decrease with combined inhibition (Table 4.2) In the small 
intestine, EGFR inhibition had greater efficacy in females, while IRS-1 deletion had a 
greater effect in males.(Table 4.3, Figure 4.2). In the colon, combined inhibition of IRS-1 
and EGFR significantly reduced tumor number, size and load greater than inhibition of 
either signaling molecule alone and this effect was unique to the colon of females (Table 
4.3). Female IRS-1+/-/ApcMin/+ mice given EGFR inhibitor showed at least additive 
reductions in tumor incidence and smaller tumors compared to either IRS-1+/-/ApcMin/+ 
mice given vehicle or IRS-1+/+/ApcMin/+ mice given EGFR inhibitor or vehicle diet 
(Figure 4.2, Figure 4.3). In contrast, male ApcMin/+ mice did not show a combined effect 
for reduction in tumor development since tumor load and tumor incidence were similar 
between IRS-1+/-/ApcMin/+ mice given vehicle-diet or EGFR-inhibitor diet. Together, 
these studies suggest that combined loss of both IRS-1 and EGFR signaling has the most 
significant effects to reduce tumor development in the colon and in females, making a 
case analyzing gender- and tissue-specific effects of pharmacological treatments against 
colorectal cancer.  
Our studies here demonstrated that heterozygous deletion of IRS-1 and/or chronic 
EGFR inhibition did not have significant effects to reduce body weight in female or male 
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mice. Though, previous studies in IRS-1-/- mice showed post-natal growth retardation, 
IRS-1+/- mice did not show an appreciable decrease in body weight compared to IRS-1+/+ 
mice.55,56 Studies in C57BL/J6 mice show that chronic treatment of the EGFR inhibitor 
AG1478 reduces body weight.242 In our studies, chronic EGFR inhibition on the 
C57BL/J6 background did not affect body weight, possibly due to use of the genetic 
ApcMin/+ background.  
 We hypothesized that combined heterozygous deletion of IRS-1 and inhibition of 
EGFR in ApcMin/+ mice would additively or synergistically decrease tumor development 
in the small intestine, the dominant area of tumor development in ApcMin/+ mice.37,36 
Partial deletion of IRS-1 significantly decreased tumor number and tumor load, consistent 
with our previous studies.61 Inhibition of the EGFR reduced tumor number and tumor 
load, as previously reported.134 The combined inhibition of both IRS-1 and EGFR 
pathways was more effective at decreasing tumor number in males or females than either 
alone. However in males, loss of IRS-1 alone is more effective than in females and the 
effects of loss of IRS-1 on tumor number are greater than the effects of EGFR inhibitor. 
Our studies showed that treatment with the EGFR inhibitor AG1478 reduced tumor size 
in the small intestine of both sexes. The effect of EGFR inhibition on tumor size seems 
dependent on the inhibitor and model used. Treatment of ApcMin/+ mice with EKI-785 did 
not show an effect on tumor size.134 Studies in xenograft models and those using a pan-
EGFR inhibitor in ApcMin/+, which targets all EGFR members, show decreased tumor 
size.243,244 We used partial deletion of IRS-1 to mimic effects the likely physiological 
effects of reduced expression as opposed to complete genetic deletion. Previous studies 
have reported that up-regulation and activation of the IGF-IR pathway, of which IRS-1 is 
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a mediator, contributes to resistance to EGFR inhibitors.154,221 In epithelial cell lines, 
treatment with erlotinib, a small molecule EGFR inhibitor, promotes IGF-I-induced Akt 
activity by promoting IRS-1 activation.221 This suggests that the remaining IRS-1 allele 
could be activated during EGFR inhibition to prevent strictly additive effects in the small 
intestine. To that end, there was a trend for IRS-1+/-/ApcMin/+ mice given AG1478 to have 
further reductions in tumor number and tumor load that were greater than IRS-1+/-
/ApcMin/+ mice on vehicle diet or IRS-1+/-/ApcMin/+ mice given AG1478. This suggests that 
complete inhibition of IRS-1 in conjunction with EGFR inhibition will be more potent 
and more effectively reduce tumor development in the small intestine. 
 In contrast to the small intestine, the combined inhibition of IRS-1 and EGFR 
significantly reduced tumor development in the colon and only combined inhibition 
significantly reduced tumor size.(Table 4.4, Table 4.5, Figure 4.1) Surprisingly this effect 
was specifically confined to females. Female IRS-1+/-/ApcMin/+ mice given EGFR 
inhibitor show dramatic reductions in tumor number, size, load and incidence while these 
measurements were similar between male IRS-1+/-/ApcMin/+ mice given EGFR inhibitor or 
vehicle (Table 4.2, Table 4.4, Table 4.3, Figure 4.1). Female IRS-1+/-/ApcMin/+ mice given 
EGFR inhibitor developed few, if any, tumors and those tumors that developed were 
small, whereas EGFR inhibitor given to male IRS-1+/-/ApcMin/+ mice had no such effect 
(Figure 4.1, Figure 4.3). These studies are significant because they establish that 
combined partial loss of IRS-1, and hence IGF-IR, signaling, and inhibition of EGFR 
additively reduced tumor development in the colon. Previous studies have demonstrated 
that combined inhibition IGF-IR and EGFR signaling synergistically reduced cell growth 
in vitro and xenograft tumor growth in vivo due to increased apoptosis.218,220,154,221,234 Our 
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studies used a model of spontaneous tumor development rather than growth of 
established cancer cell lines in immuno-deficient mice. Prior studies have examined 
effects of targeting the IGF-IR specifically, yet several IGF-I/insulin ligands or receptor 
family members may still be capable of activating tumor-promoting pathways when IGF-
IR is targeted. Our studies focused on IRS-1 since this is a downstream mediator of the 
anti-apoptotic effects of IGF-I in the small intestine and colon and mediates signaling of 
several IGF-IR family members, such as the type II IGF-IR (IGF-IIR) and the insulin 
receptor as well.60,61,59 The additive decrease in tumor incidence and shift towards smaller 
tumors with haplotype insufficiency of IRS-1 combined with  EGFR inhibition suggest 
that IRS-1 may promote the survival of tumors and when inhibited together with EGFR, 
dramatically reduces the survival and progression of tumors. Our findings also adds 
support to an emerging hypothesis that resistance to EGFR inhibitor may be mediated at 
least in part by IGF-IR signaling and extend this to suggest that IRS-1 is a mediator of 
these effects. These results also suggest that complete inhibition of IRS-1 in ApcMin/+ 
mice combined with EGFR inhibition will have dramatic effects to reduce tumor 
development and we predict that no tumors will develop in the colon of IRS-1-/-/ApcMin/+ 
mice given EGFR inhibitor. However, this proved practically impossible to test. 
 One surprising observation was the difference in tumor phenotype in the colon 
between male and female IRS-1+/-/ApcMin/+ mice given EGFR inhibitor and in the efficacy 
of loss of IRS-1 or EGFR inhibition in the small intesitne. The combined effects of 
heterozygous deletion of IRS-1 and inhibition of EGFR were the same between male and 
female mice in the small intestine, so we predicted a similar observation in the colon. 
However, in the colon male mice on average were more likely to develop colon tumors 
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that female mice. While 89% of female IRS-1+/+/ApcMin/+ developed colon tumors, 100% 
of male IRS-1+/+/ApcMin/+ developed at least one colon tumor (Figure 4.2B). Even when 
given EGFR inhibitor or when IRS-1 was partially deleted, tumor incidence was still 
higher in male mice than in female mice (Figure 4.2B). This is consistent with human 
studies that have established an increased risk of colorectal cancer in men.245,246,247,248 A 
recent meta-analysis of 17 studies from 18 different populations established a pooled risk 
estimate of colorectal cancer risk in men compared to women of 1.83 (95% confidence 
interval, 1.69 -1.97).246 A female survival advantage has been found across different solid 
tumors such as melanoma and colorectal cancer.248 Our studies support evidence for such 
an advantage. Several hypothesis have been suggested as to why females show a lower 
risk of developing colorectal cancer, including dietary intake and physical activity.249,250 
However, our studies controlled for any lifestyle effects, suggesting that differences may 
be inherent linked to the physiology of the different sexes. Our previous studies have not 
shown a sex-specific difference with regards to the IRS-1-mediated effects on intestinal 
growth.59 There is some evidence that post-menopausal women on estrogen and 
progesterone hormone replacement therapy have an overall reduced risk of colorectal 
cancer suggesting that estrogen and/or progesterone may have a protective role in the 
development of colorectal cancer.251,252,253 The importance of our study is that it suggests 
that combined inhibition of both EGFR and IGF-IR/IRS-1 signaling pathways may be 
more effective against colon cancer in females than males. 
 Another observation was that while inhibition of either pathway reduced tumor 
load in the small intestine and in the colon, the combined effect of heterozygous deletion 
of IRS-1 and EGFR inhibition was more pronounced in the colon compared to the small 
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intestine. IRS-1 mediates the anti-apoptotic effects of IGF-I in an organ-specific manner. 
Complete IRS-1 deficiency dramatically reduces IGF-I-induced increase in muscle 
growth, yet only partially inhibits IGF-I-induced small intestine growth.59 In other 
studies, homozygous deletion of IRS-1 reduced mucosal mass of the colon and ablated 
IGF-I-induced increases in mucosal and muscularis weight.60 These studies suggest that 
IRS-1 has more pronounced effects to mediate the anti-apoptotic effects in the colon and 
suggests a possible mechanism as to why heterozygous deletion of IRS-1 combined with 
EGFR inhibition has more pronounced effects to additively reduce tumor development in 
the colon. It must be noted our results reflect the effects of heterozygous deletion of IRS-
1 and may not be the case with homozygous deletion of IRS-1. IRS-1-/- mice are born at a 
reduced frequency and no IRS-1-/-/ApcMin/+ mice were born during this study.59 However, 
we predict that complete disruption of IRS-1 combined with EGFR inhibition would 
additively or synergistically reduce tumor development in ApcMin/+ mice.  
 Together these results demonstrate that combined heterozygous deletion of IRS-1 
and pharmacological inhibition of EGFR in ApcMin/+ mice have additive effects to reduce 
tumorigenesis in the colon of female mice and not male mice. Although combined 
inhibition of both IRS-1 and EGFR in the small intestine did not show additive effects to 
reduce tumor development, these results are promising and pointing to interactions 
between loss of IRS-1 and inhibition of the EGFR to more effectively decrease tumor 
development even in the small intestine of ApcMin/+ mice. These studies support a role for 
IRS-1 in mediating IGF-IR signaling in EGFR resistance. In addition, the results also 
support further analysis into gender-specific effects of pharmacological treatments 
against colorectal cancer. 
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Table 4.1. Inhibition of IRS-1 or EGFR does not affect final body weight. 
 
 
Genotype Treatment sex Body Weight
IRS-1+/+/ApcMin/+ Vehicle F 17.4+0.7
IRS-1+/-/ApcMin/+ Vehicle F 17.3+0.9
IRS-1+/+/ApcMin/+ AG1478 F 18.9+0.5
IRS-1+/-/ApcMin/+ AG1478 F 16.5+0.1
IRS-1+/+/ApcMin/+ Vehicle M 20.5+1.2
IRS-1+/-/ApcMin/+ Vehicle M 23.5+0.9
IRS-1+/+/ApcMin/+ AG1478 M 22.2+1.5
IRS-1+/-/ApcMin/+ AG1478 M 22.9+0.9
Table 3.1. Mean + S.E.M, Tumor Measurements in the Whole 
Small Intestine
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Table 4.2. Percent reduction in tumor number relative to vehicle-treated IRS-1+/+/ 
ApcMin/+ mice. 
 
a = p < 0.05 versus IRS-1+/+/ApcMin/+ on vehicle diet 
Table 3.3. % Reduction in Tumor number relative to Vehicle - treated IRS-1+/+/ApcMin/+ mice
Genotype Treatment All Male Female All Male Female
IRS-1+/+/ApcMin/+ Vehicle 0.0+14.4 0.0+15.9 0.0+20.8 0.0+16.3 0.0+19.4 0.0+22.9
IRS-1+/-/ApcMin/+ Vehicle 34.8+8.8 48.8+8.9 22.1+17.7 59.4+9.7a 62.4+10.0 68.4+15.8
IRS-1+/+/ApcMin/+ AG1478 45.0+9.9a 36.8+24.1 49.3+9.0 37.5+18.2 15.4+23.1 52.6+22.3
IRS-1+/-/ApcMin/+ AG1478 65.5+4.8a 65.3+5.9a 66.9+7.2a 67.9+11.0a 50.0+15.3 91.4+5.8a
COLONSMALL INTESTINE
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Table 4.3. Heterozygous deletion of IRS-1 or EGFR inhibition reduces tumor load in 
the small intestine and the combination does not additively reduce tumor load. 
 
a = p<0.05 vs. IRS-1+/+/ApcMin/+ on vehicle diet 
b = p<0.05 vs. IRS-1+/-/ApcMin/+ on vehicle diet 
 
Table 3.2. Mean + S.E.M, Tu or Measurements in the Whole Small Intestine
A. Whole Population (Males & Females)
Genotype Treatment n sex Number Size Load
IRS-1+/+/ApcMin/+ Vehicle 13 MF 84.3+12.2 0.82+0.05 71.4+10.9
IRS-1+/-/ApcMin/+ Vehicle 15 MF 54.9+7.4a 0.84+0.04 46.3+6.9a
IRS-1+/+/ApcMin/+ AG1478 13 MF 46.4+8.3a 0.62+0.04a,b 29.8+6.5a
IRS-1+/-/ApcMin/+ AG1478 19 MF 29.1+4.0a,b 0.70+0.03a,b 20.4+3.1a,b
B. Separate Sexes
Genotype Treatment n sex Number Size Load
IRS-1+/+/ApcMin/+ Vehicle 9 F 80.0+16.6 0.74+0.03 62.0+14.0
IRS-1+/-/ApcMin/+ Vehicle 6 F 62.3+14.1 0.80+0.07 51.7+13.6a
IRS-1+/+/ApcMin/+ AG1478 9 F 40.6+7.2a 0.58+0.04a,b 23.5+4.4
IRS-1+/-/ApcMin/+ AG1478 11 F 26.5+5.7a,b 0.63+0.03a 16.0+3.3a,b
IRS-1+/+/ApcMin/+ Vehicle 4 M 94.0+14.9 1.02+0.08 92.5+11.6
IRS-1+/-/ApcMin/+ Vehicle 9 M 50.0+8.4a 0.86+0.05 42.8+7.4a
IRS-1+/+/ApcMin/+ AG1478 4 M 59.5+22.6 0.69+0.05a,b 44.0+18.1a
IRS-1+/-/ApcMin/+ AG1478 8 M 32.6+5.6a 0.79+0.03a 26.6+5.4a
SMALL INTESTINE
SMALL INTESTINE
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Table 4.4. Combined heterozygous deletion of IRS-1 and EGFR inhibition more 
effectively reduces tumor number, size, and load in the colon of female mice. 
 
a = p<0.05 vs. IRS-1+/+/ApcMin/+ on vehicle diet 
b = p<0.05 vs. IRS-1+/-/ApcMin/+ on vehicle diet 
Table 3.3. Mean + S.E.M, Tumor Measurements in the Colon
A. Whole Population (Males & Females)
Genotype Treatment n sex Number Size Load
IRS-1+/+/ApcMin/+ Vehicle 13 MF 2.5+0.4 1.3+0.2 3.8+0.8
IRS-1+/-/ApcMin/+ Vehicle 15 MF 1.0+0.2a 1.0+0.3 1.7+0.5a
IRS-1+/+/ApcMin/+ AG1478 13 MF 1.5+0.4 0.7+0.2 1.8+0.6a
IRS-1+/-/ApcMin/+ AG1478 19 MF 0.8+0.3a 0.4+0.1a,b 1.0+0.5a
B. Separate Sexes
Genotype Treatment n sex Number Size Load
IRS-1+/+/ApcMin/+ Vehicle 9 F 2.1+0.5 1.1+0.2 2.9+0.8
IRS-1+/-/ApcMin/+ Vehicle 6 F 0.7+0.3a 0.6+0.4 0.9+0.6a
IRS-1+/+/ApcMin/+ AG1478 9 F 1.0+0.5 0.6+0.3 1.3+0.7a
IRS-1+/-/ApcMin/+ AG1478 11 F 0.2+0.1a 0.1+0.1a 0.1+0.1a
IRS-1+/+/ApcMin/+ Vehicle 4 M 3.3+0.6 1.8+0.1 5.9+1.5
IRS-1+/-/ApcMin/+ Vehicle 9 M 1.2+0.3a 1.3+0.3 2.2+0.8
IRS-1+/+/ApcMin/+ AG1478 4 M 2.8+0.8 1.0+0.3 3.0+1.5a
IRS-1+/-/ApcMin/+ AG1478 8 M 1.6+0.5a 1.0+0.3 2.2+1.0a
COLON
COLON
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Table 4.5. Percent reduction in tumor size relative to vehicle-treated IRS-1+/+/ApcMin 
mice 
 
a = p<0.05 vs. IRS-1+/+/ApcMin/+ on vehicle diet 
b = p<0.05 vs. IRS-1+/-/ApcMin/+ on vehicle diet 
 
Table 3.3. % Reduction in Tumor size relative to Vehicle - treated IRS-1+/+/ApcMin/+ mice
Genotype Treatment All Male Female All Male Female
IRS-1+/+/ApcMin/+ Vehicle 0.0+6.1 0.0+8.3 0.0+4.7 0.0+12.5 0.0+2.6 0.0+18.1
IRS-1+/-/ApcMin/+ Vehicle 2.1+5.0 15.1+5.1 9.3+9.6 21.3+18.0 29.9+17.6 36.7+30.8
IRS-1+/+/ApcMin/+ AG1478 25.2+4.4a,b 31.8+5.1a 21.1+5.9b 47.6+15.4 46.4+16.9 48.5+22.3
IRS-1+/-/ApcMin/+ AG1478 15.3+3.4a 22.6+3.2a 14.3+4.6 66.6+10.9a 49.4+14.0 91.1+6.0a
SMALL INTESTINE COLON
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Figure 4.1 Combined heterozygous deletion of IRS-1 and inhibition of EGFR 
additively reduces tumor incidence in female mice ApcMin/+ mice, but not male 
ApcMin/+ mice. A. Bright field images of representative colons from female IRS-
1+/+/ApcMin/+ and IRS-1+/-/ApcMin/+ mice given either diet containing the EGFR inhibitor 
AG1478 or vehicle diet for 12 weeks. Note the lack of tumors that develop when both 
IRS-1 and EGFR are inhibited. B. Histograms showing tumor incidence (% mice that 
developed one or more tumors) in female (left) or male (right) IRS-1+/+/ApcMin/+ and IRS-
1+/-/ApcMin/+ mice given either vehicle diet or diet containing the EGFR inhibitor 
AG1478. 
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Figure 4.2. Combined inhibition of IRS-1 and EGFR does not have additive effects 
to reduce tumor number, size, or load in the small intestine. Mean + S.E.M for A. 
tumor number, B. tumor size, and C. tumor load (number x size) for each tumor region in 
female (left) or male (right) IRS-1+/+/ApcMin/+ and IRS-1+/-/ApcMin/+ mice given either diet 
containing the EGFR inhibitor AG1478 or vehicle diet for 12 weeks. n>4, SI-1 is the 
most proximal region and contains the duodenum and SI-3 is the most distal region and 
contains the ileum. a = p<0.05 vs IRS-1+/+/ApcMin/+  given vehicle diet; b = p<0.05 vs 
IRS-1+/-/ApcMin/+ given vehicle diet 
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Figure 4.3 Female IRS-1+/-/ApcMin/+ mice given diet AG1478 develop small tumors. 
A. Histogram showing the percentage of tumors of a particular size compared to the 
overall tumor number in female mice. Note the lack of medium (1 < mm < 2) and large (2 
< mm < 3, 3 < mm) tumors in female IRS-1+/-/ApcMin/+ mice given the EGFR inhibitor. B. 
Histogram showing % of tumors of a particular size in male mice. Note that while IRS-
1+/+/ApcMin/+ and IRS-1+/-/ApcMin/+ mice given the EGFR inhibitor have an increase in 
small and medium sized tumors, there was no effect with combined inhibition of IRS-1 
and EGFR in male mice. 
	   	  
 
 
CHAPTER 5 
DISCUSSION AND FUTURE DIRECTIONS 
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A. SOCS are negative regulators and biomarkers of cancer in the 
gastrointestinal tract.(Adapted from 80) 
Results in chapter II show that heterozygous or homozygous loss of SOCS2 
increases tumor number, size, and load in the small intestine and colon of ApcMin/+ mice 
and increases tumor incidence in the colon. Together with evidence that partial loss of 
SOCS2 in GH-Tg mice promotes dysplastic growth, these studies provide strong 
evidence that loss of SOCS2 promotes the growth of pre-cancerous lesions in the 
intestine. Thus, in addition to evidence that SOCS2 genes are silenced by promoter 
methylation in cancers of other organs (Table 1.1) and evidence for a role of other SOCS 
in gastrointestinal cancers, especially SOCS1 and SOCS3, a central role emerges for 
SOCS proteins as intrinsic negative regulators of tumor development in the 
gastrointestinal tract. Furthermore, SOCS proteins may have distinct roles to suppress 
development of different tumor types in the intestine. This regional- and context-specific 
role of the SOCS proteins may allow for their use as biomarkers of GI cancer or different 
subtypes.  
SOCS1 and SOCS3 play a particular role in inflammation-associated 
tumorigenesis in several types of GI cancer. Available evidence suggests that SOCS1 and 
SOCS3 acts as suppressors of inflammation-associated cancer by decreasing 
proliferation, promoting apoptosis, and, in certain cases, reducing activation of NFκB and 
STATs.113, 114 SOCS1 or SOCS3 silencing appears to drive tumorigenesis in context of 
inflammation, though some studies suggest an overlap between pathways linked to 
sporadic as well as inflammation-associated cancers.  For example, in a study of tissue 
from patients with sporadic rather than IBD-associated CRC, there was a significant 
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correlation between nuclear accumulation of STAT3 and β-catenin, and this was 
associated with poor patient survival.254 Likewise, in spontaneous stomach cancer, 
STAT3 positivity in tumors correlated with poorer prognosis, and this was unrelated to 
Helicobacter pylori infection or gastritis.255 In esophageal squamous cell carcinoma, 
STAT3 is enhanced in tumor cells, and in vitro studies showed that transfected β-catenin 
induced transcription and expression of STAT3, and that dominant-negative TCF4 
reversed this effect.256 These studies all suggest that STAT3 plays a role in sporadic as 
well as inflammation-associated tumorigenesis; therefore, SOCS proteins are likely 
regulators of both tumor types. However, few studies have examined the interplay 
between SOCS proteins and sporadic cancer pathways such as Wnt/β-catenin.  
The most striking direct evidence of SOCS2 as a tumor suppressor thus far lies in 
our studies of intestinal tumorigenesis. Studies showing increased small intestine and 
colon tumor load and incidence in SOCS2-/-/ApcMin/+ mice illustrate an intrinsic tumor 
suppressor role of SOCS2 in the absence of detectable inflammation, and our published 
studies show that the absence of SOCS2 has no effect of tumor formation in the 
AOM/DSS model.116,117 Studies described in chapter II also show that loss of SOCS2 
promotes increases in serine-phosphorylation of STAT3 as opposed to tyrosine-
phosphorylation, which SOCS3 is known to inhibit.113 This is exciting as it suggests that 
differential phosphorylation of STAT3 may be one mechanism that explains the 
preferential effects of SOCS1 and SOCS3 to limit inflammation-associated tumors, while 
SOCS2 limits spontaneous tumorigenesis in the intestine.  
One common theme of among GI cancers is that SOCS proteins are silenced by 
aberrant hyper-methylation in tumor tissue.104,106,257,258,259,260,261,262,263,264,265,266,267,268,269,270 
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Recent studies show that IL-6 regulates the transcription factor Fli-1, which is required 
for expression and activity of DNA methyltransferase enzyme (dnmt-1).184 Additional 
studies showed that IL-6 directly contributes to aberrant methylation of the tumor 
suppressor p53.184 To date, the mechanisms regulating SOCS methylation are unknown. 
IL-6-mediated hyper-methylation of SOCS could be an as-yet-undefined mechanism of 
tumorigenesis in the GI tract, at least in the setting of inflammation.  
The prevalence of SOCS hyper-methylation in GI cancers highlights the 
importance of developing therapies to reverse the epigenetic silencing of tumor 
suppressor genes. In cholangiocarcinoma cell lines that exhibit SOCS3 promoter 
methylation, treatment with the demethylating agent 5-aza-2’-deoxycytidine (DAC) 
reversed SOCS3 silencing and decreased STAT3 activation, providing exciting pre-
clinical data on the prospect of using DAC to restore SOCS expression in cancer cells.267 
In addition to epigenetic therapies, small molecule SOCS agonists may be useful 
therapies to restore SOCS action and prevent or treat cancer. JAK inhibitors are currently 
being tested for a variety of myelo-proliferative disorders, but may have broader 
implications for other cancers where aberrant cytokine or STAT signaling occurs, such as 
those GI cancers where one or more SOCS proteins are silenced.271 SOCS-based 
therapies may be attractive as combinational therapies with more traditional strategies 
such as conventional chemotherapy, radiation therapy, or even biologic therapies. The 
rationale underlying this suggestion is that SOCS are endogenous tumor suppressors and 
may have fewer side effects. Thus, it would be of interest in the future to test whether 
SOCS overexpression or SOCS mimetics synergize with or reduce the necessary dose of 
traditional therapies in ablating or inhibiting tumor cell growth in vivo or in vitro. While 
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some SOCS mimetics based on SOCS peptides have been reported, a remaining obstacle 
is to ensure permeability into cells.   
 
B. Serine Phosphorylation of STAT3 and cancer 
Constitutive activation of STAT3 is associated with poor prognosis in colorectal 
cancer, protection from apoptosis, and is commonly thought to occur through tyrosine 
phosphorylation of STAT3.254, 272, 273,274,275 In chapter II, we demonstrated that 
homozygous deletion of SOCS2 in ApcMin/+ mice increases serine phosphorylation of 
STAT3 in tumor and non-tumor intestinal tissue by both western blot and 
immunohistochemistry, but tyrosine phosphorylation of STAT3 was unaffected. These 
studies support an emerging hypothesis that serine phosphorylation of STAT3 has a role 
in cellular transformation and growth and regulates tumorigenic growth. 
Upon cytokine or growth factor activation, STAT3 is phosphorylated at tyrosine 
residue 705 and/or at serine residue 727. Phosphorylation at Y705 has been shown to be 
required for dimerization and nuclear translocation of STAT3.173,188 The role of 
phosphorylation at S727 is context- and cell-specific.194,276,193,277 In some studies, serine 
phosphorylation is not required for DNA binding, but has been shown to be required for 
maximal transcriptional activity.276,278 Others studies have suggested that STAT3 
negatively regulates tyrosine phosphorylation of STAT3 through both ERK-dependent 
and –independent mechanisms.193,192,277 Importantly, serine phosphorylation has 
demonstrated growth effects independent of tyrosine phosphorylation, including 
increased anchorage-independent growth in cancer cell lines and tumor formation in 
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immune compromised mice.190 The role of serine phosphorylation in normal growth was 
demonstrated in mice with an inactivating serine to alanine mutation at residue 727 of 
STAT3 (SA/SA).191 When combined with heterozygous loss of STAT3 (SA/-), these 
mice had a 10-15% reduction in birth weight, reduced survival, and had a 40-50% 
reduction in post-natal body and organ growth one week after birth.191 These mice had 
reduced levels of plasma IGF-I in 8-day old littermates, suggesting that mechanisms of 
reduced growth occur through reduced circulating IGF-I.191 Though SA/SA mice 
appeared grossly normal, there was reduced transcriptional activation in response to IL-6 
and OSM, suggesting that in vivo serine-phosphorylation of STAT is necessary for 
maximal transcriptional activation of these cytokines.191 Thus, one direction our 
laboratory would like to take in the future is to examine the S727A STAT3 mutant and 
test whether these animals show diminished risk of tumors. Use of constructs expressing 
this STAT isoform could also test directly whether serine phosphorylation of STAT is 
necessary for tumor promoting roles of SOCS2 silencing.  
In congruence with its suggested role in growth, serine phosphorylation of STAT3 
has recently been detected in vivo in mammary gland, prostate tumors, and in chronic 
myloid leukemia and in vitro in H-Ras(V12) transformed cells, bladder, lung, and 
medullary thyroid cancer cell lines.189,174,190,172,279 Serine-phosphorylation was required 
for H-Ras-, N-Ras-, or K-Ras-induced tumor growth in soft agar, where STAT3 was 
shown to contribute to Ras-mediated oncogenic transformation.279 Of particular 
importance, serine phosphorylation of STAT3 has recently been associated with tumor-
initiating stem cells (TISCs) or cancer stem cells (CSC) in glioblastoma, a frequent and 
aggressive cancer.280 This subpopulation of cells retains stem-cell characteristics and is 
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highly resistant to chemotherapeutics and ionizing radiation.281,280 STAT3 is 
constitutively phosphorylated at S727 in these cells and inhibition of STAT3 reduces 
their proliferation  and sensitizes them to chemotherapy.280 In addition, recent studies to 
derive rabbit embryonic stem cells found that LIF, which was required for maintenance 
of these stem cells, promoted preferential phosphorylation at serine 727 of STAT3.280 In 
chapter II, serine-phosphorylation of STAT3 was localized to the crypts in normal small 
intestine and was particularly evident in small cells intercalated between paneth cells, a 
region known to contain both intestinal stem cells or crypt based columnar cells.282 
Results of these studies in stem-like cells, in addition to a demonstrated role in normal 
and neoplastic growth, suggest that serine phosphorylation of STAT3 may influence 
growth by affecting the local stem cell populations. 
 
C. STATS and stem cells 
As previously mentioned, activated STAT3 is able to promote neoplastic growth 
in the presence of activating oncogenic mutations, in both sporadic and inflammation-
associated colorectal cancer. Among the STAT family, STAT3 is the only STAT that 
when deleted in whole animals is embryonic lethal, suggesting a central role for this 
STAT in embryonic development.283 In addition, studies in chapter II suggest that serine 
phosphorylated STAT3 is localized to the lower half of the crypt, where intestinal stem 
cells (ISCs) are thought to reside. A series of studies in the Drosophila midgut has 
recently highlighted the role of the JAK-STAT pathway in homeostasis and maintenance 
of the intestinal stem cell population.284  
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The Drosophila midgut is quickly becoming an excellent model to study 
behaviors of ISCs since it parallels stem cell differentiation in humans.285,286 A 
population of self-renewing ISCs is maintained in the base membrane along with non-
dividing, undifferentiated ISC daughter cells, called enteroblasts (EBs), that can 
differentiate into one of two lineages through Delta ligand-Notch receptor signaling, 
absorptive enterocytes (ECs) or secretory enteroendocrine cells (EEs).287 Intestinal 
damage to due microbial infection, induced apoptosis, or JNK-mediated stress signaling 
induces the expression of three cytokine-like ligands called unpaired (Upd1-3) in the 
surrounding muscle cells to influence nearby enterocytes.287,285,288 Unpaired binds to 
domeless, an IL-6-like receptor, that phosphorylates and activates a JAK homologue, 
Hopscotch (Hop), which in turn activates STAT92E, the sole STAT homologue in 
Drosophila.287,284 STAT92E induces the expression of domeless and a negative regulator 
of Upd signaling, socs36E.287  
 The Upd/Hop/STAT pathway is implicated in maintenance and differentiation of 
ISCs.284 Overexpression of Upd or Hop increases enterocytes mitosis in both terminally 
differentiated cells and ISCs.287 Mutations in STAT92E inhibited the expression of 
differentiation markers and reduced the size of enterocytes nuclei.287 JAK-STAT 
signaling functions cooperatively with Delta-Notch signaling to promote terminal 
differentiation and lineage decision, where NotchHigh/HopLow cells are driven towards an 
absorptive EC fate and NotchLow/HopHigh cells are driven towards a secretory EE cell 
fate.285 As such, activated JAK-STAT signaling is not normally found in terminally 
differentiated enterocytes and loss of JAK-STAT signaling attenuates ISC 
differentiation.289,285 Together, these studies support a role dual role for JAK-STAT 
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signaling in regulating the proliferation and differentiation of ISC and ISC daughter cells, 
though JAK-STAT signaling does not seem to have a role in self-renewal.287,289,286 Dr. 
Scott Magness, who will be a mentor for my post-doctoral research, recently developed 
techniques that allow the isolation and in vitro culture of  ISCs capable of self-renewal 
and differentiation into enterocyte lineages.290,291 Using these techniques, future studies 
could test the ability of JAK-STAT signaling in mouse ISCs to influence maintenance 
and differentiation, in particular, whether serine or tyrosine phosphorylation has a role in 
promoting ISC growth and/or differentiation. 
 
D. Using gene expression microarray to identify signaling pathways. 
Our studies in chapter II demonstrated that increased tumorigenesis in SOCS2-/-
/ApcMin/+ mice is associated with increased local IGF-I expression, serine-
phosphorylation, and AP-1 DNA binding. However, we cannot rule out that other 
unknown mechanisms are promoted in response to loss of SOCS2 and whether these 
pathways are related to specific growth factors, such as IGF-I or EGF. Our studies in 
chapter III in IEC-6 cells showed that combined treatment of IGF-I and EGF additively 
increased nuclear β-catenin and TCF transcriptional activity. However, whether IGF-I 
and EGF have additive effects to promote transcription of β-catenin-dependent or 
independent genes is unknown. Ongoing studies to investigate the effects of SOCS2 
deletion or EGF/IGF-I on expression of specific genes and pathways are using microarray 
technology to elucidate activation or repression of various genes and networks. Studies in 
Dr. David Threadgill’s lab have highlighted the use of GeneSpring and Ingenuity 
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software to identify pathways related to cell signaling and survival.292 Such studies are 
already currently underway in our lab. A post-doc, Dr. Shengli Ding and graduate 
student, Amanda Mah, have already performed microarray analysis on RNA from pooled 
tumors and matching non-tumor tissue collected from SOCS2+/+/ApcMin/+, SOCS2-/-
/ApcMin/+, SOCS2+/+, and SOCS2-/- mice. Data analysis is in progress. Future studies will 
investigate gene expression from tumors isolated in young mice, when tumors first 
present, to examine signaling expression when adenomas are just beginning to form as a 
result of loss of SOCS2 expression. We predict that genes that regulate AP-1 activation 
or expression will be altered, as well as STAT-regulated genes. 
 
E. Use of combined targeted therapies in colorectal cancer. 
 In chapter III, we demonstrated that combined IGF-I and EGF treatment 
synergistically increases proliferation, nuclear β-catenin, and TCF transcriptional 
activation. We also showed in chapter IV, that inhibition of the EGFR combined with 
heterozygous IRS-1 deletion additively reduces tumor development in the colon of 
female ApcMin/+ mice and may interact to decrease small bowel tumors. These results 
suggest that IGF-I and EGF interact to promote a key-tumor promoting pathway and 
enhance proliferation and that combined inhibition of both these pathways may be a 
promising treatment against colorectal cancer.  
Studies in NSCLC and breast cancer support this hypothesis, where aberrant 
activation of the IGF-I pathway occurs in cells that are resistant to targeted EGFR 
inhibitors.153, 226 In some cases, this is thought to occur though activation IRS-1.154,221 
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Though small molecule and antibody inhibitors have been developed that specifically 
target IGF-IR, we chose to use a model of IRS-1 inactivation on the ApcMin/+ 
background.145 Inactivation of IRS-1 is thought to inhibit the growth effects of all IGF 
ligands and we have previously demonstrated that partial loss of IRS-1 significantly 
reduces tumor load in ApcMin/+mice.61 In addition, at the time of the study, specific IGF-
IR inhibitors had not been tested in the ApcMin/+ mouse model. Recently, antibodies 
against IGF-I (KM3168) and IGF-II (KM1468) given by intraperitoneal (i.p.) injection to 
ApcMin/+ mice led to reduced polyp number when given alone and additive effects when 
combined.293 These inhibitors show promise in testing the utility of combined targeted 
therapies in mouse models, such as the ApcMin/+ mouse. 
 Other inhibitors for have surfaced for use in combination with EGFR inhibitors, 
most notably VEGF. Targeted therapeutics have been developed that inhibit both the 
EGFR and VEGFR and reduced tumor growth orthopically in the nude mice.294 This has 
also been demonstrated in a similar manner for NSCLC and salivary adenoid carcinoma 
cells.295,296,297 Though, the efficacy of these treatments has yet not been evaluated in 
patients with colorectal cancer, these studies support our general hypothesis that 
combined inhibition of tumor-promoting pathways may be more effective in reducing 
tumor development than single-agent therapies. 
 
F. Effect of underlying genetic mutations on efficacy of target therapeutics 
Our studies in chapter IV showed an additive effect to reduce tumor incidence and 
tumor size with combined heterozygous deletion of IRS-1 and EGFR inhibition (Figure 
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4.1, Figure 4.3). While these studies support the use of combined targeted therapeutics to 
reduce tumor development, one cannot overlook the patient populations that will most 
benefit from this type of treatment. Recent lessons from studies of using the targeted 
EGFR inhibitors, cetuximab and panitumumab, in metastatic colorectal cancer patients 
demonstrate that underlying genetic mutations can dramatically affect the efficacy of 
such treatments to reduce colorectal cancer. Though preclinical studies demonstrated a 
remarkable effect of these inhibitors to reduce tumor development, only 10-20% of 
colorectal cancer patients responded to this therapy.298,220 An initial retrospective analysis 
revealed that colorectal cancer patients who have activating KRAS mutations do not 
benefit from cetuximab or panitumumab treatment.299,300 Activating KRAS mutations 
have since been defined as a negative predictor of clinical outcome of cetuximab-based 
treatments.228 This breakthrough has led to the changes in FDA guidelines for these 
specific inhibitors, specifying that cetuximab and panitumumab should not be given to 
patients with KRAS mutations.301 A recent study demonstrated longer disease-free 
survival in patients with wild-type (WT) KRAS.229 Since, other mutations such as BRAF 
and PTEN mutations have also been defined as negative predictors of cetuximab clinical 
outcome.228 These studies suggest that combined inhibition of EGFR and IGF-IR would 
be most effective in patients that do not harbor these mutations, since IGF-IR is also 
known to activate RAS/MAPK and PI3K/PTEN pathways. 
Even with identification of such mutations, even the best responders to targeted 
EGFR develop resistance to cetuximab and panitumumab in 12 to 19 months.228 These 
secondary resistance mechanisms are still unknown and up-regulation of the IGF-IR 
pathway could represent one such mechanism. Our studies demonstrated that when IRS-1 
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signaling was inactivated, thus impairing signaling through the IGF family, treatment 
with the EGFR inhibitor was more effective than inhibition of either IRS-1 or EGFR. 
This suggests that IGF-I pathways are still active in tumors that survive EGFR inhibition. 
Indeed, studies by Ming Yu in the Threadgill lab have shown that tumors that survive in 
ApcMin/+ mice despite an EGFR inactivating mutation (EGFRwav-2), have elevated IGFBP5 
and IGF-IR expression (communication with Dr. Ming Yu and David Threadgill). We 
propose that IGF-IR targeted therapies may be useful in overcoming the secondary 
resistance seen in responders to EGFR inhibitor treatment. The animal models and 
strategies used in this thesis may be used to address the role of IGF-IR signaling in 
resistance to EGFR inhibitors. 
 
G. Novel tumor imaging techniques to identify micro-adenomas and therapeutic 
mechanisms 
Our studies in Chapter IV showed that female IRS-1+/-/ApcMin/+ mice treated with 
an EGFR inhibitor show additive reductions in tumor incidence greater than inhibition of 
IRS-1 or EGFR alone. The lack of obvious tumors in these mice was striking and 
suggests that combined inhibition of these pathways disrupts early stages of tumor 
development such as the initiation and establishment of adenomas. Genetic and 
pharmacological disruption of the EGFR in ApcMin/+ has been shown to inhibit the 
establishment of adenomas.134 What is not known is whether combined inhibition of IRS-
1 and EGFR pathways promotes changes in the formation of aberrant crypt foci, the 
earliest indicator of neoplastic dysplasia, and microadenomas.302 These features are near 
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impossible to detect by bright-field microscopy and are currently only detected through 
laborious histological detection. In addition, only histological detection can truly identify 
adenomas from similar, but benign, hyperplastic and lymphoid polyps. 
Current studies in our lab have focused on developing enhanced tumor imaging 
techniques that would allow identification of adenomas, from benign polyps and areas of 
inflammation and dysplasia. Molecular probes have been developed that are activated by 
biomarkers up-regulated in adenomas, such as cathepsin B.303,304 These probes are 
administered intravenously and are undetectable unless cleaved by locally activated 
enzymes causing to fluoresce at near-infared fluorescence and have been shown to be 
effective in detecting tumors in ApcMin/+ mice.303,304 Recent studies in our laboratory 
combined the use of these probes with capsule endoscopy, a capsule designed to be 
swallowed by a patient and record images as it goes through the digestive tract.305 These 
studies demonstrated the cathepsin B probe, Prosense680TM, was able to detect adenomas 
in both ApcMin/+ mice and models of colits-induced colon cancer, but did not detect 
benign lesions.305 More probes have been developed and these are currently being tested 
by a post-doc in the lab, Dr. Shengli Ding. Recently, a probe Annexin-750, can detect 
areas of apoptosis and would be useful in our model of combined IRS-1 and EGFR 
inhibition to determine if the mechanisms of tumor inhibition involve apoptosis.306 Once 
tested, the ability of these probes detect microadenomas will be evaluated in AOM-
treated and early-age ApcMin/+ mice to test if these probes can detect early stage 
adenomas, which are not normally visible by bright-field microscopy. 
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H. Gender effects on colorectal cancer risk and potential mechanisms 
We observed in chapter II and chapter IV that male ApcMin/+ mice on the 
C57BL/J6 background were more likely to develop colon tumors than female ApcMin/+ 
mice. This was quantified in Figure 4.1B where male IRS-1+/+/ApcMin/+ mice on vehicle 
or EGFR inhibitor diet had a higher tumor incidence compared to female IRS-
1+/+/ApcMin/+ mice on the same diets. Female mice also had dramatic reductions in tumor 
load and incidence in response to combined heterozygous deletion of IRS-1 and 
inhibition of EGFR.(Table 4.4, Table 4.5, Figure 4.1, Figure 4.3) These observations 
support previous studies in humans, demonstrating an increased risk of colorectal cancer 
in men across multiple race/ethnic groups.245,246,248 A meta-analysis of 17 independent 
studies found a pooled increased risk of 1.83 for advanced neoplasia in men and positive 
association between gender and advanced cancer.246 Men also show a stronger 
association between increased BMI and colorectal cancer risk.249,247 A female survival 
advantage has been demonstrated in melanoma, lung, esophageal, and pancreatic cancers 
as well as in soft tissue sarcoma.248 Environmental and genetic factors play a role in the 
increased risk of colorectal cancer in men. These effects are most likely not due to 
preventative screening behaviors as men are more often screened for colorectal cancer.307 
Men have been reported to consume more alcohol and more high-fat meat, and eat less 
dietary fiber, than women, which may contribute to increased risk.250,249 However, one 
cannot overlook the genetic differences inherent between the sexes. 
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Several studies suggest female sex steroids may have a role in reducing risk of 
colorectal cancer in women.308,251,252,253 The Women’s Health Initiative (WHI) recently 
showed a reduced risk of colorectal cancer risk with use of estrogen and progesterone 
hormone replacement therapy (HRT) in post-menopausal women.308 In the Cancer 
Prevention Study cohort, estrogen-only HRT was associated with reduced risk of 
colorectal cancer and a strong inverse relationship between long-term estrogen use and 
colorectal cancer risk.308 In another study, use of oral HRT was associated with a 63% 
relative reduction in the risk of colorectal cancer in post-menopausal women.251 While 
mechanisms as to how estrogen and/or progesterone treatment reduces colorectal cancer 
risk are still unknown, one possible mechanism lies in estrogen action on growth 
hormone. A few studies demonstrate that estrogen inhibits the metabolic actions of GH 
by reducing JAK2 tyrosine phosphorylation and GH-induced STAT reporter 
activity.309,310 Long-term estrogen was found to increase SOCS2 and SOCS3 mRNA in 
the liver through estrogen receptor α.311 Since our studies in Chapter II demonstrated that 
heterozygous and homozygous deletion of SOCS2 in ApcMin/+ mice reduced intestinal 
tumorigenesis, future studies could investigate whether estrogen mediates a protective 
effect against colorectal cancer through SOCS2. This is just one mechanism whereby 
sex-hormones augment tumor-promoting pathways and studies in this thesis highlight the 
need for gender-specific evaluations of the cancer therapies.  
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I. Summary and Working Model 
These studies show that SOCS2 and EGF have opposite effects to influence IGF-
IR signaling. In the working model shown in Figure 5.1, GH activates the GH receptor 
and thus induces local IGF-I expression to have paracrine/autocrine effects in the 
intestine to increase proliferation and survival of intestinal epithelial cells and promote 
intestinal tumorigenesis. SOCS2 normally inhibits GH-induced local expression of IGF-I 
and IGF-IR activation as well as inhibits serine phosphorylation of STAT3. In the 
absence of SOCS2, IGF-I expression is increased and, thus, increases activation of the 
IGF-IR. IGF-I-induced receptor activation, as well as signaling from additional cytokine 
and/or growth factors, promote the phosphorylation of STAT3 at serine residue 727 
without affecting tyrosine phosphorylation. Serine phosphorylation has been shown to 
promote the activation of AP-1 transcription factor binding to DNA to promote gene 
transcription that enhances intestinal tumorigenesis. EGF has opposite effects on IGF-IR 
signaling and, instead, acts to promote enhanced IGF-I-induced DNA synthesis and 
proliferation by enhancing total IGF-IR and promoting synergistic activation of β-
catenin/TCF-mediated gene transcription. Though the exact mechanism of synergistic β-
catenin activation remains unknown, we suspect further expression analysis will reveal 
activation of PI-3K or MAPK-driven pathways. Our studies in chapter IV show that not 
only do combined IRS-1 and EGFR inhibition synergistically reduce tumor development, 
but that this occurs in a gender- and region-specific manner, in the colon of female 
ApcMin/+ mice. Combined, these studies suggest new pathways through which growth 
factors regulate tumor development and highlight novel avenues of cancer therapeutics, 
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such as SOCS protein mimetics and use of combined therapeutics to overcome resistance 
to targeted inhibitors. 
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Figure 5.1. A Hypothetical model of SOCS2 and EGF action of IGF-IR signaling in 
intestinal cancer. Future directions will be aimed at identifying alterations in signaling 
pathways and networks as a result of loss of SOCS2 in ApcMin/+ mice and EGF and IGF-I 
interactions in IEC-6 cells using microarray  
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